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CHAPTER 1
General introduction part 1
mecHanisms oF Hypertension and 
proteinuria during angiogenesis 
inHibition:eVolVing role oF endotHelin-1
Stephanie Lankhorst, mariëtte H.W. Kappers, Joep H.m. van esch, a.H. Jan danser, 
anton H. van den meiracker.
J Hypertension. 2013; 31(3): 444-454 
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abstract 
Angiogenesis inhibition by blocking vascular endothelial growth factor (VEGF)-
mediated signalling with monoclonal antibodies or tyrosine kinase inhibitors has 
become an established treatment of  various forms of  cancer. This treatment is 
frequently associated with the development of  hypertension and proteinuria. Since 
VEGF increases the expression and the activity of  nitric oxide synthase in endothelial 
cells, a decrease in the bioavailability of  nitric oxide has been proposed as a key 
mechanism leading to hypertension during angiogenesis inhibition. However, results of  
clinical and experimental studies exploring this possibility are conflicting.  Rarefaction, 
i.e. a structural decrease of  microcirculatory vessels, has been reported during anti-
angiogenic treatment, but evidence that it plays a role in development of  hypertension 
is lacking. Elevated circulating and urinary levels of  endothelin-1 have been observed 
in clinical and experimental studies with angiogenesis inhibitors. Furthermore, the 
observation that endothelin receptor blockers can prevent or revert the rise in blood 
pressure during angiogenesis inhibition and attenuate proteinuria, provides strong 
evidence that an activated endothelin-signalling pathway is a final common mediator of  
angiogenesis-inhibition-induced rise in blood pressure and renal toxicity. 
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introduction
Angiogenesis, the formation of  new blood vessels from pre-existing vasculature, 
is critical to solid tumor growth as well as metastasis. This process is regulated by 
various growth factors of  which vascular endothelial growth factor (VEGF) with 
its corresponding receptors plays a prominent role.1, 2 Inhibition of  angiogenesis 
with humanized monoclonal antibodies to VEGF or with inhibitors of  the VEGF 
receptors (RTKIs) has become an established treatment for various forms of  cancer. 
Hypertension and proteinuria are common side effects of  this treatment.1, 3-7 These 
features are also characteristic for preeclampsia. Accumulating evidence indicates that 
an imbalance between pro- and anti-angiogenic factors is involved in the clinical features 
of  preeclampsia. According to current insight, placental overproduction and release 
of  the anti-angiogenic factors in the maternal circulation inhibit angiogenesis and like 
exogenous VEGF inhibition applied as anticancer treatment, results in hypertension 
and proteinuria.8-10 How exogenous VEGF inhibition during anti-angiogenic treatment 
or endogenous VEGF inactivation during preeclampsia leads to hypertension and 
proteinuria is not precisely known. Recently, we and others have shown that activation 
of  the endothelin pathway may be an important final mechanism.11-13 In this article the 
effects of  interference with VEGF signalling, either exogenously or endogenously, on 
the development of  hypertension and proteinuria, will be reviewed. 
VegF, VegFrs and biological eFFects oF VegF 
signaling 
The mammalian VEGF belongs to a gene family that includes 5 different glycoproteins 
and the placental growth factors (PlGFs) 1 and 2 (Figure 1). Of  the VEGF family 
VEGF-A, commonly referred to as VEGF, is best characterized.14, 15 VEGF is produced 
and secreted by different cells including endothelial cells (ECs), podocytes, macrophages, 
and fibroblasts.16, 17 VEGF produced and secreted by tumor cells targets ECs to promote 
tumor angiogenesis.18 VEGF is up-regulated by hypoxia-inducible factor (HIF) 1α 
and several other factors.2, 16 VEGF binds to three tyrosine kinase receptors: VEGF 
receptor 1 (VEGFR-1 or fms-like tyrosine kinase 1 (Flt-1) murine homologue), VEGF 
receptor 2 (VEGFR-2 or kinase domain region (KDR) human homologue or Flk-1 
murine homologue) and VEGFR-3 (also known as FLT4). VEGFR-1 and VEGFR-2 
are predominantly expressed on vascular ECs, whereas VEGFR-3, stimulated by 
VEGF-C, is largely restricted to lymphatic ECs.19 VEGFRs contain an extracellular 
region, a transmembrane domain and a cytoplasmatic bipartite kinase domain with 
tyrosine residues (Figure 1). Neurophilins 1 and 2 serve as coreceptors for VEGF by 
increasing the affinity of  ligands to the VEGFRs.19 Under physiological conditions 
most of  the biologically relevant VEGF-signaling in ECs is mediated by VEGFR-2.20 
The extracellular domain of  Flt-1 or VEGFR-1 is also present at low concentrations 
as a soluble protein (sFlt-1). In preeclampsia the placental production of  sFlt-1 is 
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considerably increased.9, 21 In the maternal circulation sFlt-1 binds to VEGF acting as 
an endogenous VEGF antagonist.9 
VEGF exerts many biological activities, including angiogenesis during embryogenesis, 
menstrual cycle and wound healing, but also has been recognized as a positive regulator 
of  growth and metastasis of  malignancies. Genetic ablation experiments in mice have 
shown that a single VEGF allele is insufficient to establish a proper vascular network and 
knockout mice die early in embryogenesis.22 Besides its pro-angiogenic activity VEGF 
increases vascular permeability and is required for the maintenance of  a differentiated 
phenotype of  ECs and especially for the establishment and maintenance of  endothelial 
fenestrae.23-25 More recent studies have shown that autocrine VEGF signalling is a 
prerequisite for EC survival.26 Genetic deletion of  VEGF in ECs without interruption 
of  the paracrine VEGF-signalling pathway, leads to progressive EC degeneration and 
sudden death in transgenic mice.26 Finally, VEGF-signalling has shown to be essential 
for the maintenance of  the glomerular filtration barrier.27
exogenous inHibitors oF tHe VegF signalling 
patHWay 
Three approaches have been developed to inhibit the VEGF-signalling pathway (Figure 
1).2 Firstly, bevacizumab (Avastin, Genentech, South San Francisco, CA, USA) is a 
humanized monoclonal antibody that selectively binds VEGF. This compound has been 
approved for systemic use in various forms of  cancer.17, 28 In addition, bevazicumab is 
applied in ocular diseases.29, 30 Secondly, RTKIs, of  which sunitinib (SU011248, Sutent, 
Pfizer Inc., New York, NY, USA), sorafenib (Bay 43-9006, Nexavar, Bayer Pharma AG, 
Berlin, Germany) and pazopanib (Votrient, ClaxoSmithKline, United Kingdom) have 
been FDA-approved for treatment of  various cancers, block the intracellular domain 
of  the tyrosine kinase receptors.31, 32 These agents have a low molecular size and can be 
taken orally. The RTKIs typically target a number of  tyrosine kinases.18 Thirdly, VEGF-
trap (Aflibercept, Eylea, Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA) is a 
soluble receptor that binds to VEGF and therefore shares close similarity to sFlt-1. It 
has been approved for the intra-ocular treatment of  age-related macular degeneration.33
Because under physiological conditions at least 99% of  ECs is quiescent, adverse 
effects during anti-angiogenesis treatment were expected to be minimal. However, 
in line with knockout experiments in mice showing that VEGF is essential for EC 
survival.26 and maintenance of  glomerular filtration barrier function.9, 27, inhibition of  
VEGF is associated with considerable cardiovascular and non-cardiovascular toxicity, 
including hypertension, left ventricular dysfunction, cardiac ischemia, myocardial 
infarction, proteinuria, renal function impairment, thrombosis, cerebral and intestinal 
haemorrhage, thyroid dysfunction and skin manifestations.1, 34, 35
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Figure 1. overview of the VegF family, VegF receptors and possibilities of interference. plgF, placental 
growth factor; VegF, vascular endothelial growth factor; VegFr, vascular endothelial growth factor receptor
incidence, time course and seVerity oF 
Hypertension
Blood pressure (BP) rises in virtually every patient treated with a VEGF inhibitor. The 
overall incidence of  hypertension induced by bevacizumab and RTKIs ranges from 
9% to 67%, whereas more severe hypertension (Grades 3, 4) has been reported in 
3-18% of  patients treated with these agents.3 Compared to normotensive subjects, 
patients with a history of  hypertension appear to be more at risk for the development 
of  severe hypertension during angiogenesis inhibition.36 According to the Common 
Toxicity Criteria for Adverse Events, hypertension in clinical trials is diagnosed when 
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BP is higher than 140/90 mmHg or diastolic BP (DBP) has increased by more than 20 
mmHg (Table 1). These threshold values are higher than those used in guidelines of  
hypertension societies.1, 37 According to the criteria of  these guidelines the incidence 
of  systolic hypertension in previously normotensive subjects was around 80% at the 
end of  the second cycle of  sunitinib.38 The incidence of  hypertension appears to 
be dose-related as has been shown for bevacizumab, and can increase to over 90% 
when bevacizumab and sunitinib are combined.1, 3 In sporadic cases, hypertension is 
complicated by the posterior reversible encephalopathy syndrome.39 Some clinical and 
experimental studies have investigated the time course of  the rise in BP after starting 
anti-angiogenic therapy.11, 38, 40-43 From these studies it appears that the rise in BP can 
develop within hours to days after treatment initiation.11, 41-43 Although hypertension has 
initially been considered to be a toxic effect of  anti-angiogenic therapy, evidence has 
accumulated that the development of  hypertension is predictive for a favourable anti-
tumor response and improved survival.38, 44-49  A meta-analysis concerning patients with 
renal cancer treated with sunitinib has shown that the progression-free survival was 12.5 
months in patients who developed hypertension compared to 2.5 months in patients 
who did not. For overall survival these values were respectively 30.9 and 7.2 months.38, 
48, 49 These findings support the view that identical mechanisms may underlie the anti-
tumor response and the development of  hypertension.50 Although prospective studies 
are needed to confirm the association between the development of  hypertension and 
the anti-tumor response during anti-angiogenic therapy, it has already been suggested 
that dose-titration with the objective to increase BP has the potential to result in a better 
anti-tumor effect and hence to improve clinical outcome.38, 51
incidence and seVerity oF proteinuria 
The incidence of  proteinuria associated with angiogenesis inhibition appears to be 
lower than that of  hypertension and its severity may vary from <1 gram/day (Grade 
1) (Table 1) to nephrotic range proteinuria.5, 52 In a meta-analysis involving 1850 
patients with different forms of  cancer the relative risks to develop proteinuria and 
hypertension were respectively 1.4 and 3.0 for a low and 2.2 and 7.5 for a high dose of  
bevacizumab.7 In a more recent meta-analysis involving 12.268 patients with various 
cancers the incidence of  all grades of  proteinuria was 13.3%, and of  Grade 3 or 4 
proteinuria (proteinuria >3.5 g/24h) 2.2%.53 Compared to chemotherapy alone, the 
relative risk after addition of  bevacizumab was 4.8 for high grade proteinuria and 7.8 for 
nephrotic syndrome range proteinuria. As observed for hypertension higher doses of  
bevacizumab were associated with a greater risk of  proteinuria and regarding to the type 
of  malignancy renal cell carcinoma was associated with the highest risk.53 Information 
about the incidence and severity of  proteinuria with the RTKIs sunitinib and sorafenib 
is limited to case reports.54-56 In an open label phase II study of  the RTKI cediranib, 
(AZD2171) involving 46 patients with ovarian cancer, 14 patients (30%) developed 
proteinuria (7 Grade 1 and 7 Grade 2).57 In 7 of  14 women, proteinuria developed 
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within 2 weeks after initiation of  treatment. As observed for bevacizumab, the risk to 
develop proteinuria was dose-related. In this study all patients who developed Grade 2 
proteinuria also developed hypertension, but of  the 20 women who developed Grade 
3 hypertension only 7 developed proteinuria, indicating that these two toxicities are not 
superimposable. Similar observations have been made for bevacizumab.58
Table 1. common terminology criteria for hypertension and proteinuria used in cancer trials
Renal biopsies performed in patients who developed severe proteinuria during 
angiogenesis inhibition have revealed different findings with thrombotic 
microangiopathy as the most commonly reported lesion.59-62 In animals the glomerular 
lesion associated with anti-VEGF therapy is very similar to glomerular endotheliosis 
seen in preeclampsia.9, 27, 41, 63-66 Glomerular endotheliosis is characterized by marked 
swelling of  glomerular ECs and effacement of  the podocyte food processes. It might 
be hypothesized that endotheliosis by obliterating the glomerular capillary tufts and 
changing the EC phenotype from an anti- to a prothrombotic state, precedes the 
development of  thrombotic microangiopathy. 
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mecHanism oF Hypertension 
Impairment of NO-signalling pathway
VEGF increases the expression of  endothelial nitric oxide synthase (eNOS) and activates 
its activity through phosphorylation.1, 20, 67-69 This phosphorylation occurs downstream 
of  the VEGFR-2 and is mediated by the calcium-dependent phospholipase C/
phosphoinoside-3-kinase and the calcium-independent phosphatidylinositol 3-kinase/
Akt pathways.1, 70 As eNOS is both upregulated and activated by VEGF, a decrease in 
NO bioavailability during angiogenesis inhibition, contributing to the vasoconstriction 
and rise in BP, is likely to occur. Meanwhile, clinical and experimental studies have been 
performed to explore whether VEGF inhibition is accompanied by a decrease in NO 
production and/or a decrease in the NO-mediated vasodilator tone.44, 71 In a cross-
sectional study in renal cell carcinoma patients, the excretion of  urinary NO metabolites 
in patients with and without anti-angiogenic treatment was compared. Compared 
to controls the excretion of  NO metabolites was identical in patients treated with 
bevacizumab but on average almost reduced by 50% in patients on RTKIs (0.36 vs 0.62 
µmol per mg creatinine).44 Urinary prostaglandin metabolites did not differ between 
the patients with and without anti-angiogenic therapy, likely excluding that prostacyclin 
production inhibition is involved in the BP rise with this treatment. In another study, 
plasma nitrate/nitrite levels were measured before and 6 weeks after treatment with the 
RTKI vandetanib in 17 breast cancer patients.71 Compared to baseline levels plasma 
nitrate/nitrite levels modestly decreased, whereas BP had on average increased by 
13 mmHg. In this study flow-mediated dilatation (FMD) of  the brachial artery as a 
marker of  NO-dependent vasodilation was also measured. FMD did not change (12.0% 
before and 13.8% after vandetanib). FMD before and during treatment with the RTKI 
telatinib has been investigated by Steeghs et al.72 In 18 patients with advanced solid 
tumors, FMD after 5 weeks administration of  the RTKI telatinib decreased from 
6.0% to 3.9% (decrease of  35%), but nitroglycerine-induced brachial artery dilatation 
also decreased from 17.0% to 11.9% (decrease of  30%), indicating a diminished 
response of  vascular smooth cells (VSMCs) to NO rather than a selective decrease 
in NO bioavailability.72 In an ex vivo study, applying the Langendorff  model to assess 
the coronary microcirculation, endothelium-dependent and endothelium-independent 
vasodilatory responses to respectively bradykinin and sodium nitroprusside were both 
impaired.11 Remarkably, in this model we also observed a diminished response to the 
vasoconstrictor angiotensin II, suggesting generalized VSMC function impairment, at 
least in the coronary microvascular circulation, during sunitinib administration.11 Finally, 
in a study performed in chronically instrumented awake swine exposed to sunitinib for 
7 days, we found that acute BP rise to the NOS inhibitor Ng-nitro-L-arginine after 7 
days of  sunitinib administration was increased as compared to the rise without sunitinib 
(32 mmHg versus 24 mmHg, P<0.05), suggesting an increase rather than a decrease in 
NO-mediated vasodilator tone during sunitinib exposure.73
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Taken together, the studies so far reported with regard to the effect of  angiogenesis 
inhibition on the NO system are conflicting. The reason for these discrepant findings 
is not clear. Apparently the endothelial dysfunction and/or activation associated with 
exogenous VEGF inhibition may or may not be accompanied by a decrease in NO 
bioavailability or its responsiveness.
Rarefaction
VEGF acts as a survival signal to ECs, and in cancer xenograft models EC loss within 
tumors is observed within days after initiation of  anti-angiogenic therapy. Consequently, 
rarefaction, i.e. the presence of  a diminished number of  microvessels, has frequently 
been proposed as a mechanism to explain the development of  hypertension during anti-
angiogenic therapy.4, 26, 74 Clinical evidence that rarefaction occurs during anti-angiogenic 
therapy is limited to some small studies.72, 75-77 Using intravital video-microscopy 
Mourad et al. found a small decrease in dermal capillary density at the dorsum of  the 
fingers from 83 to 75 per mm2 in 18 patients treated with bevacizumab for 6 months.76 
In another study, using side dark field video-microscopy, a decrease in oral mucosal 
capillary density from 20.8 capillaries per image at baseline to 16.7 capillaries per image 
after 5 weeks treatment with the RTKI telatinib has been reported in 7 patients.72 In 
a study in 16 patients with metastatic renal cell carcinoma, nailfold capillary density 
decreased from 50 per mm2 at baseline to 43 per mm2 during sunitinib treatment.77 After 
venous congestion, capillary density decreased from 69 to 65 per mm2.77 These studies 
indicate that rarefaction develops during anti-angiogenic therapy, but the magnitude 
rarefaction is limited. Moreover, it is unknown to what extent cutaneous rarefaction 
reflects rarefaction elsewhere in the body. For instance, in rats exposed to sunitinib 
for 7 days resulting in an increase in mean arterial pressure of  30 mmHg, we found no 
evidence for rarefaction in the myocardium (unpublished observation). 
Although rarefaction occurs with angiogenesis inhibitors, its  role in the development 
or maintenance of  hypertension remains questionable.78 First of  all the rise in BP can 
occur within one day after initiation of  anti-angiogenic therapy and it is unlikely that 
rarefaction at that time is already present.41, 43, 73 Secondly, discontinuation of  anti-
angiogenic therapy is associated with a rapid normalisation of  the increased BP. Thirdly, 
a mathematical model based on the hamster cheek pouch microcirculation indicates 
that 42% rarefaction of  fourth order arterioles is necessary to increase resistance in 
that vascular bed by 5%.79 This indicates that a considerable amount of  rarefaction is 
required to induce an increase in vascular resistance and hence in BP, assuming that 
cardiac output remains unchanged. It is unlikely that such a rarefaction decrease ever 
occurs during anti-angiogenic therapy. Finally, the rarefaction observed in patients with 
untreated hypertension has been reported to disappear upon BP normalization with 
antihypertensive treatment.80 Thus the observed rarefaction might be consequence 
rather than cause of  the hypertension.78
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Activation of the endothelin-signalling pathway 
Endothelin-1 (ET-1) is the predominant member of  the endothelin family and the 
most potent vasoconstrictor yet identified. ET-1 is secreted from endothelin secretory 
granules, also known as Weibel-Palade bodies.81 Exocytosis of  ET-1 from these bodies 
occurs in response to hypothermia, mechanical stress and agonists like histamine 
and thrombin.82 A second pathway of  ET-1 release is constitutive. ET-1 mediates 
vasoconstriction and proliferation by interacting with G-protein coupled membrane-
bound ETA and ETB receptors on VSMCs. The ETB receptor is also expressed on 
ECs. Activation of  the ETB receptor on ECs induces eNOS-mediated NO synthesis 
and stimulates the production of  prostacyclin.83 In addition, the ETB receptor mediates 
ET-1 clearance. ET-1 synthesized by ECs is released toward the basolateral side of  
these cells and ET-1 is considered to act primarily as a paracrine/autocrine peptide.84 
Besides exerting vasoconstriction, ET-1 is also involved in cell growth and proliferation 
through activation of  the mitogen-activated protein-kinase (MAPK) pathway.85
The first clinical evidence for the involvement of  an activated endothelin-pathway in 
RTKI-induced hypertension stems from a study with sunitinib from our group.11 In 
patients with renal cancer and gastrointestinal stromal cancer, administration of  sunitinib 
for 4 and 10 weeks was associated with a doubling of  plasma ET-1 concentration.11 
Furthermore, in a study in rats we found that administration of  sunitinib for 7 days was 
also associated with a 3- to 4-fold increase in serum ET-1 concentration and in urinary 
ET-1 excretion and returning to pre-sunitinib values after its discontinuation.41 Proof  
that ET-1 is involved in the rise in BP induced by angiogenesis inhibition has been 
provided by pharmacological studies in rats and swine.41, 73, 86 In telemetry-instrumented 
rats the rise in BP induced by the experimental RTKI ABT-869 completely reversed 
with co-administration of  the ETA-receptor blocker atrasentan.
86, whereas the sunitinib-
induced rise in BP was largely prevented by the mixed ETA/B receptor antagonist 
macitentan.41 Furthermore, in chronically instrumented awake swine, the sunitinib-
induced rise in BP and systemic vascular resistance could be completely reversed to 
pre-sunitinib values with the mixed ETA/B receptor antagonist tezosentan, while this 
compound did not lower BP under baseline conditions.73
Interestingly, in preeclampsia, increased circulating levels of  ET-1 (1.5 to 2-fold) 
compared to normal pregnancies have repeatedly been reported.87-91 Since treatment 
with endothelin receptor blockers is not allowed in preeclamptic women, insight into 
a pathophysiological role of  the endothelin pathway in preeclampsia is restricted to 
experimental studies. Murphy et al. showed that infusion of  sFlt-1 in pregnant rats 
for 6 days starting on the 13th day of  gestation resulting in a preeclamptic phenotype 
was associated with a 3-fold increase in preproET-1 expression in the renal cortex.92 
In addition, these authors demonstrated that the sFlt-1-induced rise in BP could be 
completely abolished by the ETA-receptor antagonist ABT 627. This study supports 
the hypothesis that ET-1, via activation of  ETA receptors, mediates hypertension in 
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response to excess sFlt-1 during pregnancy. 
Mechanism of activation of the endothelin-signalling pathway
The observation that with both exogenous and endogenous VEGF inhibition the ET-1 
pathway is activated is difficult to reconcile with findings showing that incubation of  
bovine aortic ECs with VEFG is associated with an enhanced preproET-1 mRNA 
expression and ET-1 production.93 It is therefore possible that activation of  the ET-1 
pathway observed with anti-angiogenic therapy and in pregnancy is a consequence as 
well as a reflection of  EC activation or dysfunction and not as a direct effect of  VEGF 
inhibition.94
Already in 1990, Boulanger and Lüscher showed that inhibition of  NO with L-NMMA 
potentiated the release of  ET-1 from cultured ECs.95 This potentiation was inhibited 
by the protein synthesis inhibitor cycloheximide, suggesting that de novo synthesis of  
ET-1 is involved. In eNOS deficient mice modest elevations of  circulating ET-1 have 
been reported.96 More recently, Weng et al. demonstrated that very low concentrations 
of  NO suppressed the release of  ET-1 from human umbilical vein ECs (HUVECs), in 
parallel with a decreased expression of  preproET-1 mRNA.97 Additional experiments 
showed that the NO-mediated suppression of  ET-1 release from ECs is mediated by 
cGMP.98 Apart from the observation that a decrease in vascular NO availability can result 
in increased ET-1 levels, there is also compelling evidence that the vasoconstriction 
induced by NOS blockade with L-arginine analogues is largely due to enhanced ET-1 
signalling.99-101 These studies indicate that a loss of  EC-derived NO production results 
in increased ET-1 signalling, which because of  the predominant abluminal secretion of  
ET-1 may or may not be reflected by elevated circulating ET-1 levels. 
Salt sensitivity
Long-term BP control is governed by the kidneys via the regulation of  extracellular 
fluid volume inherent to the regulation of  sodium balance.102 Obviously, renal injury 
occurring during anti-angiogenic therapy and in preeclampsia can contribute to the 
maintenance of  hypertension.36 Studies performed by Gu et al. have shown that subtle 
renal function impairment induced by a low dose of  the RTKI sunitinib is associated 
with salt-dependent hypertension due to a rightward shift and a reduced slope of  the 
pressure natriuresis curve.103 In in vitro experiments, these authors showed a decrease 
in eNOS expression in cultured glomerular ECs and proximal tubular cells in response 
to sunitinib. A decreased expression of  eNOS and neuronal NOS within the kidney 
and a rightward shift of  the pressure natriuresis curve have also been reported during 
infusion of  an antibody against the VEGF type 2 receptor.20, 104 Based on these findings 
and the knowledge that impaired renal NO production contributes to salt-sensitive 
hypertension, both by inducing renal vasoconstriction and impairing renal sodium 
excretion, it is reasonable to assume that apart from structural changes, functional renal 
changes contribute to the development and maintenance of  hypertension induced by 
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anti-angiogenic therapy.105-107 The observed activation of  the ET-1 pathway during anti-
angiogenic therapy may contribute to this process by enhancing renal vasoconstriction 
(Figure 2).108 
Figure 2. proposed scheme of etiology of angiogenesis inhibition-induced hypertension. of note, 
impairment of lymphangiogenesis only occurs with rtKis that target the VegF-3 receptor.
Recent studies have provided evidence that mononuclear phagocyte system (MPS) cells 
in the interstitial space regulate salt-dependent volume and BP by a VEGF-C-dependent 
buffering mechanism.109 In response to a high-salt diet, hyperosmotic sodium storage 
through binding of  sodium to proteoglycans occurs in the interstitial space. This storage 
stimulates MPS cells to produce VEGF-C via activation of  osmotic stress receptors. 
VEGF-C in turn stimulates lymphangiogenesis and increases eNOS expression through 
activation of  the respective VEGFR-2 and VEGFR-3. Inhibition of  this system in 
combination with high salt intake induces excess interstitial salt retention and in rats it 
is associated with the development of  hypertension.109, 110 Thus, apart from impairment 
of  renal function, blockade of  the MPS-VEGF-C-lymphangiogenesis pathway may 
also contribute to the maintenance of  hypertension during anti-angiogenic therapy with 
RTKIs, targeting the VEGFR-3 (Figure 2).
Oxidative stress
Oxidative stress may contribute to the development of  hypertension during anti-
angiogenic therapy in part through oxidation of  NO to NO-peroxynitrite.111 Our group 
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has explored the possibility whether the BP rise induced by sunitinib is accompanied 
by increased production of  markers of  oxidative stress and whether this BP rise can 
be prevented or reversed by antioxidants.41, 73 Urinary excretion of  thiobarbituric acid 
reactive substances (TBARS), as a measure of  lipid peroxidation, did not increase in 
rats exposed to sunitinib and co-administration of  the superoxide dismutase (SOD) 
mimetic Tempol only weakly attenuated the sunitinib-induced rise in BP. However, the 
sunitinib-induced proteinuria and increase in urinary ET-1 excretion were both markedly 
decreased. In a subsequent study performed in chronically-instrumented awake swine a 
mixture of  antioxidants to achieve extensive reactive oxygen species (ROS) scavenging 
reduced BP by 13 mmHg under control conditions. After one week exposure to 
sunitinib MAP had increased by 14 mmHg. Administration of  the antioxidant mixture 
at that time reduced MAP by only 5 mmHg.73 Thus, conform the observations in rats, 
also in swine no evidence was found for an increase in ROS-mediated vasoconstriction 
during angiogenesis inhibition with sunitinib. 
Other potential mechanisms
In an explorative clinical study, plasma levels of  catecholamines, renin, aldosterone, 
urotensin II and endothelin have been measured in 20 patients treated with sorafenib.40 
After a 3-week treatment period, systolic BP (SBP) had increased by 20 mmHg in 
60% of  patients. Despite this BP rise, plasma concentrations of  the above mentioned 
parameters remained unchanged. In contrast, in a clinical study with sunitinib, we found 
that BP rise was accompanied by a decrease in plasma renin concentration, whereas 
plasma aldosterone concentration remained unchanged.11 A decrease in renal renin 
expression has also been reported in mice exposed to an anti VEGFR-2 antibody.20 
Like the study with sorafenib, no effect on plasma catecholamines was observed in 
our clinical study with sunitinib.11 Based on the findings of  these studies, activation 
of  the renin-angiotensin system and/or the sympathetic nervous system as potential 
mechanisms for the development of  hypertension during antiangiogenic therapy can 
be excluded.
mecHanism oF proteinuria during 
angiogenesis inHibition
Although hypertension may enhance the severity of  proteinuria during anti-angiogenic 
therapy, experiments in mice with targeted disruption of  VEGF production in podocytes 
indicate that the development of  proteinuria is unrelated to the rise in BP.60 VEGF 
produced by podocytes binds VEGFR on glomerular ECs and is critical for inducing 
and maintaining endothelial fenestrations in capillaries.60, 112 Administration of  VEGF 
neutralizing antibodies to mice as well as injection of  adenovirus encoding for sFlt-1 in 
pregnant and non-pregnant rats have been reported to induce proteinuria.9, 63 Selective 
depletion of  VEGF in podocytes leads to proteinuria, accompanied by down-regulation 
of  the slit diaphragm-associated protein nephrin, a major constituent of  the glomerular 
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filtration barrier.60, 63, 113 Since podocytes lack VEGF receptors one may wonder how 
anti-angiogenic therapy reduces podocyte nephrin production. Recently, Collino et al. 
have provided evidence for involvement of  ET-1.114 These investigators found that 
conditioned medium obtained from glomerular ECs incubated with preeclamptic sera 
induces nephrin and synaptodin loss from podocytes, which could be prevented by 
ETA receptor antagonism.
114 Subsequent experiments showed that ET-1 triggered the 
nephrin shedding from cultured podocytes.  On the baseis of  these data not only loss 
of  the protective effect of  VEGF, but also the activation of  the ET-1 pathway observed 
during angiogenesis inhibition and preeclampsia may contribute to the development of  
proteinuria by causing nephrin loss from podocytes.
treatment oF VegF-inHibition induced 
Hypertension
As no randomised controlled trials concerning the optimal treatment of  angiogenesis-
inhibition-induced hypertension are available, no clear recommendation for a particular 
antihypertensive agent or class of  antihypertensive agents can be given at this stage.
Angiotensin II, via activation of  the MAP-kinase pathway, exerts mitogenic activity, 
it has been suggested therefore that agents like angiotensin-converting enzyme 
inhibitors (ACEis) or angiotensin II type 1 receptor antagonists (ARBs) may have 
additional beneficial effects when used in the treatment of  hypertension in patients 
with cancer.115, 116 Since hypertension induced by angiogenesis inhibition is associated 
with renin suppression.11, the antihypertensive efficacy of  ACEis or ARBs may be less 
pronounced than that of  diuretics or calcium channel blockers (CCBs).11, 20 However, 
if  the hypertension is accompanied by proteinuria, agents that interfere with the renin-
angiotensin system may be preferred because of  their renal-protective effect, which in 
part might be related to their ability to increase podocyte nephrin production as has 
been observed in diabetic nephropathy.117
The growing evidence that activation of  the endothelin-signalling pathway is involved in 
the hypertension induced by angiogenesis inhibition may favour the use of  endothelin 
receptor blockers in angiogenesis-inhibition-induced hypertension.11, 41, 86 Endothelin-
mediated ETA receptor stimulation has shown to be mitogenic in cancer cells through 
activation of  the MAPK pathway.118 Thus, besides lowering BP, endothelin receptor 
antagonism may exert anti-tumor effects. Meanwhile, pilot studies exploring the anti-
tumor effect of  ETA receptor blockade in prostate and renal cell carcinoma have been 
performed.119, 120
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conclusions 
In this review evidence is provided that activation of  the endothelin-signalling pathway 
is an important common final pathway for the development of  hypertension and 
proteinuria associated with anti-angiogenic therapy. The mechanism by which anti-
angiogenic therapy results in activation of  the endothelin-signalling pathway is not yet 
known. Because in EC cultures VEGF has shown to stimulate preproET-1 mRNA 
expression and ET-1 production.93, we suggest that activation of  the endothelin-
signalling pathway reflects the EC activation associated with anti-angiogenic treatment, 
but further studies are required to unravel the mechanism responsible for the increase 
in ET-1 production. 
Rarefaction is frequently mentioned as a BP-rising mechanism, but in our view plays not 
or at best a marginal role in the maintenance of  hypertension during anti-angiogenic 
therapy and considering the rapid onset of  the BP rise after treatment initiation no role 
at all in the development of  hypertension. Finally, the current knowledge that activation 
of  the endothelin-signalling pathway plays a role in the development of  hypertension 
during anti-angiogenic therapy may be incentive to design and to perform careful 
clinical studies to explore the efficacy and safety of  endothelin receptor blockers in 
these conditions.
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summary
Antiangiogenesis, targeting vascular endothelial growth factor (VEGF), has become a 
well-established treatment for patients with cancer. This treatment is associated with 
NO-suppression and a dose-dependent activation of  the endothelin-system, resulting 
in preeclampsia-like features, particularly hypertension and renal injury. Studies in 
eNOS-deficient mice and pharmacological treatment with endothelin receptor blockers 
and sildenafil indicate that an activated endothelin system, rather than NO suppression 
mediates the side effects of  angiogenesis inhibitors. Activation of  the endothelin-system 
is also observed in preeclamptic women, where it is related to the increased placental 
production of  sFlt-1, the soluble form of  the VEGF receptor-1. This receptors binds 
VEGF, thereby having the same consequences as antiangiogenic treatment with VEGF 
inhibitors. The side effects of  antiangiogenic treatment in patients with cancer may be 
dose-limiting, thereby impairing its therapeuticpotential. In addition, because endothelin 
exerts proangiogenic effects, investigation of  the effects of  endothelin receptor blockade 
in patients with cancer treated with angiogenesis inhibitors is warranted. 
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introduction
Angiogenesis, the formation of  new vessels from pre-existing vasculature, is critical to 
tumor growth. It is a highly regulated process with vascular endothelial growth factor 
(VEGF) as one of  the key stimulators.1 This has resulted in the development of  a large 
number of  agents to inhibit the actions of  VEGF as a new form of  cancer treatment.2 
Soon after their introduction in the clinic it appeared that this treatment was associated 
with a number of  adverse effects, particularly hypertension and renal injury, the latter 
reflected by proteinuria and renal function impairment. In the past several years 
evidence has accumulated that activation of  the endothelin (ET)-system in response to 
anti-VEGF treatment is a major mediator of  these side effects.3 
In this review we first provide information about VEGF and the different treatment 
approaches by which the actions of  VEGF can be inhibited. Subsequently, we discuss 
the frequency and time course of  hypertension and renal injury associated with anti-
VEGF treatment and the pivotal role of  ET-1 in this process. In addition, when 
appropriate, we discuss findings in preeclampsia (PE) in view of  the knowledge that PE 
also is an antiangiogenic condition with an activated ET-system.4
VegF and VegF-receptors 
The mammalian VEGF system belongs to a gene family that includes 5 different 
glycoproteins and the placental growth factors (PlGF) 1 to 4. Of  the VEGF family, 
VEGF-A, commonly referred to as VEGF, is best characterized.5 VEGF is produced and 
secreted by different cells, including endothelial cells (ECs), podocytes, macrophages, 
and fibroblasts. When produced and secreted by tumor cells, VEGF targets ECs to 
promote tumor angiogenesis. Hypoxia-inducible factors (HIF) 1α and 2α are a major 
up-regulators of  VEGF. VEGF binds three tyrosine kinase receptors: VEGF receptor 
1 (VEGFR-1 or fms-like tyrosine kinase 1 (sFlt-1) murine homologue), VEGF receptor 
2 (VEGFR-2 or kinase domain region (KDR) human homologue or Flk-1 murine 
homologue) and VEGFR-3 (also known as Flt-4). VEGFR-1 and VEGFR-2 are 
predominantly expressed on vascular ECs, whereas VEGFR-3 is mainly restricted to 
lymphatic ECs.6 VEGFRs contain an extracellular region, and a transmembrane and 
a cytoplasmatic bipartite kinase domain with tyrosine residues. Neurophilins 1 and 2 
serve as coreceptors for VEGF, increasing the affinity of  VEGF to the VEGFRs.6 
Although the affinity of  VEGF-A is greater for VEGFR-1 than VEGFR-2, most of  
the effects of  VEGF-A are mediated by the VEGFR-2.7 VEGFR-1 may therefore act 
mainly as a decoy receptor. The extracellular domain of  VEGFR-1, a splice variant of  
the gene encoding VEGFR-1, is also present at low concentrations in the circulation 
as a soluble protein (sFlt-1). Increased placental production of  sFlt-1, acting as an 
endogenous inhibitor of  VEGF and PlGF within the maternal circulation, has been 
recognized as an important mechanism in the pathogenesis of  PE.4 
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The VEGF-system exerts many activities both in physiology and pathophysiology. For 
the formation of  a well-functioning vascular network two VEGF alleles are required 
as has been demonstrated in partial knockout mice, whereas knockout of  both VEGF 
alleles is incompatible with life.8 In addition to its proangiogenic activity, VEGF 
increases vascular permeability and is required for the formation and maintenance 
of  endothelial fenestrae.9 Genetic deletion of  VEGF in ECs without interruption of  
paracrine VEGF-signaling pathways leads to progressive EC degeneration and sudden 
death in transgenic mice, indicating that autocrine VEGF-signaling is required for the 
maintenance of  the integrity of  ECs.10
VegF-signaling
The mentioned activities of  VEGF involve several signaling pathways, including 
activation of  the phosphoinositide 3-kinase (PI3K)-Akt/protein kinase B (PKB) - 
mammalian target of  rapamycin (mTOR) pathway.11 This pathway stimulates nitric 
oxide (NO) production via phosphorylation of  the three NO synthases (NOSs). The 
NOSs are ubiquitously expressed in malignant tumors and evidence is growing that 
NO has a function as a signaling molecule in the regulation of  tumor genesis.12 Other 
actions of  VEGF include the activation of  phospholipase C-g (PLC-g), protein kinase 
C (PKC), Raf-1, extracellular-signal-regulated protein kinase (ERK1/2), focal adhesion 
kinase (Fak) and mitogen-activated protein kinase (MAPK) pathways. Like the PI3K-
Akt/PKB-pathway, the PLC-g pathway plays a crucial role in the production of  NO 
by ECs. Additionally to the stimulation of  NO production, prostacyclin production by 
ECs is stimulated by VEGF.11
pHarmacological approacHes to inHibit tHe 
VegF patHWay
Already in 1971, Folkman proposed the inhibition of  angiogenesis as a therapeutic 
strategy against malignancies.13 Meanwhile a huge variety of  drugs targeting VEGF or 
its receptors has been developed for the treatment of  different forms of  cancer.2 These 
drugs can be divided in 1) monoclonal antibodies to VEGF, 2) monoclonal antibodies 
to the VEGFR-2 receptor, 3) agents that inhibit VEGF-receptors, usually denoted as 
receptor tyrosine kinase inhibitors (RTKIs) and 4) circulating VEGF receptors to trap 
VEGF. Bevacizumab (brand name Avastin) is an antibody that binds VEGF. It has 
been FDA-approved for various cancers, in addition, it is applied in age-related macular 
degeneration. RTKIs, of  which a considerable number has been FDA-approved for the 
treatment of  various cancers, block the phosphorylation of  these receptors by interacting 
with their adenosine-triphosphate (ATP) pocket.2 As a consequence RTKIs typically 
target a number of  tyrosine kinases. For instance sunitinib (brand name Sutent), aside 
from inhibiting the three VEGF receptors, also inhibits platelet derived growth factor-α 
and β, c-kit, fms-like tyrosine kinase-3 (Flt-3), colony stimulating factor receptor type 1 
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and the glial cell-line derived neutrophic factor receptor RET. Aflibercept (brand name 
Eylea) is a recombinant fusion protein consisting of  the VEGF-binding portions from 
the extracellular domains of  the human VEGFR-1 and -2, fused to the Fc portion 
of  human IgG1. It shares close similarity to sFlt-1, the extra-membranous part of  
the VEGF-1-receptor of  which the placental production and levels in the maternal 
circulation are markedly increased in PE. Main indications of  aflibercept are age and 
diabetes-related macula edema.
VegF inHibition: Hypertension and renal inJury
Since under physiological conditions ≥99% of  ECs is quiescent, it was anticipated 
that adverse effects during anti-angiogenesis treatment were minimal. However, in line 
with knockout studies in mice showing that VEGF is essential for EC survival.8 VEGF 
inhibition is associated with considerable cardiovascular and non-cardiovascular toxicity, 
including hypertension, left ventricular dysfunction, cardiac ischemia, myocardial 
infarction, renal injury, thyroid dysfunction, thrombosis, cerebral and intestinal 
hemorrhage, and skin manifestations. In virtually every patient exposed to anti-VEGF 
treatment blood pressure (BP) rises. The incidence of  hypertension induced by anti-
VEGF treatment ranges from 9% to 67%, whereas Grades 3 to 4 hypertension has been 
reported in 3-18% of  patients.11 The risk to develop severe hypertension is increased 
in patients with a history of  hypertension. The incidence of  hypertension is dose-
dependent and increases to over 90% when bevacizumab and sunitinib are combined.14 
The rise in BP is caused by a rise in systemic vascular resistance and can develop within 
hours to days after treatment initiation.3, 15 Of  interest, the development of  hypertension 
may be associated with improved survival. In patients with renal cancer treated with 
sunitinib the progression free survival was 12.5 versus 2.5 months and overall survival 
30.9 versus 7.2 months in patients who did or did not develop hypertension.16 These 
findings suggest that identical mechanisms underlie the anti-tumor response and the 
development of  hypertension. 
Proteinuria, sometimes causing nephrotic syndrome, is a key manifestation of  renal 
damage induced by anti-VEGF treatment.17 Kidney biopsies of  patients who developed 
renal injury typically show glomerular thrombotic microangiopathy.18 Likewise, kidneys 
of  rats exposed to a relatively high dose of  sunitinib for 1 week showed pronounced 
glomerular endotheliosis, a histopathological picture also present in PE, as well as 
intracapillary fibrin deposits.19
VegF inHibition and actiVation oF tHe et-axis 
ET-1 is the predominant member of  the endothelin family and the most potent 
vasoconstrictor identified. ET-1 is a 21-amino acid cyclic peptide mainly produced 
by ECs. ET-1 is constitutively produced by ECs at low quantities. In addition, upon 
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activation of  ECs, ET-1 is released from stores in the Weibel-Palade bodies. ET-1 
mediates vasoconstriction and proliferation by interacting with G-protein coupled 
membrane-bound ETA and ETB receptors on vascular smooth muscle cells. The ETB 
receptor is also expressed on ECs. Activation of  the ETB receptor on ECs induces eNOS-
mediated NO production and prostacyclin synthesis.11 In addition, the ETB receptor 
mediates ET-1 clearance. ET-1 produced by ECs is predominantly released towards 
the basolateral side of  these cells, acting primarily as a paracrine/autocrine peptide.20 
Besides exerting vasoconstriction, ET-1 is involved in cell growth and proliferation 
through activation of  the MAPK pathway.21 Because of  this property, ET-1 may be 
involved in tumor angiogenesis.22 In addition, ET-1 has been shown to induce oxidative 
stress within the placenta, which in turn may result in increased placental production of  
pro-inflammatory cytokines and sFlt-1.23 
The first clinical evidence for the involvement of  an activated ET-system during 
VEGF inhibition stems from a study with sunitinib by our group.3 In patients with 
either metastatic renal cell cancer or imatinib-resistant gastrointestinal stromal tumors, 
administration of  sunitinib was associated with a doubling of  the circulating ET-1 
concentration. In successive studies in rats we found that administration of  sunitinib for 
8 days was also associated with dose-dependent increase in serum ET-1 concentration, 
returning to pre-sunitinib values after its discontinuation.24 In our initial study, using a 
relatively high dose of  sunitinib, an increase in urinary ET-1 levels was also observed, 
but this could not be confirmed in a subsequent dose-finding study.19 In contrast to 
several experimental models of  PE, renal expression of  the genes encoding for ET-1 or 
endothelin-converting enzyme was not increased.19 In preeclamptic women, circulating 
ET-1 levels are increased compared to normotensive pregnant women. In a recent study 
we found that this rise in ET-1 closely relates to the elevated sFlt-1 levels.25 Collectively, 
these data indicate that the rise in ET-1 is not unique for sunitinib, but a common 
response to exogenous or endogenous factors targeting VEGF (Table 1).
is et-1 inVolVed in tHe blood pressure rise during 
antiangiogenic treatment?
To address this point, preclinical studies with both ETA selective and dual endothelin 
receptor blockers have been performed. In telemetry-instrumented rats exposed to 
the RTKI ABT-869, the rise in BP was abolished by an ETA receptor blocker.
26 and 
in sunitinib-exposed rats the BP rise was prevented by macitentan, a dual endothelin 
receptor blocker.27 Likewise, in instrumented awake swine, the sunitinib-induced rise 
in BP and systemic vascular resistance reversed to pre-sunitinib values by tezosentan.28 
In addition to its BP lowering effect, we also observed that the proteinuria induced by 
sunitinib could be largely prevented by the endothelin receptor blocker macitentan.27 
Importantly, this antiproteinuric effect of  macitentan appears to be independent of  
its BP lowering effect, because prevention of  the sunitinib-induced rise of  BP with 
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amlodipine did not decrease the proteinuria, in fact proteinuria tended to increase.27 
This finding concurs with studies indicating that ET-1 can induce damage to glomerular 
podocytes. For instance, a sub-pressor dose of  ET-1 administered to rats was found 
to increase glomerular permeability and inflammation as well as the excretion of  
the glomerular slit-diaphragm protein nephrin, effects that could be blocked by an 
ETA receptor antagonist.
29 More recently, Buelli et al. have shown activation of  the 
β-arrestin-1 signaling pathway by ET-1, causing transition of  podocytes from an epithelial 
to mesenchymal cell type.30 Thus besides glomerular VEGF depletion activation of  
the ET-system, as a consequence of  this VEGF depletion, likely contributes to the 
proteinuria. 
Table 1. Similarities of the endothelin system during anti-VEGF treatment and preeclampsia
MECHANISM OF ACTIVATION OF ET-AXIS
As displayed in Figure 1, several mechanisms may account for the increased ET-1 levels 
during antiangiogenesis. Using a bovine arterial EC culture line, Matsuura et al. showed 
that VEGF stimulates the expression of  preproET-1 mRNA as well as the secretion of  
ET-1.31 The VEGF-induced increased expression of  preproET-1 mRNA is mediated 
by the VEGFR-2. If  VEGF stimulates the production of  ET-1 by ECs, a decrease 
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in ET-1 levels during VEGF inhibition would be expected. Because of  the opposite 
observation it is more likely that activation of  ECs underlies the increase in ET-1 in 
response to VEGF deprivation. Indeed the glomerular endotheliosis associated with 
sunitinib administration and the increased glomerular EC expression of  intercellular 
adhesion molecule I are clear manifestations of  this EC activation.19 Since the VEGF-
signaling pathway stimulates NO production, anti-VEGF treatment is associated with 
a decrease in NO production.27 Given that NO decreases (stimulated) ET-1 release in 
aortic ECs, this decrease in NO may also contribute to the increased ET-1 production.32 
Of  note, a study in eNOS-deficient mice indicate that NO can mitigate the antiangiogenic-
induced preeclamptic-like phenotype.33 In these mice increased adenovirus-induced 
expression of  sFlt-1 resulted in a more severe phenotype than in control mice. This 
more severe phenotype is mainly ET-1-mediated as it could be reversed by an ETA 
receptor antagonist.33 In our own studies, concurrent administration of  sildenafil could 
not prevent the sunitinib rise BP in rats, supporting the view that NO deprivation is 
a much less important factor than activation of  the ET-1 system for the rise in BP 
induced by sunitinib.27 Moreover, in swine we observed that the rise in BP in response 
to Nώ-nitro-L-arginine was higher after than prior to sunitinib administration, even 
indicating an increase rather than a decrease in NO bioavailability during sunitinib in 
these animals.28 
Figure 1. putative mechanisms for the rise in et-1 during antiangiogenesis. ece denotes endothelin 
converting enzyme 
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perspectiVes and signiFicance
Antiangiogenesis targeting VEGF, irrespective of  its underlying mechanism, is associated 
with a rise in ET-1. This rise is most likely a consequence of  activation of  ECs and 
not a direct consequence of  VEGF deprivation. Preclinical studies with endothelin 
receptor blockers have clearly shown that activation of  the ET-axis plays a pathogenic 
role in the rise in BP as well the proteinuria associated with antiangiogenic treatment 
(Figure 2). Because adverse effects may be a reason to discontinue antiangiogenic 
treatment, thereby limiting their therapeutic potential, studies exploring the usefulness 
of  an endothelin receptor blocker in patients with cancer treated with these agents are 
warranted, especially so because ET-1 may exert proangiogenic effects and stimulates 
VEGF production.34 
Finally, it may be proposed that the magnitude of  the ET-1 rise during antiangiogenic 
treatment may be useful biomarker of  the efficacy of  treatment, unless loss of  the 
ETB clearance receptor occurs during anti-angiogenic treatment as has been reported in 
experimental PE.35 Although the rise in BP or the development of  hypertension has also 
been suggested as an efficacy parameter, the level of  BP is the result of  a large number 
of  stimulatory and counteracting factors, limiting its value as suitable biomarker.
Figure 2. role of et-1 in the development of hypertension and proteinuria during antiangiogenesis. 
note contributing role of VegF inhibition in development of kidney injury.
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aims oF tHe tHesis
Angiogenesis inhibition, by targeting VEGF or its receptors, has become an established 
treatment for various tumor types but is associated with adverse effects including 
hypertension, proteinuria and renal injury with activation of  the endothelin-1 system. 
Sunitinib is an orally active angiogenesis inhibitor that blocks VEGF receptors -1, -2 
and -3 and other tyrosine kinase receptors, including platelet derived growth factor 
(PDGF) and c-Kit receptors. VEGFR-1 and VEGFR-2 are predominantly expressed 
on vascular endothelial cells and peritubular capillary endothelial cells, whereas 
VEGFR-3, stimulated by VEGF-C, is restricted to lymphatic endothelial cells.  Since 
the occurrence of  side effects can be a reason to lower the sunitinib dose or even to 
discontinue  anticancer therapy, thereby compromising its potential efficacy, exploring 
therapeutic approaches to counteract these side effects is important, not only from an 
academic point of  view, but also from a clinical point of  view. 
To determine the most optimal way to prevent the sunitinib-induced adverse effects 
and to explore their interdependency, we investigate in Chapter 4 the therapeutic 
potential of  the dual endothelin receptor antagonist macitentan, the calcium channel 
blocker amlodipine, the angiotensin-converting enzyme inhibitor captopril and the 
phosphodiesterase type 5 inhibitor sildenafil. In Chapter 5 we test the dose-dependency 
of  these side effects, using a low, intermediate and high dose of  sunitinib, aiming to 
find a dose that, with regard to hemodynamic and renal side effects, is comparable 
to the dose applied in patients. With this approach, we also want to explore whether 
the proteinuria observed during antiangiogenic treatment occurs irrespective of  the 
presence of  glomerular histological changes. In Chapter 6 we aimed to explore the 
salt dependency of  angiogenesis inhibition-induced hypertension by exposing animals 
to a low and high salt diet in combination with sunitinib, using a dose of  sunitinib 
that does not impair renal function as based on the findings obtained in chapter 5. As 
a second aim, we explore whether sunitinib administration impairs the formation of  
lymph vessels within the skin, leading to skin sodium accumulation and salt-sensitivity 
of  blood pressure. 
In Chapter 7, we investigate the consequences of  a high salt diet in combination with 
sunitinib administration on renal histopathology. Especially, we want to explore whether 
in addition to glomerular lesions, the combination of  a high salt diet and sunitinib 
is accompanied by  tubulointerstitial injury and/or peritubular rarefaction. The renal 
injury during angiogenesis inhibition closely resembles the renal abnormalities observed 
in preeclampsia and associates with podocyte injury. It has been suggested that the 
appearance of  podocytes in urine, i.e., podocyturia, could be a sensitive marker for 
ongoing glomerular disease. In Chapter 8 we aimed to examine whether podocyturia 
occurs in patients treated with the VEGF inhibitor bevacizumab, using a recently 
developed qPCR technique, and whether the podocyturia does or does not relate to the 
degree of  proteinuria and cumulative dose of  bevacizumab.
aims

CHAPTER 4
treatment oF Hypertension and renal 
inJury induced by tHe angiogenesis 
inHibitor sunitinib: preclinical study
Stephanie Lankhorst, mariëtte H.W. Kappers, Joep H.m. van esch, Frank m.m. smedts, 
stefan sleijfer, ron H. mathijssen, Hans J. baelde, a.H. Jan danser, anton H. van den 
meiracker.
Hypertension 2014; 64(6):1282-1289
52
abstract
Common adverse effects of  angiogenesis inhibition are hypertension and renal injury. 
To determine the most optimal way to prevent these adverse effects and to explore 
their interdependency, the following drugs were investigated in unrestrained WKY rats 
exposed to the angiogenesis inhibitor sunitinib: the dual endothelin receptor (ET-R) 
antagonist macitentan, the calcium channel blocker (CCB) amlodipine, the angiotensin-
converting enzyme inhibitor (ACEi) captopril and the phosphodiesterase type 5 (PDE5) 
inhibitor sildenafil. Mean arterial pressure (MAP) was monitored telemetrically. After 8 
days, rats were sacrificed and blood samples and kidneys were collected. In addition, 
24-hour urine samples were collected. After sunitinib start, MAP increased rapidly by 
about 30 mmHg. Co-administration of  macitentan or amlodipine largely prevented 
this rise, whereas captopril or sildenafil did not. Macitentan, captopril and sildenafil 
diminished the sunitinib-induced proteinuria and endothelinuria and glomerular intra-
epithelial protein deposition, whereas amlodipine did not. Changes in proteinuria and 
endothelinuria were unrelated. We conclude that in our experimental model ET-R 
antagonism and calcium channel blockade are suitable to prevent angiogenesis inhibition 
induced-hypertension, while ET-R antagonism, ACEi and PDE5 inhibition can prevent 
angiogenesis-inhibition induced proteinuria. Moreover, the variable response of  
hypertension and renal injury to different antihypertensive agents, suggests that these 
side effects are, at least in part, unrelated.
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introduction
Angiogenesis, the formation of  new vessels from preexisting vasculature, is critical to 
solid tumor growth as well as to the development of  metastasis.1, 2 This process is 
regulated by numerous factors among which vascular endothelial growth factor (VEGF) 
plays a dominant role. Angiogenesis inhibition, by targeting VEGF or its receptors, has 
become an established treatment for various forms of  cancer but is featured by adverse 
effects including hypertension and renal injury.3 Hypertension has been reported in up 
to 36% of  patients treated with bevacizumab, a monoclonal antibody against VEGF, 
and in up to 60% of  patients treated with sunitinib, an orally active multitarget VEGF 
receptor tyrosine kinase inhibitor (RTKI).3 Renal toxicity, mainly proteinuria, has 
been reported in 41-63% of  patients treated with bevacizumab.4 In a recent phase 3 
randomized trial performed in patients with metastatic clear cell renal cell carcinoma, 
proteinuria occurred in 18% for patients randomized for pazopanib and in 14% for 
patients randomized for sunitinib.5 
The development of  hypertension and renal injury may compromise the use of  VEGF-
inhibition in patients with cancer who develop these side effects. Hence, exploration 
of  therapeutic approaches to counteract these side effects is important, but clinical 
studies comparing different agents to manage these particular side effects are lacking 
and unlikely will be performed in this category of  patients. In previous studies we have 
demonstrated that activation of  the endothelin-axis is involved in sunitinib-induced 
hypertension and renal injury.6 Moreover, we observed that concurrent administration 
of  the dual ETA/ETB-receptor blocker macitentan in a sunitinib hypertensive rat model 
could to a large extent prevent the sunitinib-induced rise of  blood pressure (BP) and 
proteinuria.7 Since endothelin receptor blockers are not approved for the treatment of  
systemic hypertension and renal injury we explored here to what extent angiotensin 
converting enzyme (ACE) inhibition, calcium channel blockade (CCB) as well as 
phosphodiesterase 5 (PDE5) inhibition were able to prevent hypertension and renal 
injury in our animal model. 
material and metHods
In vivo study
Male Wistar Kyoto rats (WKY, 280-300 gram) obtained from Charles River, were 
housed in individual cages and maintained on a 12-h light/dark cycle, having access 
to standard laboratory rat chow and water ad libitum. Intra-aortic BP recordings were 
performed by radiotelemetry (Data Sciences International (DSI)) and the sunitinib 
and vehicle solution were prepared and administered by oral gavage as described 
previously.6 Before and after implantation of  the telemetry transmitters (DSI 
TA11PA-C40) using 2% isoflurane anesthesia, rats received analgesic treatment using 
Temgesic subcutaneously (0.05 mg/kg; RB Pharmaceuticals Limited) for 2 days. At the 
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end of  each experiment, rats were euthanized with 60 mg/kg pentobarbital i.p. and 
blood was sampled for measurement of  serum ET-1, serum creatinine, VEGF and 
sunitinib levels, and kidneys were rapidly excised. Five experiments were performed. 
In the first experiment rats were randomly administered sunitinib (26.7 mg/kg.day of  
sunitinib-L-malate; Sutent, Pfizer, n=10) or vehicle (n=10) by oral gavage (0.5 mL) for 
8 days. The dose of  sunitinib was based on initial experimental studies, investigating its 
effectiveness in a rat breast cancer model.8 In the second experiment, rats (n=8) were 
orally administered the combination of  sunitinib and macitentan (ACT-064992, kindly 
provided by Actelion) 30 mg/kg.day, for 8 days.9 In the third experiment, rats were 
administered the combination of  sunitinib and amlodipine 3 mg/kg.day by oral gavage 
for 8 days.10, 11 In the fourth experiment, rats (n=9) were administered the combination 
of  sunitinib by oral gavage and captopril at 3 mg/kg.day or 12 mg/kg.day (C4042, 
Sigma-Aldrich) using osmotic minipumps (Alzet 2ml2) for 8 days.12, 13 In the final 
experiment, rats (n=6) were administered the combination of  sunitinib and sildenafil 
1.5 mg/kg.day (Revatio; Pfizer).14 In all experiments, 6 days before (baseline) and 6 days 
after administration of  the various agents, rats were housed in metabolic cages for 48 
hours with free access to food and water; the first day to acclimatize and the second day 
to collect 24-hour urine samples for the determination of  protein, ET-1, the nitric oxide 
(NO) metabolites (NO2+NO3 [NOx]) and cyclic GMP (cGMP). BP was not monitored 
when rats were housed in metabolic cages due to the absence of  telemetry receivers. 
Urine was collected on antibiotics (Antibiotic Antimycotic Solution, A5955, Sigma-
Aldrich) to prevent formation of  NO metabolites. Macitentan was dissolved in vehicle 
containing 0.5% methylcellulose aqueous solution and 0.05% Tween 80. Amlodipine 
besylate (Bioconnect, Huissen, The Netherlands) was suspended in 1% tragacanth gum 
solution. Sildenafil was suspended in 0.5% carboxymethylcellulose. All experiments 
were performed under the regulation and permission of  the Animal Care Committee 
of  the Erasmus MC.
Renal histology
Details of  the light and electron microscopy in this study are available in the Supplement.
Briefly, transversely sliced kidney sections were stained for for haematoxilin-eosine 
(HE) and periodic acid Schiff  (PAS). PAS-stained sections were blindly evaluated by 
a pathologist (F.M.M.S.) for the presence (1) or absence (0) of  endothelial cell and 
epithelial cell swelling in 50 glomeruli, as well as scored for the presence of  ischemia and 
intra-epithelial protein. For electron microscopy two glomeruli in each biopsy section 
were examined. The presence of  glomerular endotheliosis and podocyte morphology 
were registered. Both reflection contrast and electron micrographs were obtained from 
reprocessed paraffin embedded tissue.
Biochemical measurements
ET-1 and VEGF were assessed using a chemiluminescent ELISA QuantiGlo®, R&D 
Systems) and Quantikine Immunoassay (R&D Systems) respectively. Urine NOx 
chapter 4
55
concentration was determined by fluorimetric quantification of  nitrite content (Cayman 
Chemicals, Ann Arbor, MI).15 To investigate the systemic and  local effects of  sildenafil 
treatment, cGMP levels were determined in serum and urine respectively, using an ELISA 
kit (Enzo Life Sciences, Farmingdale, NY, USA). Serum creatinine and urinary protein 
concentrations (Cobas c502 and c702, CREP2 and TP2/TPUC3, Roche Diagnostics) 
were measured at the clinical chemical laboratory of  the Erasmus MC. Sunitinib levels 
were measured by a validated ultra-performance liquid chromatography/tandem mass 
spectrometry system.16
Statistical analysis
Data are presented as mean±SEM. Statistical analysis between groups was performed 
by unpaired t-testing or by repeated-measures ANOVA followed by Newman-Keuls or 
Dunnett’s multiple comparison testing. For correlation analysis the Pearson r correlation 
coefficient was used. GraphPad Prism version 5.0 was used for all statistical analysis.
results
In vivo study
Baseline MAP and heart rate (HR) were 99.1±4.1mmHg and 357.9±5.8 bpm. 
Administration of  sunitinib by oral gavage was associated with a rapid rise of  intra-
arterial BP (∆MAP 31.6±0.9mmHg), whereas BP remained unchanged during 
administration of  vehicle (Figure 1). The sunitinib-induced rise in BP was associated 
with a decrease in HR. Co-administration of  macitentan (∆MAP 12.3±1.5mmHg) or 
amlodipine (∆MAP 11.4±1.7mmHg) attenuated the sunitinib-induced rise in BP by 
73% (P<0.001) and 63% (P<0.001) respectively, whereas co-administration of  both 
dosages of  captopril and sildenafil had no BP-lowering effect. The sunitinib-induced 
decrease in HR was not prevented by each of  the four compounds, and even aggravated 
by the low dose of  captopril (Figure 1).
Sunitinib administration was associated with a 3-fold rise in serum creatinine 
concentration when compared with vehicle. This rise was not prevented by each 
of  the four compounds (Figure 2A). Proteinuria was below the limit of  detection 
during vehicle administration and increased to about 30 mg per day during sunitinib 
administration. The rise in proteinuria was attenuated by macitentan (P<0.01), both 
dosages of  captopril (P<0.001) and sildenafil (P<0.01). Conversely, proteinuria tended 
to increase further with amlodipine (Figure 2B).
Circulating ET-1 concentration was 0.61±0.08 pg/ml during vehicle administration and 
increased during sunitinib administration (P<0.01). Amlodipine, captopril and sildenafil 
did not influence this rise. Because of  a decrease in clearance caused by blockade of  
the ETB receptor, ET-1 rose further during co-administration of  macitentan (Figure 
2C). Sunitinib administration was also associated with a rise in 24-hour urinary ET-1 
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excretion (Figure 2D). This rise was prevented by macitentan, captopril, and sildenafil 
but not by amlodipine (Figure 2D). Proteinuria and endothelinuria did not correlate (r= 
0.17; P>0.05).
Figure 1. changes in mean arterial pressure (map) and heart rate (Hr) in response to administration of 
vehicle (n=6), sunitinib and vehicle (n=12), and co-administration of macitentan (n=8), amlodipine (n=8), 
captopril; 3 or 12 mg (n=7 each) or sildenafil (n=6). Left, Time course of changes in MAP and HR. Right, 
areas under the curve (auc). *p<0.05 vs sunitinib + vehicle; †p<0.05 vs vehicle. data of macitentan 
from Kappers et al.7
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Figure 2. serum creatinine (a), change in proteinuria (b), circulating et-1 levels (c) and change in urinary 
et-1 excretion (d) in rats after administration of vehicle (n=6), sunitinib and vehicle (n=16), and co-
administration of macitentan (n=4-6), amlodipine (n=8), captopril; 3 or 12 mg (n=5-9), or sildenafil (n=6) 
for 8 days. *p<0.05 vs sunitinib + vehicle; †p<0.05 vs vehicle 
data of macitentan from Kappers et al.7 
Urinary excretion of  NOx per 100 g BW was 2.2±0.2 μmol per day during vehicle 
administration (Figure 3). Sunitinib administration was associated with a decrease in 
urinary NOx excretion (P<0.01). This decrease was not affected by macitentan or 
amlodipine and weakly attenuated by captopril (Figure 3). Changes in NOx excretion and 
endothelinuria were not correlated (r=0.14; P>0.05). Urinary cGMP decreased during 
sunitinib administration from 4563±190 pmol/mL during vehicle to 1387±105 pmol/
mL per day (P<0.05). This decrease was prevented by concurrent administration of  
sildenafil. Circulating cGMP concentration was not affected by sunitinib administration 
nor by the combination of  sunitinib and sildenafil (data not shown). 
Mean serum concentration of  sunitinib was 376±87 ng/mL. This concentration 
increased during treatment with sildenafil and by both dosages of  captopril, to 
800±151, 679±17 and 1082±238 ng/mL, respectively (P<0.05), confirming that 
their renoprotective effects were not due to a suppression of  sunitinib bioavailability. 
Circulating VEGF increased from 4.9±2.3 pg/mL during vehicle to 947.8±45.1 pg/
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mL during sunitinib administration. This rise was unaffected by sildenafil and the low 
dose of  captopril (959±132 and 905±141 pg/mL), and attenuated by the high dose of  
captopril 689±67 pg/mL (P<0.05 vs sunitinib alone). Unfortunately, plasma to measure 
sunitinb and VEGF during treatment with amlodipine or macitentan was no longer 
available. 
Figure 3. change in nitric oxide metabolites (nox) excretion in urine of WKy rats after administration of 
vehicle (n=4), sunitinib (n=9), and co-administration of macitentan (n=7), amlodipine (n=8) or captopril; 
3 or 12 mg (n=7 each) for 8 days. *p<0.05 vs baseline, †p<0.05 vs sunitinib. data of macitentan from 
Kappers et al.7  bW indicates body weight.
Renal histology
Sunitinib administration was associated with a rise in kidney weight-to body weight ratio 
from 3.0±0.04 to 3.5±0.04 g/kg (P<0.001). This rise was not changed by any of  the 
four agents. 
Periodic acid Schiff-stained kidney sections showed marked glomerular changes, 
including intra-epithelial droplets and, epithelial and endothelial cell swelling with 
narrowing of  the capillary lumina after administration of  sunitinib (Table 1). Neither 
macitentan nor the low dose of  captopril reversed the sunitinib-induced glomerular 
ischemia or endothelial and epithelial cell swelling. Only a high dose of  captopril and 
sildenafil were more renoprotective. However, consistent with the decrease in proteinuria, 
glomerular intra-epithelial protein deposition diminished during co-administration of  
macitentan and captopril (Figure S1, Table 1). In rats co-administered sunitinib and 
amlodipine, glomerular ischemia and endothelial and epithelial cell swelling were more 
prominent compared to rats exposed to sunitinib alone, as was the glomerular intra-
epithelial protein deposition (Table 1). Reflection contrast and electron microscopy 
showed intra-epithelial resorption droplets and severe glomerular endotheliosis during 
administration of  sunitinib. This was partly prevented by macitentan, and reversed with 
a high dose of  captopril and sildenafil (Figure S2). 
chapter 4
59
Table 1. light microscopic evaluation of kidney sections obtained from rats exposed to sunitinib and 
coadministration of macitentan, amlodipine, captopril, and sildenafil for 8 days with controls
discussion
Administration of  the multi-target VEGF receptor blocker sunitinib is accompanied 
by a rise in BP, renal injury and proteinuria, activation of  the ET-1 axis and renin 
suppression.6, 7, 17 Previously, we found that the rise in BP and proteinuria could largely 
be prevented by the dual ETA/B receptor antagonist macitentan, indicating that activation 
of  the ET-1 axis is critical for the development of  these side effects. Here we explored 
whether alternative antihypertensive agents attenuate the occurrence of  these side 
effects and to what extent they are interrelated.
Co-administration of  amlodipine with sunitinib was associated with a marked attenuation 
of  the rise in BP, comparable to the degree observed with macitentan. However, renal 
injury could not be prevented while proteinuria even tended to increase. In contrast, co-
administration of  captopril and sildenafil was associated with a decrease in proteinuria 
and renal injury, but without effect on BP. These findings strongly suggest that renal 
toxicity is a BP-independent adverse effect of  short-term angiogenesis inhibition. 
Obviously, over more prolonged periods of  time hypertension may further aggravate the 
renal injury by angiogenesis inhibition, whereas vice versa, renal injury may contribute 
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to a further rise in BP. Histological examination of  the kidneys showed extensive 
glomerular ischemia in over 80% of  the glomeruli during sunitinib administration. 
These histological abnormalities were largely prevented by the high dose of  captopril 
and by sildenafil, but not by macitentan, the lower dose of  captopril or amlodipine 
(Table 1). Unexpectedly, these beneficial effects of  the high dose of  captopril and of  
sildenafil on renal histology did not reflect in an attenuation of  the sunitinib-induced 
rise in serum creatinine. Apparently serum creatinine concentration was not an accurate 
marker to reliably assess renal injury during the relatively short observation period in the 
present study. As an estimate of  glomerular filtration rate we also measured endogenous 
creatinine clearances, but these provided identical results as the measurements of  serum 
creatinine concentration (data not shown).
The beneficial effects of  sildenafil and high dose of  captopril on proteinuria occurred 
independently of  a BP-lowering effect. A BP-independent beneficial effect of  sildenafil 
on renal function has also been reported in DOCA-salt hypertensive rats.18 This 
nephroprotective effect of  sildenafil appears to be associated with anti-inflammatory, 
antifibrotic and antiapoptotic effects with down-regulation of  transforming growth 
factor-β1 expression. Furthermore, sildenafil attenuates diabetic nephropathy in 
non-insulin-dependent Otsuka Long-Evans Tokushima fatty rats.19 ACE-inhibitors 
are well-known for their antiproteinuric effect beyond BP reduction. In part this is 
related to a decrease in glomerular filtration pressure by preferential dilatation of  
efferent glomerular arterioles. In addition ACE inhibitors, like captopril, increase NO 
bioavailability by decreasing the breakdown of  bradykinine. Finally, ACE inhibition can 
induce podocyte repopulation and thereby attenuating glomerular injury and proteinuria 
induced by anti-VEGF treatment.20 The protective effect on renal injury was only seen 
with the high dose of  captopril. This is in line with recommendations in hypertensive 
patients with proteinuria, in whom maximal ACE inhibition is advocated for optimal 
renal protection.21
In rats exposed to the RTKI sorafenib (20 mg/kg per day) for 4 weeks, a rise in systolic 
BP of  almost 60 mmHg and marked albuminuria has been reported.12 In this study 
concurrent administration captopril was associated with a marked reduction in both 
albuminuria and renal histological abnormalities and also with a 50% reduction of  
the rise in BP. Captopril in that study was given orally in a daily oral dose of  40 mg. 
Captopril in our study (3 and 12 mg/kg per day) was given subcutaneously by means of  
osmotic minipumps. The doses selected were based on previous studies performed in 
our lab in spontaneously hypertensive rats.13 These studies showed that subcutaneously 
administered captopril at doses of  3 and 6 mg/kg per day for 1 week lowered mean 
arterial pressure (MAP) by respectively 14 and 28 mmHg. In addition, this BP reduction 
was associated with an about 10-fold rise in renin.13 This rise is of  comparable 
magnitude as that observed in young hypertensive patients exposed to ACE-inhibition 
or a change from a very high to a very low salt intake. Based on these findings we 
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are confident that the maximal dose of  captopril of  12 mg/kg per day was sufficient 
to induce pronounced blockade of  the RAS with beneficial renal, but not with BP-
lowering effects. Interestingly, Curwen et al. observed in rats exposed to a relatively low 
dose of  the RTKI cediranib, resulting in a BP rise of  about 10 mmHg, that captopril 
(30 mg/kg orally) could completely reverse this rise in BP. In contrast, the same dose of  
captopril was without any effect in rats exposed to a relatively high dose of  cediranib, 
resulting in a 40 mmHg BP rise.22 These findings indicate that other factors than RAS 
activation are instrumental for the development of  hypertension when higher doses 
of  a RTKI are administered and that the RAS is likely down-regulated in an attempt to 
attenuate the development of  severe hypertension. This probably also was the case in 
our rat model, where sunitinib administration caused a rise in MAP of  30 mmHg. This 
rise in BP related to the relatively high dose of  sunitinib (resulting in plasma levels that 
were 5-10 times higher than those in humans) was considerably larger than observed in 
our clinical study.6 In that study MAP rose by 12 mmHg, but interestingly, this moderate 
rise in BP was also already associated with >60% renin suppression, indeed suggesting 
that the BP elevation in response to RTKIs treatment in humans is not RAS-dependent 
and, consequently, less responsive to anti-RAS agents. Renin suppression during anti-
angiogenic treatment might also be caused by an increase in aldosterone production. 
Only a limited number of  studies has looked at the effect of  RTKIs on aldosterone.6, 
23, 24 In these studies no increase in circulating aldosterone levels or urinary aldosterone 
excretion has been observed. Recently, VEGF-stimulated aldosterone release has been 
reported.25 Therefore reduced rather than increased aldosterone production during 
anti-angiogenic treatment is to be expected. 
As reflected by the decrease in urinary NO metabolites and cGMP, anti-angiogenic 
treatment is associated with a decrease in the activity of  the NO system.26, 27 Using 
the human forearm model it has recently been reported that intra-arterial infusion 
of  bevacizumab inhibits the local vasodilator response to acetylcholine, but not to 
sodium nitroprusside, implying impairment of  endothelium-dependent vasodilation.28 
This decreased activity of  the NO system can contribute to the development of  
hypertension as well as renal injury.7, 24 There are sporadic reports that an exogenous 
NO donor can lower BP in patients who develop hypertension during angiogenesis 
inhibition.29 In the current study, the PDE5 inhibitor sildenafil was used to increase 
NO responsiveness. With this agent the sunitinib-induced reduction in urinary cGMP 
excretion was completely prevented, but this was not associated with any BP-lowering 
effect. Sildenafil was used in a daily dose of  1.5 mg/kg. This dose is equivalent to a 
daily dose of  100 mg in patients and has been shown to prevent the rise in systolic 
BP from 129±8 mmHg in control rats to 183±6 mmHg in rats exposed to the NOS 
inhibitor L-NAME.14 The rise in BP induced by sunitinib could largely be prevented 
by the calcium channel blocker amlodipine, which is in line with an experimental study, 
demonstrating that nifedipine could completely reverse the rise in BP induced by the 
RTKI cediranib.22 
treatment of hyper tension and renal injur y 
62
As reported previously by our group, angiogenesis inhibition by sunitinib is associated 
with activation of  the endothelin system.7 During sunitinib administration, both the 
circulating ET-1 concentration and the 24h urinary excretion of  ET-1 were increased. 
ET-1 within the kidney is produced by glomerular endothelial, mesangial cells as well 
as renal tubular cells, and urinary ET-1 excretion is considered to reflect the degree 
of  renal ET-1 production.30, 31 Recently, it has been shown that ET-1 produced by 
endothelial cells induces nephrin shedding from podocytes, which could be prevented 
by ETA receptor antagonism.
32 Since mutations in the gene encoding for nephrin are 
associated with severe forms of  the nephrotic syndrome, it has been speculated that 
increased glomerular endothelial cell production of  ET-1 is one of  the mediators of  
proteinuria.33 Based on these data not only loss of  the protective effect of  VEGF on 
glomerular endothelial cells, but also the activation of  the ET-1 system observed during 
angiogenesis inhibition may contribute to the development of  proteinuria. To obtain 
further insight in this mechanism we explored whether endothelinuria and proteinuria 
were correlated. This seemed not to be the case. 
Randomised controlled trials concerning the optimal treatment of  angiogenesis-
inhibition-induced hypertension are lacking, therefore no clear recommendation for 
a particular antihypertensive agent or class of  antihypertensive agents can be given. 
Based on the present observations together with other experimental and clinical studies, 
showing that the hypertension induced by sunitinib is associated with renin suppression, 
dihydropyridine calcium channel blockers rather than anti-RAS agents are probably 
more effective for the treatment of  hypertension.34 Given their beneficial effects on the 
occurrence of  proteinuria, an anti-RAS agent can be combined with a calcium channel 
blocker in case of  the development of  renal injury. In addition, it has been shown that 
an anti-RAS agent can enhance the effect of  sunitinib in a murine xenograft tumor 
model.35 Although NO-donors like nitrates or PDE5 inhibitors may also be beneficial, 
it has been suggested that these agents may potentially compromise the anti-angiogenic 
effect and therefore they can best be avoided.22 The knowledge that activation of  the 
endothelin-axis is involved in the hypertension induced by angiogenesis inhibition, may 
also favor the use of  endothelin receptor blockers in angiogenesis-inhibition-induced 
hypertension.6, 7, 36 ETA-receptor stimulation has been shown to be mitogenic in cancer 
cells through activation of  the MAPK pathway.37 Thus, besides lowering BP, endothelin 
receptor antagonism may exert anti-tumor effects.38, 39 However, due to adverse effects, 
single endothelin receptor blockers are currently not being marketed for the treatment 
of  systemic hypertension, but only for pulmonary hypertension.40 In addition, since 
macitentan is a strong inducer of  the CYP3A4 enzyme, while sunitinib is metabolized by 
this enzyme, this combination should be avoided because of  unwanted pharmacokinetic 
interaction. 
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perspectiVes
Anti-angiogenic treatment targeting the VEGF-VEGFR pathway is complicated by 
the development of  hypertension and renal injury. Occurrence of  these particular side 
effects may compromise anti-cancer treatment, but the most optimal way to treat these 
remains to identified. Given the lack of  large clinical studies, this study provides further 
insight into the mechanisms underlying sunitinib-induced hypertension and proteinuria 
as well as ways to counteract these adverse events.  Translation of  these findings to the 
clinic strongly suggests that dependent on the toxicity encountered, different classes 
of  antihypertensive agents should preferably be used, i.e. a calcium channel blocker 
in the case of  hypertension and a RAS blocker in the case of  renal injury. Of  interest, 
both captopril and sildenafil increased the steady-state sunitinib concentrations. The 
underlying pharmacokinetic interaction is currently unknown, but warrants further 
investigation in humans, not only because it may enhance the anti-cancer effectiveness 
of  sunitinib, but also its side-effect profile.  
noVelty and signiFicance
What is new? 
This is the first study that provides information about treatment of  hypertension and 
renal injury during anti-angiogenic treatment by comparing different antihypertensive 
agents. 
What is relevant? 
Our findings show that the effect of  different antihypertensives to counteract 
hypertension and renal injury is variable, suggesting that different pathogenetic pathways 
underlie these side effects and that they require a dedicated treatment approach. 
Summary  
In a rat model of  sunitinib-induced hypertension and renal injury we found evidence for 
beneficial antihypertensive and renoprotective effects with calcium channel blockade 
and ACE or phoshodiesterase inhibition respectively, thereby providing a rational 
basis for optimal treatment of  the reno-cardiovascular side effects associated with 
angiogenesis inhibition.
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supplement
expanded metHods
Light microscopy
The left kidney was rapidly excised from euthanized rats, decapsulated, weighed and 
sliced transversely into 2-mm thick sections. Slices were fixed in a 3.5-4% formaldehyde 
solution for light microscopic evaluation. After fixation in the formaldehyde solution, 
tissue was dehydrated and paraffin-embedded. Deparaffinized 2-μm thick sections 
were stained for haematoxilin-eosine (HE) and periodic acid Schiff  (PAS). PAS-
stained sections were blindly evaluated by a pathologist (F.M.M.S.) for the presence 
(score 1) or absence (score 0) of  endothelial cell and epithelial cell swelling. Glomerular 
ischemia was scored semiquantitatively and defined as the degree of  open glomerular 
capillaries, wrinkling of  the glomerular basement membrane and filling of  Bowmans 
space. Wide open glomerular capillaries filling Bowman’s space entirely corresponded 
with no ischemia. Partially open glomerular capillaries with mild wrinkling of  the 
glomerular basement membrane and Bowman’s glomerular space largely filled was 
classed as moderate ischemia. Totally collapsed glomeruli and extensive wrinkling 
of  the glomerular basement membrane and only partial filling of  Bowman’s space 
corresponded with severe ischemia. Furthermore, the presence of  glomerular intra-
epithelial protein deposition was evaluated using a semiquantative scale: 0 (no protein), 
1 (protein present in 1-50% of  the epithelial cells) and 2 (protein present in >50% of  
the epithelial cells). Fifty glomeruli per kidney section (PAS staining) were evaluated. 
All images were obtained using a Reichert microscope and Leica DFC420 camera (40x 
objective) and Leica LAS software.
Electron microscopy
Formalin fixed paraffin embedded renal tissue was reprocessed for reflection contrast 
microscopy and electron microscopy. In brief, 1mm3 tissue blocks were deparaffinized, 
rehydrated, and post fixed with 1.5% glutaraldehyde, followed by incubation in 1% 
osmium tetroxide (OsO4) in 0.1 M sodium cacodylate for 1 h. After each step of  the 
fixation, the fish were rinsed twice with 0.1 M sodium cacodylate and finally dehydrated 
in a series of  70%, 80%, 90% and 3× 100% ethanol, prior to immersion in a 1:1 
epon:propylene oxide solution for 1 h. The samples were washed afterwards with pure 
epon, embedded in pure epon LX112 and polymerized at 60 °C for 2 days. Sequential 
100 um sections were placed on glass slides for reflection contrast microscopy or on 
grids for electron microscopy. The preparations were examined under a Leitz Orthoplan 
microscope (Leitz, Wetzlar, Germany) equipped for epi-illumination, which was adapted 
for reflection contrast microscopy as described previously. The slides were examined 
under a 100× objective lens. A JEOL JEM-1011 electron microscope equipped with a 
MegaView III digital camera was used for ultra-structural analysis.
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Figure S1. Kidney sections from WKy rats administered vehicle (a), sunitinib (b), macitentan (c), 
amlopidine (D), captopril (E/F) or sildenafil (G), stained with PAS stain (magnification x500). After 
administration of sunitinib for 8 days marked glomerular changes could be observed, including intra-
epithelial droplets (arrowhead). consistent with the decrease in proteinuria, glomerular intra-epithelial 
protein deposition diminished during co-administration of macitentan, captopril and sildenafil.
Figure S2.  Reflection contrast and transmission electron micrographs of representative kidney sections 
from rats administered vehicle (A1; magnification x1500, A2; magnification x5000, A3; magnification 12000), 
sunitinib (B1; magnification x1500, B2; magnification x5000, B3; magnification x12000) or in combination 
with macitentan (C1; magnification x1500, C2; magnification x5000, C3; magnification x12000), amlodipine 
(D1; magnification x1500, D2; magnification x5000, D3; magnification x12000), low (E1; magnification 
x1500, E2; magnification x5000, E3; magnification x12000) and high dosage of captopril (F1; magnification 
x1500, F2; magnification x5000, F3; magnification x12000), or sildenafil (G1; magnification x1500, G2; 
magnification x5000, G3; magnification x12000). After sunitinib administration for 8 days intra-epithelial 
resorption droplets (white arrows) and glomerular endotheliosis (endothelial cell swelling; asterix) were 
observed. none of the abnormalities above could be observed in control kidney sections (a1-3) and they 
were partly prevented by macitentan, and reversed with a high dose of captopril and sildenafil. 
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GREATER SENSITIVITY OF BLOOD PRESSURE THAN 
RENAL TOXICITY TO TYROSINE-KINASE RECEPTOR 
INHIBITION WITH SUNITINIB
Stephanie Lankhorst, Hans J. Baelde, Mariëtte H.W. Kappers, Frank M.M. Smedts, 
Stefan Sleijfer, Ron H. Mathijssen, A.H. Jan Danser, Anton H. van den Meiracker.
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ABSTRACT
Hypertension and renal injury are off-target effects of  sunitinib, a tyrosine-kinase 
receptor inhibitor used for the treatment of  various tumor types. Importantly, these 
untoward effects are accompanied by activation of  the endothelin system. Here, we set 
up a study to explore the dose-dependency of  these side effects. Normotensive Wistar-
Kyoto rats were exposed to 3 different doses of  sunitinib or vehicle. After 8 days rats 
were sacrificed. Telemetrically measured blood pressure (BP) rose dose-dependently, 
from 13 to 30 mmHg. Proteinuria was present at all doses, but a rise in cystatin C occurred 
only at the intermediate and high dose. Compared to vehicle circulating endothelin-1 
increased dose-dependently, whereas 24-hour urinary endothelin excretion decreased. 
Light and electron microscopy revealed glomerular endotheliosis and ischemia with 
the intermediate and high doses of  sunitinib, but completely absent histological 
abnormalities with the low dose. Podocyte number per glomerular circumference did 
not change. Glomerular Nephrin, Neph1, podocin, and endothelin converting enzyme 
gene expression were downregulated in a dose-dependent manner. We conclude that the 
sunitinib-induced rise in BP requires lower doses than its induction of  renal function 
impairment and that functional changes in glomerular filtration barrier contribute to 
the occurrence of  proteinuria, given the lack of  histopathological changes with the low 
dose of  sunitinib.
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INTRODUCTION 
Neoangiogenesis, the formation of  vessels from preexisting vasculature, is critical to 
solid tumor growth as well as to metastasis. Vascular endothelial growth factor (VEGF) 
plays a dominant role in this process. Therefore angiogenesis inhibition, by targeting 
VEGF or its receptors, has become an established treatment for several tumor types.1 
Sunitinib is an orally active angiogenesis inhibitor that blocks the VEGF receptors -1, 
-2 and -3 and other tyrosine kinase receptors, including platelet derived growth factor 
(PDGF) and c-Kit receptors. Off-target effects of  sunitinib and other anti-angiogenic 
agents, sometimes necessitating discontinuation of  treatment, are hypertension, 
proteinuria and renal failure.2-4 
In the kidney, glomerular endotheliosis and thrombotic microangiopathy are the most 
frequently observed histological abnormalities seen during treatment with sunitinib.5, 6 
These abnormalities are comparable to those observed in preeclampsia likely due to the 
fact that both conditions share the same pathogenetic mechanism, i.e., disruption of  
the VEGF signalling pathway, which in preeclampsia is caused by increased placental 
production of  the soluble Fms-like tyrosine kinase 1 (sFlt-1).7
In previous clinical and experimental studies we observed that activation of  the 
endothelin system is involved in the rise in blood pressure (BP) during sunitinib 
treatment.3, 8, 9 Recent studies have shown that ET-1 induces podocyte injury mediated 
by activation of  the ETA receptor on podocytes.
10, 11 It may be hypothesized therefore 
that the renal injury occurring during anti-angiogenic treatment is mediated both by a 
direct effect related to interruption of  VEGF-signaling and by an indirect effect related 
to activation of  the ET-1-system. In our previous studies, we used a sunitinib dose of  
26.7 mg/kg.day by oral gavage. This high dose was associated with a rapid development 
of  severe hypertension, proteinuria and irreversible glomerular renal injury, making 
it difficult to infer to what extent the renal injury is BP-independent.12 Additionally, 
the extent of  sunitinib-mediated side-effects in this particular model at this dose is 
much more severe than seen in patients, rendering it questionable whether this dose 
adequately reflected the off-target effects of  sunitinib in clinical practice. Here, we 
tested the dose-dependency of  these side effects, aiming to find a sunitinib dose that, 
with regard to hemodynamic and renal side effects, including ET-1 elevation, better 
resembles the dose applied in patients. With this approach, we also wanted to unravel 
whether the proteinuria observed during anti-angiogenic treatment occurs irrespective 
of  the presence of  glomerular histological changes. 
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MATERIALS AND METHODS
Animal study
Normotensive, male Wistar Kyoto rats (WKY, 280-300 gram) obtained from Charles 
River, were housed in individual cages and maintained on a 12-h light/dark cycle, 
having access to standard laboratory rat chow and water ad libitum. Intra-aortic BP 
recordings were performed by radiotelemetry and sunitinib (SU11248; Sutent, Pfizer) 
and vehicle solution were prepared and administered by oral gavage as described 
previously.9 After implantation of  the telemetry transmitters, rats received analgesic 
treatment using Temgesic subcutaneously (0.05 mg/kg; RB Pharmaceuticals Limited) 
for 2 days. At the end of  each experiment, rats were euthanized with 60 mg/kg 
pentobarbital i.p. and blood was sampled for measurement of  circulating ET-1, 
cystatin C levels, VEGF and sunitinib levels, and kidneys were rapidly excised. Rats 
were randomly administered a low (7 mg/kg.day) or intermediate (14 mg/kg.day) dose 
of  sunitinib-L-malate (n=6 each), a high dose of  sunitinib-L-malate (26.7 mg/kg.day; 
n=14), or vehicle (n=8) by oral gavage (0.5 mL) for 8 days.  In all experiments, before 
(baseline) and after administration of  sunitinib, rats were housed in metabolic cages 
for 48 hours with free access to food and water; the first day to acclimatize and the 
second day to collect 24-hour urine samples for the determination of  protein, cyclic 
GMP and ET-1. BP was not monitored when rats were housed in metabolic cages 
due to the absence of  telemetry receivers. All experiments were performed under 
the regulation and permission of  the Animal Care Committee of  the Erasmus MC. 
Biochemical measurements
ET-1 and VEGF were assessed using a chemiluminescent ELISA (QuantiGlo®, R&D 
Systems, range 0.34 - 250 pg/mL) and Solid Phase Sandwich ELISA (Quantikine, R&D 
Systems, range 31.2 - 2000 pg/mL) respectively. cGMP levels were determined in urine, 
using an ELISA kit (Enzo Life Sciences, Farmingdale, NY, USA). Serum cystatin C and 
urinary protein concentrations (Cobas c502 and c702, CYSC and TP2/TPUC3, Roche 
Diagnostics) were measured at the clinical chemical laboratory of  the Erasmus MC. 
Sunitinib levels were measured by a validated ultra-performance liquid chromatography/
tandem mass spectrometry system, at the laboratory of  Translational Pharmacology of  
the Erasmus MC Cancer Institute.13 
Renal histology
Details of  the light microscopy (LM) and electron microscopy (EM) in this study are 
available in the Supplement.
Podocyte and glomerular quantification 
IHC staining for Wilms tumor protein (WT1), a podocyte-specific transcription 
factor, was performed to identify podocytes. In brief, three-micron paraffin sections 
were deparaffinized, rehydrated, and used for immunostaining after antigen retrieval 
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procedure. Endogenous peroxidase activity was blocked for 15 minutes in 0.1% H2O2 
in water. After washing with PBS, sections were incubated with mouse anti WT1 mAb 
antibodies (WLM04, Abcam) diluted in 1% bovine serum albumen in PBS for 2 hours, 
1 hour incubation with anti-mouse envision (DAKO), and the slides were developed 
with diaminobenzidine. Slides were counterstained with hematoxylin, dehydrated, and 
mounted. The number of  positive nucleoli per glomerulus in 25 glomeruli was counted 
and the glomerular surface area was measured with the Philips Image Management 
System 2.3 software (Philips Medical Systems Nederland B.V., The Netherlands).
Intercellular adhesion molecule 1 (ICAM-1) staining was performed on frozen sections 
using an anti-rat CD54 monoclonal antibody (clone 1A29). An HRP labeled Anti-
Mouse IgG (H+L) Antibody (KPL, Maryland, USA) was used as a secondary antibody. 
mRNA expression
Quantitative polymerase chain reaction (qPCR) was performed to quantify mRNA 
expression. The RNA was isolated using the TRIzol method and reversed to cDNA 
using an AMV cDNA synthesis kit (Roche, Indianapolis, IN). For the qPCR reaction, 
iQ SYBR Green supermix (BioRad) was used. Relative transcription levels for Neph1, 
Nphs1, Nphs2 were determined and corrected to the podocyt specific gene Wt1 using 
the CFX manager software (BioRad) with primer sequences as described earlier.14 
The Edn1, Ece1, and Vegfa mRNA levels were measured and corrected to a general 
housekeeping gene hypoxanthine phosphoribosyltransferase 1 (Hprt1). The primer 
sequences used are shown in Table S1 (available in the Supplement).
Statistical analysis
Data are presented as mean±SEM. Statistical analysis between groups was performed 
by unpaired t-testing or by repeated-measures ANOVA followed by Newman-Keuls 
or Dunnett’s multiple comparison testing. Correlations were performed by Pearson’s 
testing. GraphPad Prism version 5.0 was used for all statistical analysis.
RESULTS
Plasma concentrations of sunitinib 
Plasma concentrations of  sunitinib increased dose-dependently with the three oral 
doses of  sunitinib (Figure 1A). Sunitinib’s plasma concentration at the lowest dose was 
comparable with the systemic concentrations reached in patients treated with a standard 
daily dose of  sunitinib of  50 mg.15 Sunitinib is metabolized by cytochrome P450 3A4 
to the active compound N-desethyl sunitinib. Even at the lowest dose of  sunitinib, the 
plasma concentration of  this compound in rats was much higher than in patients during 
standard dosing (Figure 1B). The ratio metabolite/sunitinib was 5.1±0.7 compared to 
an average of  0.3 in humans (data not shown), implying a higher rate of  N-de-ethylation 
in rodents.
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Figure 1. Trough plasma concentrations of sunitinib (A) and its active metabolite, N-desethyl sunitinib or 
SU12662, (B) in rats in response to administration of a low (7 mg/kg.day), an intermediate (14 mg/kg.day) 
and a high dose of sunitinib (26.7 mg/kg.day). *P<0.05 vs sunitinib (26.7 mg); #P<0.05 vs. sunitinib (14mg)
Dose-dependency of blood pressure rise, renal function impairment and 
proteinuria in sunitinib-exposed rats
Mean arterial BP (MAP) increased dose-dependently, ranging from 13.4±3.3 mmHg at 
the lowest to 31.1±0.9 mmHg at the highest dose versus vehicle (Figure 2A). With all 
three doses, the rise in MAP dose-dependently was accompanied by a decrease in heart 
rate (Figure 2B). 
Compared to vehicle, cystatin C increased with the high and intermediate doses, but 
was identical to that in vehicle-treated rats with the low dose of  sunitinib (Figure 2C). 
Proteinuria markedly increased with the high dose of  sunitinib, whereas the intermediate 
and low dose of  sunitinib, were associated with modest proteinuria (Figure 2D). Cystatin 
C and proteinuria were not related to MAP or ET-1. 
Dose-dependent changes in cGMP, ET-1 and VEGF 
Sunitinib was associated with dose-dependent decreases in urinary cGMP excretion 
(Figure 3A). In previous clinical and preclinical studies we have shown that sunitinib 
administration is associated with activation of  the ET-1-axis.8, 9, 12 At the different 
doses of  sunitinib, circulating ET-1 increased dose-dependently (Figure 3B). Changes 
in urinary cGMP excretion and in ET-1 were unrelated (r=0.18, P>0.05). Circulating 
ET-1 and MAP were related (r=0.49; P<0.05). Urinary ET-1 excretion at baseline was 
9.1±0.5 pg/day. This excretion slightly decreased by 2.3±0.7 pg/day with vehicle and 
by 5.4±1.9 pg/day at the low, 4.1±1.1 pg/day at the intermediate and 4.1±1.1 pg/day at 
the high sunitinib dose (P<0.05 suntinib versus vehicle).  
Plasma VEGF dose-dependently and markedly increased in response to sunitinib 
administration (Figure 3C). Plasma VEGF was related to MAP, sunitinib and N-desethyl 
sunitinib (r=0.61, r=0.72 and r=0.83 respectively, P<0.01). The rise in circulating VEGF 
was not accompanied by a rise in the renal expression of  the gene encoding VEGF-A 
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(Figure 4A). The expression of  the gene encoding for ET-1 did not change with any 
of  the doses, whereas the gene expression of  endothelin-converting enzyme (ECE) 
decreased (Figure 4B and 4C).
Figure 2. Time course of changes in mean arterial pressure (MAP; A) and heart rate (HR; B) in response 
to administration of vehicle, a low (7 mg/kg.day), an intermediate (14 mg/kg.day) and a high dose of 
sunitinib (26.7 mg/kg.day). Panels below, Areas under the curve (AUC). C and D, Serum cystatin C, and 
change in proteinuria (before and after treatment) respectively in rats after administration of vehicle, a 
low (7 mg/kg.day), an intermediate (14 mg/kg.day) and a high dose of sunitinib (26.7 mg/kg.day). *P<0.05 
vs sunitinib (26.7 mg); †P<0.05 vs vehicle; #P<0.05 vs. sunitinib (14mg)
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Figure 3. Change in urinary cyclic GMP (cGMP) excretion (A), circulating ET-1 levels (B) circulating VEGF 
levels (C) in rats after administration of vehicle, a low (7 mg/kg.day), an intermediate (14 mg/kg.day) and 
a high dose of sunitinib (26.7 mg/kg.day). *P<0.05 vs sunitinib (26.7 mg); †P<0.05 vs vehicle; #P<0.05 vs. 
sunitinib (14mg)
Figure 4. Relative renal mRNA expression level of VEGF-A (A), ET-1 (B) and ECE (C) after correction 
for the housekeeping gene Hprt. Relative renal mRNA expression of Neph1 (D), nephrin (Nphs1; E), and 
podocin (Nphs2; F). mRNA levels were corrected for the podocyte specific gene Wt1. †P<0.05 vs vehicle
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Renal histopathology
Kidney weight-to-body weight ratio was 3.0±0.04 g/kg in vehicle-treated rats. This ratio 
increased to 3.3±0.2, 3.4±0.1 and 3.5±0.04 g/kg, respectively, at the low, intermediate 
and high dose of  sunitinib (P<0.05 for all). LM of  kidney sections revealed that the 
intermediate and high dose of  sunitinib were associated with increases in endothelial 
cell swelling (Figure S1C and S1D). No endothelial cell swelling was present at the low 
dose of  sunitinib (Figure S1B). PTAH staining showed fibrin deposits in glomerular 
capillaries (Figure S1E) and in small arteries at the high dose of  sunitinib only (Figure 
S1F).
Quantification of  renal histopathology based on LM images is displayed in Figure 
S2. The glomerular ischemia score in rats exposed to vehicle and low-dose sunitinib 
was identical, while this score increased dose-dependently with the intermediate and 
high dose of  sunitinib. Comparable dose-dependent findings were obtained for the 
deposition of  intraepithelial droplets. Peritubular capillary density or the presence of  
interstitial fibrosis and tubular atrophy between high dose of  sunitinib and controls did 
not differ (data not shown).
Transmission EM of  kidney sections showed normal foot processes and cytoplasmatic 
morphology at the low dose of  sunitinib (Figure S4B). At the high dose of  sunitinib, 
endothelial cell swelling with luminal obliteration and loss of  intercellular fenestrations 
occurred (Figure S4C), whereas multiple intraepithelial droplets were present at the 
intermediate and high dose of  sunitinib (Figure S4D).  
Glomerular circumference, podocyte number and gene expression
Glomerular circumference tended to increase with the intermediate and high dose 
of  sunitinib, but the number of  podocytes per glomerular circumference remained 
unchanged (data not shown). The relative expression of  the slit diaphragm mRNAs of  
genes encoding Neph1, nephrin and podocin decreased at the high and intermediate 
dose of  sunitinib compared to vehicle (Figure 4D-F). Glomerular endothelium ICAM-
1 expression was increased during sunitinib treatment (Figure S3). 
DISCUSSION
Off-target effects of  angiogenesis inhibitors that interfere with VEGF-signaling are the 
development of  hypertension and renal injury.3, 16 By applying different doses of  sunitinib, 
we explored the dose-dependency of  these side effects and their interrelation. Our 
findings indicate that the severity of  hypertension and the development of  renal injury 
are dose-related. They also show a lower threshold dose for developing hypertension 
and proteinuria than for developing renal function impairment, as reflected by the rise 
in cystatin C concentration and the severity of  glomerular ischemia. These findings 
concur well with clinical studies reporting a higher incidence of  hypertension than renal 
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function impairment in patients treated with angiogenesis inhibitors.3, 17 With the lowest 
dose of  sunitinib applied, the BP rise of  about 10 mmHg is of  similar magnitude 
as the BP rise we have observed in patients after 2 and after 4 weeks administration 
of  sunitinib, stressing the potential relevance of  our low-dose model for the clinical 
situation.9 Of  note, the plasma sunitinib concentration with the low dose of  sunitinib 
was comparable to the concentration measured in patients treated with a standard dose 
of  sunitinib of  50 mg per day.15 However, the concentration of  its active metabolite 
n-desethyl sunitinib was markedly higher, indicating increased metabolism of  the parent 
compound in rats, as has been reported previously.18
Glomerular endotheliosis, sometimes accompanied by thrombi, is a hallmark of  
angiogenesis inhibition-induced renal injury.5 In the present study, glomerular 
endotheliosis with almost complete obliteration of  glomerular capillaries was observed at 
the highest dose of  sunitinib, whereas endotheliosis was less severe with the intermediate 
absent with the low dose of  sunitinib. Using fibrin staining, fibrin clots in glomerular 
capillaries and small arteries, indicating thrombotic microangiopathy, were present at 
the high but not at the low and intermediate doses of  sunitinib. Glomerular thrombotic 
microangiopathy has been reported in patients treated with anti-angiogenic treatment 
and can also occur in preeclampsia.5, 6, 19 Exposure to sunitinib was not associated with a 
decrease in renal peritubular capillaries or interstitial fibrosis, indicating that the adverse 
renal effects are restricted to the glomeruli.
Genetic depletion studies in mice have shown that podocyte-specific heterozygosity for 
VEGF-A results in renal disease by 2.5 weeks of  age characterized by proteinuria and 
endotheliosis.20 Also rats or mice injected with a sFlt-1 or overexpressing sFlt-1 by virus 
injection develop endotheliosis and proteinuria.7, 21, 22 Collectively, these findings indicate 
that interference with the VEGF-A signaling pathway, either genetically or by a soluble 
receptor trapping VEGF, or by a tyrosine kinase directly targeting VEGF-receptors, 
results in a similar glomerular phenotype. 
In the kidney, VEGF is abundantly expressed in podocytes, whereas glomerular 
capillary endothelial cells preferentially express VEGF-receptors.23 VEGF produced by 
podocytes is essential for the maintenance of  the integrity of  glomerular endothelial 
cells.20, 24 In addition, VEGF is also required for the maintenance of  podocyte function 
and slit-diaphragm proteins, implying that podocyte-derived VEGF exerts both 
paracrine and autocrine effects.25 In preeclamptic patients and mice exposed to a VEGF-
antibody or sFlt1, nephrin expression decreases.22, 26 Moreover, in rats with progressive 
glomerulonephritis increased expression of  sFlt1 resulted in massive proteinuria and 
down-regulated nephrin expression.23 More recently, interaction of  the cytoplasmatic 
domains of  nephrin and VEGFR-2 has been demonstrated in both in vivo and in vitro 
studies.27 Upon VEGF binding this nephrin-VEGFR-2 interaction diminishes, resulting 
in a change in shape and size of  cultured podocytes.27 Sunitinib administration in the 
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current study was also associated with a dose-dependent decreased expression of  the 
gene encoding nephrin as well as a decrease in the genes expressing Neph1 and podocin, 
encoding for slit-diaphragm proteins that bind to nephrin (Figure 4).28 Given that null 
mutations in the genes encoding nephrin, Neph1 and podocin are all associated with 
severe forms of  congential nephrotic syndrome, it seems reasonable to conclude that 
the diminished expression of  these genes is involved in the development of  proteinuria 
during treatment with sunitinib as well as treatment with other agents interfering with 
VEGF signalling.28, 29 
In line with our previous observations, sunitinib treatment was associated with 
activation of  the circulating endothelin system, which was already present at the low 
dose of  sunitinib.3, 8, 9 The observed rise in ET-1 may be a direct consequence of  VEGF 
inhibition, as shown in human lung microvascular endothelial cells.30 The rise may also 
be related to the activation of  the endothelium in response VEGF inhibition. This, 
however, was not supported by the present finding that despite activation of  glomerular 
endothelial cells as reflected by the presence of  glomerular endotheliosis and increased 
glomerular expression of  ICAM-1, expression of  gene encoding for ET-1 within the 
kidney was not increased. In addition to a direct adverse effect of  VEGF inhibition on 
podocyte function and expression of  slit-diaphragm proteins, ET-1 can exert negative 
effects on podocyte function, which additionally to the disruption of  VEGF pathway, 
may contribute to glomerular injury and proteinuria.10, 11, 31, 32 For instance, a sub-pressor 
dose of  ET-1 administered to Sprague-Dawley rats was found to increase glomerular 
permeability and inflammation as well as nephrinuria, effects that could be blocked by 
an ETA-receptor antagonist.
31 In cultured podocytes, ET-1 through activation of  ETA 
receptors induces nephrin shedding concomitant with a redistribution of  the podocyte’s 
cytoskeleton.10 Very recently, Buelli et al. have shown activation of  the β-arrestin-1 
signalling pathway by ET-1, resulting in transition of  podocytes from an epithelial to 
mesenchymal cell type.11 Given the present observation that urinary ET-1 excretion 
was not increased during sunitinib administration or even decreased, the possibility 
that activation of  ET-1 axis has contributed to the proteinuria in our rat model remains 
questionable. If  ET-1 is involved it should, based on the present findings and an earlier 
study, reach the podocytes by ultrafiltration.31 
Some limitations of  our study should be mentioned. The duration of  exposure to 
sunitinib was only 8 days. It would be interesting to see whether the rise in BP and 
renal pathology is progressive during more prolonged exposure. With the lowest 
dose of  sunitinib the serum concentration of  the active metabolite was considerably 
higher than observed in patients, yet the rise in blood pressure was comparable. Finally, 
although in the present study we have focussed on the renal effects of  sunitinib, it is 
well known that VEGF inhibition can also negatively affect other organs, especially the 
myocardium and endocrine organs.  In more long-term studies it would be interesting 
to see whether the lowest or even a still lower dose of  sunitinib as used in the present 
Dose-dependency of blood pressure and renal toxicity
82
study still preferentially affects the kidney or also has adverse effects on the mentioned 
organs when administrated for prolonged periods.  
Perspectives
This study shows activation of  the circulating, but not of  the renal ET-axis, already 
at a relatively low dose of  sunitinib. This activation likely contributes to the off-target 
effects of  sunitinib. In future experiments it should be explored whether blockade of  
the endothelin pathway can completely prevent the development of  hypertension and 
renal injury in rats exposed to low doses of  sunitinib for prolonged periods. This would 
provide evidence that activation of  the endothelin pathway is an essential mediator for 
the rise in BP and renal toxicity associated with anti-angiogenic treatment.
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NOVELTY AND SIGNIFICANCE
What is New?
This is the first study with the TKI sunitinib that explores the dose-dependency of  
hypertension and renal injury, aiming to find a sunitinib dose that, with regard to side 
effects, closely mimics the human situation
What is Relevant?
Our findings indicate that sunitinib-induced hypertension requires a lower dose than its 
induction of  renal function impairment
Summary
This study shows activation of  the systemic endothelin-axis, already at a low dose of  
sunitinib. This activation may not only contribute to the rise in blood pressure but also 
to the proteinuria and renal damage occurring during anti-angiogenic treatment
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SUPPLEMENT
EXPENDED METHODS
Light microscopy
The left kidney was rapidly excised from euthanized rats, decapsulated, weighed and sliced 
transversely. Slices were fixed in a 3.5-4% formaldehyde solution for light microscopic 
evaluation. After fixation in the formaldehyde solution, tissue was dehydrated and 
paraffin-embedded. Deparaffinized 2-μm thick sections were stained for haematoxilin-
eosine (HE) and periodic acid Schiff  (PAS). PAS-stained sections were blindly evaluated 
by a pathologist (F.M.M.S.) for the presence or absence of  glomerular ischemia and 
intra-epithelial protein deposition in 50 glomeruli. Glomerular ischemia was scored 
semiquantitatively and defined as the degree of  open glomerular capillaries, wrinkling 
of  the glomerular basement membrane and filling of  Bowmans space. Wide open 
glomerular capillaries filling Bowman’s space entirely corresponded with no ischemia. 
Partially open glomerular capillaries with mild wrinkling of  the glomerular basement 
membrane and Bowman’s glomerular space largely filled was classed as moderate 
ischemia. Totally collapsed glomeruli and extensive wrinkling of  the glomerular 
basement membrane and only partial filling of  Bowman’s space corresponded with 
severe ischemia. Furthermore, the presence of  glomerular intra-epithelial protein 
deposition was evaluated using a semiquantative scale: 0 (no protein), 1 (protein present 
in 1-50% of  the epithelial cells) and 2 (protein present in >50% of  the epithelial cells). 
Fifty glomeruli per kidney section (PAS staining) were evaluated. Phosphotungstic acid-
haematoxylin (PTAH) staining was used to identify fibrin deposits.
To assess the number of  peritubular capillaries (PTC), 4μm formalin fixed paraffin-
embedded tissue sections were cut and stained with CD31. Staining was performed 
following routine diagnostic procedures on the Benchmark Ultra stainer (Venatana 
Discovery), using buffers provided by Ventana that are validated for diagnostics. 
Antibody against CD31 (1:50 dilution, ab28364, Abcam, Cambridge, UK) were used 
to detect ptc’s. The tissue sections were stained simultaneously to reduce inter-staining 
variation. Incubation with antibody was done for 60 minutes, after antigen retrieval 
of  64min at pH8.4. After staining, sections were blindly evaluated at 40x objective 
by a pathologist (M.C.v.G.) selecting 10 random, non-overlapping fields. Images were 
acquired using a Canon EOS 1100D camera and an Olympus BX40 microscope. The 
medulla and the subcapsular cortex with a width of  5 tubuli were excluded when images 
were acquired. Per image field, the number of  PTC’s and the number of  tubuli were 
counted, and a ratio was made (ptc:tubuli). Evaluation of  the staining has been adapted 
from Steegh et al.1
In addition, in order to assess the presence of  interstitial fibrosis (ci) and tubulus atrophy 
(ct), 3µm sections were PAS stained following routine diagnostic procedures. Sections 
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were subsequently analyzed (M.C.v.G.) using a 20x objective and scored for ci and ct 
according to the Banff  classification of  renal allograft rejection.2   
Electron microscopy
Kidney samples were processed for transmission EM as previously described.3 
Immediately after resection, cortical renal tissue was cut into blocks and immersed 
in Karnovsky´s fixative containing 2% glutaraldehyde in 0.1 M sodium cacodylate 
buffer, pH 7.4.  After fixation, 1 mm3 pieces were cut and postfixed in 1% OsO4 in 
0.1 M cacodylate buffer for 1 h.  The specimens, were hereafter dehydrated in ethanol, 
immersed in acetone and embedded in Epon 812 R (Merck). Survey sections (2 μm) 
were stained with toluidine blue. Ultrathin (50-70 nm) sections with 2-3 randomly 
selected glomeruli were cut, mounted on copper grids and contrasted with uranyl 
acetate and lead citrate. Serial sections (8-10 sections per grid and 4-5 neighboring grids) 
were examined using a Philips Morgagni 261 EM microscope. Sections were blindly 
evaluated by a renal pathologist (A.H.) for the occurrence of  glomerular endotheliosis 
(endothelial cell swelling, encroachment of  the capillary spaces and loss of  endothelial 
fenestration) and podocyte morphology as previously defined.3
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Figure S1. Figure S1. Kidney sections from WKY rats administered vehicle (A) or sunitinib; including a 
low dose (B), intermediate dose (C) or high dose (D), stained with HE stain (magnification x500). After 
administration of a high dose of sunitinib for 8 days marked glomerular changes could be observed, 
including intra-epithelial droplets and reduction in the number of capillaries. PTAH staining shows fibrin 
deposits in glomerular capillaries (E) and small arteries (F) with high dose of sunitinib (n=1).
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Figure S2. Light microscopic evaluation of kidney sections obtained from rats exposed to a low, an 
intermediate and a high dose of sunitinib for 8 days compared to controls. All evaluations were performed 
in 50 glomeruli of a PAS-stained section and the numbers of glomeruli with each score were counted. 
*P<0.05 vs sunitinib (26.7 mg); †P<0.05 vs vehicle; #P<0.05 vs. sunitinib (14mg)
Figure S3. Kidney sections from WKY rats administered vehicle (A) or sunitinib (B). ICAM-1 staining 
shows increased glomerular endothelium staining, suggesting endothelium activation at all dosages of 
sunitinib (n=1). 
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Figure S4. Transmission electron micrographs of representative kidney sections from Wistar Kyoto (WKY) 
rats treated with vehicle (A) or sunitinib (B-D). (A) Normal capillary lumina (asterix) and endothelial 
cells with preserved fenestration (arrows) in rat receiving vehicle. (B) Podocytes showing preserved foot 
processes (arrows) and normal cytoplasmic morphology (asterix) in low dose sunitinib-treated rat. (C) 
Glomerular endotheliosis with endothelial swelling (ES), loss of fenestration (arrows) and maximal luminal 
obliteration in high dose sunitinib-treated rat. (D) Podocyte containing multiple intracellular droplets 
(arrow) in intermediate dose sunitinib-treated rat. Scale bars = 2 µm.
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Table S1. Real time PCR primers
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abstract
In response to salt loading Na+ and Cl- accumulates in the skin in excess of  water, 
stimulating skin lymphangiogenesis via activation of  the mononuclear-phagocyte system 
(MPS) cell-derived VEGFC-VEGF type 3 receptor signalling pathway. Inhibition of  this 
pathway results in salt-sensitive hypertension. Sunitinib is an antiangiogenic agent that 
blocks all three VEGF receptors and increases blood pressure. In the present study we 
explored whether sunitinib causes salt-sensitive hypertension and whether impairment 
of  skin lymphangiogenesis is an underlying mechanism. Normotensive Wistar Kyoto 
rats were exposed to a normal or high salt (NS or HS) diet with or without sunitinib 
administration. Sunitinib induced a 15 mmHg rise in telemetrically measured blood 
pressure, which was aggravated by a HS diet, resulting in a decline of  the slope of  the 
pressure-natriuresis curve. Without affecting body weight, plasma sodium concentration 
or renal function, Na+ and Cl- skin content increased by 31 and 32% with the HS diet and 
by 49 and 50% with the HS diet plus sunitinib (P=NS), whereas skin water increased by 
17 and 24% respectively. Skin MPS cells increased both during sunitinib and a HS diet. 
No further increment was seen when HS diet and sunitinib were combined. HS diet 
increased lymphangiogenesis whereas sunitinib treatment decreased lymphangiogenesis 
very modestly. We conclude that sunitinib administration is associated with salt-sensitive 
hypertension that can be only partly explained by impaired skin lymphangiogenesis, 
suggesting that other factors are involved.
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introduction
Angiogenesis, the formation of  new vessels from pre-existing vasculature, is critical to 
solid tumor growth and metastasis. This process is regulated by numerous factors among 
which vascular endothelial growth factor (VEGF) plays a predominant role. Different 
strategies to inhibit the VEGF-signaling pathway by targeting VEGF or its receptors have 
been developed and are now established modalities for the treatment of  a wide range 
of  malignancies.1-4 VEGF inhibition is associated with hypertension, proteinuria and 
renal function impairment in a substantial portion of  patients, sometimes necessitating 
discontinuation of  treatment.5, 6 Sunitinib is an orally active angiogenesis inhibitor that 
blocks the VEGF receptors (VEGFR)-1, -2 and -3, and other tyrosine kinase receptors, 
including platelet derived growth factor (PDGF) and c-Kit receptors by interacting with 
their ATP-binding pockets.7 VEGFR-1 and VEGFR-2 are predominantly expressed on 
vascular endothelial cells, whereas VEGFR-3, stimulated by VEGFC, is restricted to 
lymphatic endothelial cells.7 
In a previous study, Gu et al. have shown that the multi-targeted VEGFR inhibitor 
SU5416 enhances dietary salt-induced hypertension and kidney injury in normotensive 
Sprague-Dawley rats.8 The authors suggested that the SU5416-induced decrease in 
renal nitric oxide (NO) production in proximal tubular epithelial cells via inhibition 
of  endothelial NO synthase (eNOS) underlies this salt-sensitive hypertension.8 Recent 
evidence indicates that in response to a high salt diet, sodium and chloride accumulates 
in the skin in excess of  water.9 This results in a hypertonic interstitial fluid compartment 
leading to accumulation of  mononuclear phagocyte system (MPS) cells.10, 11 In response 
to the hypertonic environment, MPS cells produce increased amounts of  the tonicity-
responsive enhancer-binding protein (TonEBP), that initiate expression and secretion 
of  VEGF-C. By activation of  the lymph-endothelial VEGF-3 receptor, VEGF-C 
increases the density of  the cutaneous lymph vessels as an adaptive mechanism to 
clear the excessive electrolytes.10, 11 Interruption of  this pathway in mice and rats is 
associated particularly with Cl- accumulation and salt-sensitive hypertension.9, 11 Since 
sunitinib, aside from blocking VEGFR-1 and VEGFR-2 signaling, also blocks the 
VEGFR-3 signaling that mediates lymphangiogenesis, we hypothesized that sunitinib 
administration impairs lymphangiogenesis in response to a high salt diet and that 
this impairment leads to Na+ and especially Cl- accumulation in the skin interstitium, 
contributing to salt-sensitive hypertension. To test this hypothesis, we measured blood 
pressure telemetrically, and determined skin electrolytes, MPS cell infiltration and skin 
lymphangiogenesis in normotensive Wistar-Kyoto rats exposed to a normal or a high 
sodium diet with and without addition of  sunitinib.  
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metHods
Animals
All experiments were performed under the regulation and permission of  the Animal 
Care Committee of  the Erasmus MC. Male Wistar Kyoto rats (WKY, 180-200 gram, 
n=30), obtained from Harlan Laboratories, were individually housed and maintained 
on a 12-h light/dark cycle, having access to standard laboratory rat chow (normal salt 
diet (NS); 0.5-1.0% NaCl) and tap water ad libitum. Intra-aortic blood pressure (BP) 
recordings were performed by implanted radiotelemeters (PA-C40, Data Sciences 
International) and sunitinib (SU11248; Sutent, Pfizer) and vehicle solution were prepared 
and administered by oral gavage as described previously.12 After implantation of  the 
telemetry transmitters, rats received analgesic treatment using Temgesic subcutaneously 
(0.05 mg/kg; RB Pharmaceuticals Limited) for 2 days, followed by a recovery period of  
10 days. After this, animals were randomly allocated to groups that received either a high 
salt (HS) diet (8% NaCl + 0.9% saline drinking water, n=15) or a normal salt diet for 2 
weeks (n=15). Rats were then randomly administered a dose of  sunitinib (7 mg/kg.day, 
n=8) or vehicle (n=7) by oral gavage (0.5 mL) for 8 days, on top of  the NS or HS diet. 
At the end of  each experiment, rats were euthanized with 60 mg/kg pentobarbital i.p. 
Blood was sampled for measurement of  creatinine, cystatin C levels and electrolytes, 
and kidneys were rapidly excised, and ears and skin were collected. 
In all experiments, before the start of  the specific diet (Baseline 1), and immediately 
before (Baseline 2) and after 8-day administration of  vehicle or sunitinib, rats were 
housed in metabolic cages for 48 hours with free access to food and water; the first 
day to acclimatize and the second day to collect 24-hour urine samples. BP was not 
monitored when rats were housed in metabolic cages due to the absence of  telemetry 
receivers.  
Skin and ear samples were collected for histology. Chemical analysis of  the skin 
included Na+, K+, Cl-, and water measurements using a dry ashing method as described 
previously.13
Biochemical Measurements
Plasma creatinine and cystatin C (Cobas c502 and c702, CYSC, Roche Diagnostics), and 
plasma and urinary electrolytes were measured at the clinical chemical laboratory of  the 
Erasmus MC.
Immunohistochemistry and immunofluorescence of lymph capillaries and 
MPS cells 
Lymph vessel and MPS cell density were assessed in the right ear by thin-section 
histology using a podoplanin antibody as described previously.11 Briefly, right ears 
of  the rats were fixed in 5% formalin and 4% PFA respectively, and embedded in 
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paraffin. Podoplanin staining was performed using Avidin/Biotin Blocking Kit (Vector 
Laboratories, Burlingame, USA) and the HRP super staining kit (ID Labs, Ontario, USA) 
according to the manufacturer’s instructions. Deparaffinized slides were boiled two 
times for 5 min at 600 W in a microwave in 0.1 M citrate buffer (pH 6.0). After cooling 
down to room temperature, slides were incubated in 3% H2O2 for 10 min. Blocking was 
performed with the Avidin/Biotin Blocking according to the manufacturer’s protocol 
and with SuperBlock for 7 min. After washing with phosphate-buffered saline (PBS) 
three times, slides were incubated with a podoplanin antibody (1:2000, RELIATech 
GmbH) for 1 h, followed by incubation with the polyvalent antibody and HRP for 10 
min. Slides were washed three times with PBS between every step. Specific stainings 
were detected using AEC Chromogen/Substrate (3-Amino-9-ethylcarbazole, ID Labs). 
Lymph capillaries were counted at 100X amplification starting from the same edge of  
each ear in 5 consecutive fields.
MPS cells were visualized by indirect immunofluorescence. Nonspecific binding sites 
were blocked with 10% normal donkey serum (Jackson ImmunoResearch, West Grove, 
USA) for 30 min. Sections were then incubated with a CD68 antibody, a monocyte-
macrophage marker (1:1000, AbD Serotec). All incubations were performed in a humid 
chamber. For fluorescence visualization of  bound primary antibodies, sections were 
further incubated with Cy3-conjugated (Jackson ImmunoResearch) or Alexa Fluor 
488-conjugated (Invitrogen, Paisley, UK) secondary antibodies for 1 h in a humid 
chamber at room temperature. Percentage of  CD68 positive/total area was calculated 
in 5 consecutive fields and means of  these values are presented. 
Specimens were analyzed using a Zeiss Axioplan-2 imaging microscope with AxioVision 
4.8 software (Zeiss, Jena, Germany), except for whole-mount stained samples, which 
were analyzed by multiphoton confocal microscope Zeiss LSM 710 with ZEN 2012 
software (Zeiss). Investigators were blinded for treatment group assignments.
Statistical Analysis
Data are presented as mean±SEM. Statistical analysis between groups was performed 
by unpaired t-testing or by repeated-measures ANOVA followed by Newman-Keuls or 
Dunnett’s multiple comparison testing. Correlations were performed using Pearson’s 
testing. GraphPad Prism version 5.0 was used for all statistical analysis.
results
HS diet enhances the hypertensive effect of sunitinib and decreases the 
slope of the pressure-natriuresis curve 
MAP during a NS diet was 101±0.9 mmHg (Figure 1A). A HS diet increased MAP by 
27±3 mmHg (P<0.05 vs. NS diet). Sunitinib increased MAP by 15±1 mmHg during a 
NS diet (P<0.05 vs. NS diet alone) and by 23±4 mmHg during a HS diet (P<0.05 vs. HS 
diet alone). The sunitinib-induced increase in area under the curve under HS conditions 
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(85 mmHg x days) was enhanced by 124% (P<0.05) versus the increase under NS 
conditions (38 mm Hg x days) (Figure 1B), and this resulted in a decline in the slope of  
the pressure-natriuresis curve (Figure 1C).  
Figure 1. Mean arterial pressures (MAP; A) in rats after baseline (white bars), 2 weeks of specific diet 
(light grey bars) and in combination with or without VegF inhibition (black and dark grey bars), area 
under the curve (consisting of map and number of treatment days) (b) and pressure-natriuresis curve 
during the specific diets with or without VEGF inhibition (C). NS, normal salt; HS, high salt, Veh, vehicle; SU, 
sunitinib. ∆=vs. respective vehicle group.
Body weight, plasma and skin electrolytes and kidney function 
Urinary sodium excretions during a NS diet and HS diet were 1.0±0.2 mmol/day and 
41.9±5.2 mmol/day respectively. Sunitinib did not affect these values significantly 
(1.1±0.1 mmol/day vs. 34.3±1.8 mmol/day). A HS diet or sunitinib administration 
had no effect on body weight or plasma Na+ or K+ concentration, whereas plasma Cl- 
concentration modestly increased during the HS diet with and without sunitinib  (Figure 
2A and 2B and Table 1). A HS diet increased the content of  Na+ and Cl- (mmol/g dry 
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weight) and of  water content (ml/g dry weight) in the skin, and although sunitinib 
tended to increase both ions even further, these increases did not reach statistical 
significance versus HS alone (Table 1). The skin Na+, Na+ plus K+ or Cl- concentration 
per skin water (mmol/L) did not change either with the HS diet or with sunitinib 
(Table 1, Figure 3); however a linear trend was observed for Na+ per skin water (Figure 
2C). As displayed in Figure 4, both skin Na+ (A) and Cl- (B) concentrations correlated 
with blood pressure. Renal function as reflected by plasma creatinine and cystatin C 
concentration and creatinine clearance did not change in response to a HS diet with or 
without sunitinib (Table 1).
Figure 2. Body weight (A), plasma (B) and skin sodium concentrations (C) in rats after the specific diets. 
ns, normal salt; Hs, high salt;Veh, vehicle; su, sunitinib. 
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Table 1. Skin electrolyte and water distributions, plasma electrolytes and kidney function after specific 
diets with or without VegF inhibition
A HS diet and sunitinib increase skin MPS cell infiltration 
As compared with the NS diet plus vehicle, both sunitinib administration and a HS 
diet were associated with an increase in CD68 positive cell area (Figure 5). These 
data confirm the notion that MPS cells respond to VEGFR blockade in an effort to 
restructure the lymphatic capillary network.
HS diet leads to increased lymph capillary density in the skin
In addition to the increased number of  MPS cells, the number of  podoplanin-positive 
lymph capillaries increased in response to a HS diet, and a HS diet plus sunitinib 
compared with a NS diet and NS diet plus sunitinib (Figure 6). Sunitinib treatment 
tended to decrease the number of  podoplanin-positive lymph capillaries in the ears 
of  rats fed with NS diet (2.6±0.2 vs. 1.9±0.3) and in the ears of  rats fed with HS diet 
(4.4±0.5 and 3.6±0.4).
Figure 3. change (%) in skin sodium content (a), chloride content (c), sodium-potassium ratio content 
(e), skin water content (g), and skin sodium concentration (b), chloride concentration (d) and potassium 
concentration (F) compared to a normal salt diet plus vehicle. ns, normal salt; Hs, high salt, Veh, vehicle; 
su, sunitinib. 
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Figure 5. representative pathological changes in rat ears with ns diet or Hs diet in the absence (a or 
C) or presence (B or D) of sunitinib administration. MPS cells in rat ears visualized with a CD68-specific 
antibody (red), and quantification of the CD68 positive/total area (%) in rat ears after the specific diets 
(e). a, ns+veh; b, ns+su; c, Hs+veh; d, Hs+su. #p<0.05 vs. ns+veh
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Figure 6. representative pathological changes in rat ears with ns diet or Hs diet in the absence (a or c) 
or presence (b or d) of sunitinib administration. lymph capillary endothelial cells in rat ears visualized with 
a podoplanin-specific antibody (arrows), and quantification of the number of podoplanin-positive lymph 
capillaries in rat ears after the specific diets (E). A, NS+veh; B, NS+SU; C, HS+veh; D, HS+SU. †P<0.05 vs. 
Hs+veh. #p<0.05 vs. ns+veh
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discussion
In this study, we explored whether a HS diet augments the BP rise induced by the multi-
targeted VEGF inhibitor sunitinib and whether this is associated with increased skin 
electrolyte accumulation concomitant with an attenuation of  skin lymphangiogenesis. 
Our main findings are that 1) a HS diet in normotensive Wistar-Kyoto rats induces a 
marked rise in BP that is aggravated by sunitinib administration, 2) this rise in BP is not 
accompanied by an increase in body weight or changes in plasma sodium concentration 
or renal function impairment, 3) a HS leads to a proportionally comparable increase 
in skin Na+ and Cl- which is higher than the proportional increase in water content, 
4) a HS diet associates with an accentuated MPS cells infiltration in the skin that is 
not affected by sunitinib administration, and 5) sunitinib treatment tended to decrease 
lymphangiogenesis independent of  diet.
Our study shows that a HS diet in normotensive male WK rats for 2 weeks results in 
a 27 mmHg rise in BP, without increases in body weight or change in renal function. 
An identical rise in BP in response to a HS diet has been observed in normotensive 
Sprague-Dawley rats.8 The dose of  sunitinib applied in the present study induced a 
15 mmHg rise in blood pressure while rats were on a NS diet. This dose of  sunitinib 
was selected based on a previous study showing that when given for one week it did 
not impair renal function and induced a rise in blood pressure comparable to the rise 
observed in patients treated with sunitinib for four weeks at a daily oral dose of  50 mg.14 
In agreement with a previous study with the tyrosine kinase inhibitor SU5416, sunitinib 
administration aggravated the HS diet-induced rise in BP, as reflected by a decline in 
slope of  the pressure-natriuresis curve.8 
Evidence has mounted that in response to a HS diet, Na+ and Cl- in excess of  water 
accumulates in tissues.9-11 In a seminal study, Machnik et al. have shown that this skin 
electrolyte accumulation stimulates the formation of  lymph capillaries, driven by MPS 
cells infiltrating the interstitium of  the skin.11 The authors also demonstrated that 
macrophage-derived VEGF-C, via activation of  the lymph endothelium VEGFR-3, 
mediates this lymphangiogenesis and that interruption of  this pathway in mice and 
in rats associates with salt-sensitive hypertension.11 In the present study, performed 
in normotensive WKY rats, a HS diet was indeed accompanied by increased MPS 
cells infiltration and lymphangiogenesis. Since sunitinib has been shown to inhibit 
lymphangiogenesis by blocking VEGFR-3 signaling.15, we anticipated an attenuation of  
this HS diet-induced lymphangiogenesis during sunitinib administration, and indeed a 
tendency for a decrease in skin lymphangiogenesis was observed.
In mice on anti-VEGFR-3 or VEGF-C trap treatment, or in mice genetically 
overexpressing soluble VEGFR-3 (K14-FLT4 mice) a HS diet caused a much more 
pronounced increase in skin Cl- than in skin Na+ content, leading to an increase in the 
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skin Cl-/Na+ ratio.9, 16 This skin Cl- accumulation, rather than skin Na+ accumulation, 
was most strongly related to the rise in blood pressure in response to a HS diet.9 A 
HS diet after 4 weeks in our rats was associated with an about 30% increase in skin 
interstitial Na+ and Cl- contents after vehicle administration, and the increase amounted 
to about 50% after sunitinib administration compared to a NS diet plus vehicle (Figure 
3). This increase was higher than the increase in skin interstitial water, which was 
respectively 17% after 2 and 24% after 4 weeks, indeed confirming the occurrence of  
skin electrolyte accumulation in excess of  water with salt loading. 
One may wonder why sunitinib exerted only a small effect on lymphangiogenesis in the 
present study. Although an insufficient dose is the most obvious explanation, this is not 
supported by previous pharmacokinetic and in vitro studies.14, 15 We previously reported 
that the same dose of  sunitinib as used in the present study was associated with a plasma 
concentration of  sunitinib and its active metabolite N-desethyl sunitinib of  about 350 
nanogram/mL or 875 nmol/L.14 In an in vitro study, sunitinib concentrations as low as 
30 nmol/L were shown to impair lymphangiogenesis.15 Based on these data it is not very 
likely that the dose of  sunitinib was the limiting factor to impair lymphangiogenesis. 
Our findings do not support the idea that impaired skin lymphangiogenesis is a major 
contributor to the rise in blood pressure or salt-sensitivity observed with sunitinib. 
As reported earlier, administration of  tyrosine kinase inhibitors is associated with 
activation of  the endothelin system as well as suppression of  the NO pathway and 
renin suppression.12, 17, 18 As suggested by Gu et al., suppression of  the NO pathway can 
contribute to the salt-sensitive blood pressure observed with anti-VEGF treatment.8 
Likewise, it is well established that renin suppression is associated with salt-sensitive 
hypertension.19-21 To what extent activation of  the endothelin system, occurring during 
sunitinib administration, contributes to salt-sensitive hypertension is not easy to answer 
because of  the opposing effects on natriuresis mediated by the renal ETA and ETB 
receptors.22 However, it has been reported that infusion of  ET-1 in Sprague-Dawley 
rats induces hypertension when rats are on a high but not on a low salt diet.23, 24 Similarly, 
transgenic mice overexpressing endothelial ET-1 had a significantly higher blood 
pressure when on a HS diet than their wild-type littermates.25 These studies support the 
contention that an activated ET-1 system may contribute to salt-sensitive hypertension.
perspectiVes 
Our study shows that sunitinib administration to rats, in a relatively low dose not inducing 
renal function impairment, is associated with salt-sensitive hypertension. Impairment 
of  the skin MPS cells-TonEBP-VEGF-VEGFR-3-lymphangiogenesis pathway has 
been recognized as a novel mechanism involved in salt-sensitive hypertension. In 
our study sunitinib treatment blocked lymphangiogenesis only modestly. Therefore, 
it is more likely that other mechanisms such as renin suppression, a decrease in NO 
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production and activation of  the endothelin system largely contribute to the salt-
sensitive hypertension during sunitinib administration. We acknowledge that sunitinib 
was administrated for a relatively short period. Whether prolonged administration of  
sunitinib impairs the formation of  lymph vessels in response to a high salt diet remains 
to be established. Furthermore, given that interruption of  the VEGF-signaling pathway 
is associated with activation of  the endothelin system, it would be interesting to explore 
whether the sunitinib-induced salt-sensitive hypertension can be prevented by ETA-
selective or ETA/B endothelin receptor blockade.
noVelty and signiFicance
What is new?
This is the first study with the tyrosine kinase inhibitor sunitinib that explores whether 
the salt-sensitivity of  VEGF inhibition-induced hypertension is related to impairment 
of  skin lymphangiogenesis
What is relevant?
Our findings indicate that a high salt diet enhances the hypertensive effect of  
sunitinib, which may be not principally due to impaired skin lymphangiogenesis 
Summary
Other mechanisms than impaired skin lymphangiogenesis, like renin suppression, a 
diminished NO production and/or activation of  the endothelin system are likely to 
play a bigger role for the salt-sensitivity of  blood pressure induced by sunitinib. 
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ABSTRACT 
Background 
Antiangiogenic treatment with the multitargeted VEGF receptor inhibitor sunitinib 
associates with a blood pressure rise and glomerular renal injury. Recent evidence 
indicates that VEGF derived from tubular cells is required for the maintenance of  the 
peritubular vasculature. In the present study we focused on tubular and glomerular 
pathology induced by sunitinib and explored whether a high salt (HS) diet augments the 
blood pressure rise and renal abnormalities. 
Methods 
Normotensive Wistar Kyoto (WKY) rats were exposed to a normal (NS) or HS diet 
for 2 weeks, and subsequently for 8 days to sunitinib or vehicle administration after 
which rats were euthanized and kidneys excised. Mean arterial pressure (MAP) was 
telemetrically measured. Urine was sampled for proteinuria and endothelinuria, and 
blood for measurement of  endothelin-1, creatinine, and cystatin C. 
Results 
Compared to the NS diet, MAP rapidly rose by 27±3 mmHg with the HS diet. On 
sunitinib MAP rose further by 15±1 with the NS and by 23±4 mmHg with the HS 
diet (P<0.05). The HS diet itself  had no effect on proteinuria, endothelinuria or 
the plasma levels of  endothelin-1, creatinine, and cystatin C. Only with the HS diet, 
sunitinib administration massively increased proteinuria and endothelinuria and these 
2 parameters were related (r=0.50, P<0.01). Likewise, renal glomerular pathology was 
enhanced during sunitinib with the HS diet, whereas tubulointerstitial injury or reduced 
peritubular capillary density did not occur.
Conclusions 
A HS diet induces a marked blood pressure rise in WKY rats and exacerbates both the 
magnitude of  the blood pressure rise and glomerular injury induced by sunitinib.
SUMMARY 
VEGF inhibition is associated with activation of  the endothelin system and renal 
injury that may aggravate during a high salt diet. In normotensive Wistar Kyoto rats the 
renal injury induced by sunitinib, a tyrosine-kinase inhibitor targeting all three VEGF 
receptors, was associated with a massive increase in proteinuria and endothelinuria and 
progression of  histological glomerular damage.
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INTRODUCTION
Vascular endothelial growth factor (VEGF) is a key mediator of  angiogenesis that 
induces endothelial cell (EC) migration, growth, differentiation and regeneration 
through its VEGF receptors (VEGFRs).1 In the kidney, VEGF is abundantly expressed 
in podocytes and tubular epithelial cells, whereas glomerular and peritubular ECs 
express VEGFRs.2  The importance of  renal VEGF in the kidney is evidenced by 
experiments in mice showing that depletion of  one VEGF allele in podocytes induces 
severe glomerular pathology leading to proteinuria and impaired renal function.3 In 
addition, selective embryonic excision of  the gene encoding VEGF-A from renal 
tubular cells resulted in the formation of  a smaller kidney with a striking reduction in 
peritubular capillaries, indicating that VEGF-A derived from tubular cells is essential for 
the maintenance of  the peritubular vasculature.4  
In patients with different forms of  cancer, antiangiogenic treatment with agents 
inhibiting the VEGF pathway has become an approved treatment.5, 6 In previous studies, 
we and others have shown that therapeutic VEGF inhibition in patients with cancer 
is associated with a rise in blood pressure (BP) and renal injury as well as activation 
of  the endothelin system.7-11 Histologic findings in kidney biopsies from patients who 
develop kidney injury during antiangiogenic agent exposure are mainly restricted to 
the glomerulus with thrombotic microangiopathy being most frequently reported.12, 13 
In normotensive rats, angiogenesis inhibition with the multitargeted VEGFR inhibitor 
sunitinib was associated with a dose-dependent rise in BP and renal injury, reflected by 
a dose-dependent rise in cystatin C, proteinuria and glomerular endotheliosis.10 Whether 
sunitinib administration is also associated with tubular or peritubular renal injury and 
peritubular rarefaction remains to be established. 
In previous studies, we have shown that the hypertension induced by sunitinib is 
accompanied by decreased nitric oxide (NO) production and renin suppression.7-9 i.e. 
conditions related to an increased sensitivity of  BP to salt.14, 15 It might therefore be 
expected that a high salt (HS) diet results in augmentation of  the BP rise induced by 
sunitinib, as has been demonstrated earlier for the tyrosine kinase inhibitor SU5416.16 
Whether this augmentation of  BP rise translates into more pronounced renal damage 
remains to be established.
We set up the present study to investigate whether sunitinib administration to 
normotensive rats, in addition to glomerular lesions, induces tubulointerstitial injury 
and peritubular rarefaction and whether or not this is exacerbated by a HS diet.
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METHODS
Animals
All experiments were performed under the regulation and permission of  the Animal Care 
Committee of  the Erasmus MC. Male Wistar Kyoto rats (WKY, 180-200 gram, n=30), 
obtained from Harlan Laboratories, were housed in individual cages and maintained 
on a 12-h light/dark cycle, having access to standard laboratory rat chow (normal salt 
(NS) diet; 0.5% NaCl) and water ad libitum (tap water). Intra-aortic BP recordings were 
performed by implanted radiotelemeters (PA-C40, Data Sciences International) and 
sunitinib (SU11248; Sutent, Pfizer) and vehicle solution were prepared and administered 
by oral gavage as described previously.8 After implantation of  the telemetry transmitters, 
rats received analgesic treatment using Temgesic subcutaneously (0.05 mg/kg; RB 
Pharmaceuticals Limited) for 2 days, followed by a recovery period of  10 days. After 4 
weeks, the group switched to either a HS diet (8% NaCl + 0.9% saline drinking water, 
n=15) or continuation of  the NS diet for 2 weeks (n=15). Then, rats were randomly 
administered a dose of  sunitinib (7 mg/kg.day, n=8) or vehicle (n=7) by oral gavage (0.5 
mL) for 8 days, on top of  the two specific diets. 
At the end of  each experiment, rats were euthanized with 60 mg/kg pentobarbital i.p. 
and blood was sampled for measurement of  creatinine and cystatin C levels, and kidneys 
were rapidly excised. In all experiments, before start of  the specific diet (Baseline 1), and 
immediately before (Baseline 2) and after 8-day administration of  vehicle or sunitinib, 
rats were housed in metabolic cages for 48 hours with free access to food and water; 
the first day to acclimatize and the second day to collect 24-hour urine samples for the 
determination of  sodium excretion, proteinuria and endothelinuria. BP could not be 
monitored when rats were housed in metabolic cages due to the absence of  telemetry 
receivers under those conditions. A timeframe is given in Figure 1.
Figure 1. A timeframe of the study
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Biochemical measurements
Endothelin (ET-1) was assessed using a chemiluminescent ELISA (QuantiGlo®, 
R&D Systems, range 0.34 - 250 pg/mL). Plasma creatinine, plasma cystatin C and 
urinary protein concentrations (Cobas c502 and c702, CYSC and TP2/TPUC3, Roche 
Diagnostics) were measured at the clinical chemical laboratory of  the Erasmus MC. 
Renal histology
Glomerular injury
The left kidney was rapidly excised from euthanized rats, decapsulated, weighed 
and sliced transversely. Slices were fixed in a 3.5-4% formaldehyde solution for light 
microscopic (LM) evaluation. After fixation, tissue was dehydrated and paraffin-
embedded. Deparaffinized 2-μm thick sections were stained for haematoxilin-eosine 
(HE) and periodic acid Schiff  (PAS). PAS-stained sections were blindly evaluated 
by a pathologist (F.M.M.S.) for the presence (1) or absence (0) of  endothelial and 
epithelial cell swelling, glomerular ischemia and intra-epithelial protein in 50 glomeruli. 
Glomerular ischemia was scored semiquantitatively and defined as the degree of  open 
glomerular capillaries, wrinkling of  the glomerular basement membrane, and filling 
of  Bowman’s space. Wide open glomerular capillaries filling Bowman’s space entirely 
corresponded with no ischemia. Partially open glomerular capillaries with mild wrinkling 
of  the glomerular basement membrane and Bowman’s glomerular space largely filled 
were classed as moderate ischemia. Totally collapsed glomeruli and extensive wrinkling 
of  the glomerular basement membrane and only partial filling of  Bowman’s space 
corresponded with severe ischemia. Furthermore, the presence of  glomerular intra-
epithelial protein deposition was evaluated using a semiquantative scale: 0 (no protein), 
1 (protein present in 1-50% of  the epithelial cells) and 2 (protein present in >50% of  
the epithelial cells). Fifty glomeruli per kidney section (PAS staining) were evaluated. 
Chronic and acute tubulointerstitial injury
Since peritubular capillary density correlates well with renal interstitial fibrosis and tubular 
atrophy (IF/TA), this parameter was used to assess capillary density.17, 18 Transversely 
sliced 2-µm thick kidney sections were stained with periodic acid Schiff   (PAS) to analyse 
kidney histomorphology. Subsequently, all sections were semi-quantitatively scored by 
a renal pathologist (M.C.v.G.) in a blinded manner using a 20x objective, and scored 
for IF (ci) and TA (ct) according to the Banff  classification of  renal allograft.19 Each 
parameter was graded in 10 sequential fields with a score of  0-3 in which 0 meant no 
changes in pathology; Grade 1, <25% of  change; Grade 2, 25-50% of  change; Grade 3, 
>50% of  tissue affected. Acute tubular ischaemic injury was also scored, and expressed 
by tubular dilatation, cast deposition, brush border loss and/or necrosis, using a 20x 
objective.20 Each parameter was graded in 10 fields with a score of  0 to 5 in which 
Grade 0 meant no changes in pathology and Grade 5, extensive damage, involvement 
of  >75% of  the cortex.
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mRNA expression
Quantitative polymerase chain reaction (qPCR) was performed to determine mRNA 
expression. RNA was isolated using the TRIzol method and reversed to cDNA using an 
AMV cDNA synthesis kit (Roche, Indianapolis, IN). For the qPCR reaction, iQ SYBR 
Green supermix (BioRad) was used. The Edn1, Ece1, Vegfa, and neutrophil gelatinase-
associated lipocalin (NGAL) mRNA levels were measured and expressed relative to 
a general housekeeping gene hypoxanthine phosphoribosyltransferase 1 (Hprt1). The 
primer sequences used are shown in Table 1. 
Table 1. Real time PCR primers
Statistical analysis
Data are presented as mean±SEM. Statistical analysis between groups was performed 
by unpaired t-testing or by repeated-measures ANOVA followed by Newman-Keuls or 
Dunnett’s multiple comparison testing, or two-way ANOVA. GraphPad Prism version 
5.0 was used for all statistical analysis.
RESULTS
Increased blood pressure rise during sunitinib and HS diet
No difference in (gain of) body weight between the four groups or rats was observed. 
As expected, urinary sodium excretion massively increased from 1.45±0.11 mmol/
day during a NS diet to 43.57±3.09 mmol/day during a HS diet. Plasma sodium 
concentration did not differ between the four groups (data not shown). Mean arterial 
pressure (MAP) during the NS diet was 101±0.9 mmHg. The HS diet for 2 weeks 
increased MAP by 27±3 mmHg (P<0.05 vs. NS diet) (Figure 2A). The rise in MAP was 
already present within 1 week of  the HS diet. Sunitinib increased MAP by 15±1 mmHg 
during the NS diet (P<0.05 vs. NS diet alone) and by 23±4 mmHg during the HS diet 
(P<0.05 vs. HS diet alone, P<0.05 vs NS diet+sunitinib) (Figure 2A). Compared to 
the respective vehicle groups, the delta AUC of  MAP was 38 mmHg times days in NS 
diet+sunitinib group and 85 mmHg times days in HS diet+sunitinib group (P<0.05) 
(Figure 2B). Plasma creatinine and cystatin C levels in the four groups were similar. 
Creatinine clearance, irrespective of  sunitinib administration, tended to be higher 
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during a HS diet. It changed from 3.11±0.26 mL/min during NS diet, to 3.48±0.46 
mL/min during HS (P>0.05).  
Figure 2. Mean arterial pressures (MAP) after 2 weeks of normal and high salt diet, adding vehicle or 
sunitinib treatment (A), and area under the curve (AUC; B) consisting of mean arterial pressure and 
number of treatment days. Abbreviations: NS, normal salt; HS, high salt; Veh, vehicle; SU, sunitinib; MC, 
metabolic cage. ∆=vs. respective vehicle group.
Figure 3. Circulating endothelin-1 (ET-1; A), endothelinuria (B), proteinuria (C) and the relation of urinary 
ET-1 and protein excretion (D) after sunitinib or vehicle treatment during the specific diets. Abbreviations: 
NS, normal salt; HS, high salt; Veh, vehicle; SU, sunitinib. *P<0.05 vs NS+SU
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Dietary salt enhances sunitinib induced circulating and urinary endothelin 
and proteinuria 
Compared to a NS diet, circulating ET-1 levels increased from 0.53±0.30 pg/
mL to 0.78±0.28 pg/mL during NS diet+sunitinib, to 0.82±0.13 pg/mL during 
HS diet+vehicle and to 0.79±0.35 pg/mL, during HS diet+sunitinib (Figure 3A). 
Endothelinuria increased about 6-fold vs NS diet+sunitinib when sunitinib was 
administrated to rats during the HS diet (P<0.05, Figure 3B). Baseline protein excretion 
was 11.4±1.4 mg/day before NS diet and 9.9±1.3 mg/day before HS diet. The HS 
diet increased proteinuria to 18.6±1.1 mg/day (P=NS, Figure 3C). Proteinuria showed 
the same pattern as endothelinuria as it only increased massively to 45.6±21.5 mg/
day (P<0.05) after sunitinib was added to the HS diet. The urinary proteinuria and 
endothelin excretions rates were correlated (Figure 3D). 
Glomerular Injury
The glomerular ischemia scores in rats exposed to vehicle during the NS and the HS 
diet were identical, and the score increased during sunitinib administration irrespective 
of  salt diet (P<0.05, Table 2). Similar findings were obtained for the deposition of  intra-
epithelial protein droplets. At most, the HS diet tended to enhance sunitinib-induced 
glomerular ischemia and intra-epithelial protein deposition. Epithelial cell swelling 
markedly increased during the HS diet with sunitinib, compared to the HS diet alone or 
the NS diet with sunitinib (P<0.05, Table 2). Representative pathological changes are 
shown in Figure 4 (figure legend on page 120).
Table 2. Light microscopic evaluation of kidney sections obtained from rats exposed to a normal and high 
salt diet and in combination with or without VEGF inhibition
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Figure 4. Kidney sections from WKY rats after receiving a normal salt with vehicle (A), a normal salt 
diet with sunitinib (B), a high salt diet with vehicle (C), and a high salt diet with sunitinib (D), stained with 
HE (left panel) and PAS stain (right panel, magnification x500). A1: showing no ischemia characterized by 
minor lobulation of the glomeruli which fill Bownman’s space, and no presence of glycoproteins (A2). 
B1: showing distinct lobulation of the glomeruli indicating ischemia, and a very mild deposit of protein 
droplets (B2, arrow). C1: showing no ischemia, Bowman’s space is entirely filled, but lobulation of the 
glomerulus is present. Protein droplets are hardly found (C2). D1: mild ischemia with distinct lobulation 
of the glomerulus which does not fill Bowman’s space. PAS stain shows extensive deposits of protein 
droplets in epithelial cells (D2, arrows).
Chronic and acute tubulointerstitial injury
PAS-stained sections of  the kidneys showed no marked renal abnormalities in any 
treatment group (Figure 5). In 50% of  the NS diet+sunitinib group, mild tubular injury 
was observed. This percentage was slightly elevated during the HS diet (57%), but no 
further enhancement was observed after adding sunitinib on top of  HS (38%). Sunitinib 
administration had no effect on the density of  peritubular capillaries either during the 
NS or HS diet.
Figure 5. Cross section of PAS-stained kidney sections showing normal architecture, without any 
alterations. No interstitial fibrosis or tubular atrophy or globally sclerotic glomeruli are seen, therefore 
no indications of chronic renal scaring (magnification 10x). A, NS+veh; B, NS+SU; C, HS+veh; D, HS+SU
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Decreased renal expression of Edn-1, Ece1 and Vegfa mRNA during HS 
diet and sunitinib
VEGF-A decreased during the HS and HS diet with sunitinib, compared to the NS 
diet (P<0.05). The rise in endothelinuria was not accompanied by a rise in the renal 
expression of  the gene encoding for ET-1. In fact, compared to the NS diet ET-1 
mRNA levels decreased during the NS diet with sunitinib, the HS diet and the HS 
diet with sunitinib (P<0.05), while endothelin converting enzyme (ECE) mRNA levels 
decreased during the NS diet with sunitinib only (P<0.05, Figure 6).
Figure 6. Relative renal mRNA expression level of vascular endothelial growth factor (VEGF-A; A), 
endothelin-1 (ET-1; B) and endothelin converting enzyme (ECE; C) after correction for the housekeeping 
gene Hprt. #P<0.05 vs NS+veh
Increased renal expression of NGAL mRNA during HS diet and sunitinib 
The expression of  the gene encoding for NGAL, a tubular injury marker, did not change 
after the HS diet with or without sunitinib. However, compared to the NS diet with 
sunitinib the expression of  gene of  NGAL increased during a HS diet with sunitinib 
(Figure 7).
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Figure 7. Relative renal mRNA expression level of NGAL after correction for the housekeeping gene 
Hprt. *P<0.05 vs. NS+SU
DISCUSSION 
Hypertension and renal injury are well-recognized adverse side effects of  agents targeting 
the VEGF-signalling pathway.21, 22 In the present study, we focused on glomerular and 
tubulointerstitial pathology in response to the multitargeted VEGF inhibitor sunitinib 
and the potential aggravating effects of  a HS diet. The new findings are that a HS diet 
exacerbates both the magnitude of  the rise in BP and severity of  glomerular injury 
induced by sunitinib, but that sunitinib administration for 8 days either with a normal 
or a HS diet is not associated with histological tubulointerstitial injury. In addition, we 
found that the HS-induced increase in urinary ET-1 excretion was markedly further 
augmented by sunitinib.
The dose of  sunitinib of  7 mg/kg per day was associated with a BP rise of  15 mmHg, 
comparable to the BP rise observed in patients treated with sunitinib.8, 10 Although a 
HS diet for 4 weeks amplified the sunitinib-induced rise in BP by 47 mmHg times days, 
the HS diet by itself  already induced a considerable BP rise in WKY rats. This latter 
finding concurs well with a study in normotensive Sprague-Dawley (SD) rats, showing 
that a 8% HS diet for 8 weeks induced a 28 mmHg rise in MAP as measured by the 
tail cuff  method.23 Contrary to the present findings, the rise in BP in SD rats became 
only evident after 5 of  the 8 weeks of  the HS diet, whereas in the present study the 
marked rise in BP was already present within 1 week. These findings may imply a greater 
salt-sensitivity of  BP in WKY than in SD rats. Moreover, BP in the present study was 
measured with the much more sensitive telemetry method.
The augmented salt-sensitivity of  BP during sunitinib can be explained by earlier 
findings, showing that the rise in BP induced by angiogenesis inhibition is accompanied 
by renin suppression and a decrease in the NO synthase.7-9 Administration of  the NO 
synthase inhibitor N
ω
-Nitro-L-arginine methyl ester (L-NAME) in rats results in a salt-
Chapter 7
123
sensitive rise in BP, in part by preventing the adaptive rise in renal medullary blood 
flow and rise in renal interstitial pressure in response to a HS diet.14 The fact that renin 
suppression is associated with salt-sensitive BP is known for many years. When renin 
is suppressed, it cannot further decline during salt loading and hence not counteract 
the volume-dependent rise in BP.24 Another potential mechanism by which sunitinib 
administration leads to salt-sensitive hypertension is impairment of  lymphangiogenesis 
by blockade of  the VEGFR-3 signalling pathway.25, 26 Rodent studies have shown that 
interstitial hypertonic volume retention during salt loading is associated with increased 
lymphangiogenesis in the skin. Blockade of  this lymphangiogenesis by trapping 
VEGF-C, the agonist of  the VEGF-3 receptor, results in a moderate salt-sensitive 
hypertension.26 Whether sunitinib at the dose used in the present study inhibits salt-
induced lymphangiogenesis remains to be established.
In SD rats, the HS diet-induced rise in BP was associated with a decreased renal expression 
of  VEGF mRNA and VEGF protein levels and an increased urinary excretion of  the 
endogenous VEGF inhibitor soluble FMS-like tyrosine kinase-1 (sFlt-1).23 Likewise, the 
HS diet in our WKY rats was associated with a decreased renal Vegf  expression. Given 
that a systemic infusion of  angiotensin II increases renal Vegf  expression, suppression 
of  the renin-angiotensin system during a high salt intake may underlie the decrease in 
VEGF expression observed in the present study.27 
Despite the marked rise in BP, a HS diet was not accompanied by proteinuria, impairment 
of  renal function or histological glomerular or tubulointerstitial changes. However, with 
regard to renal injury, a clear interaction between the HS diet and sunitinib exposure was 
present. Administration of  sunitinib to rats on a HS diet when compared to rats on a 
NS diet was associated with pronounced proteinuria and endothelinuria and glomerular 
epithelial cell swelling as well-increased expression of  the gene encoding for NGAL, a 
marker of  tubular injury. Administration of  the tyrosine kinase inhibitor SU5416 at a 
dose of  10 mg/kg.day for 2 weeks in SD rats on a HS diet has been shown to induce 
a pronounced rise in BP (MAP 158 mmHg), severe proteinuria, glomerulosclerosis, 
extracellular matrix expansion and tubulointerstitial injury with infiltration of  
inflammatory cells.16 Despite a comparable degree of  hypertension, such pronounced 
renal histopathological changes were not observed in our WKY rats when exposed to 
sunitinib+HS. Possibly WKY rats are less prone to renal damage than SD rats. Also, 
the exposure of  our rats to sunitinib lasted 8 days and the compound was given orally, 
whereas in SD rats, SU5416 was administered intra-peritoneally.  
We and others have reported that administration of  RTKIs or a rise in sFlt-1 in 
preeclamptic patients, is associated with activation of  the endothelin system and that 
this activation plays a central role in the BP rise.7, 8, 10, 28 In the present study, circulating 
ET-1 levels tended to be higher during sunitinib administration, but especially the 
combination of  a HS diet and sunitinib was associated with a huge increase in urinary 
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ET-1 excretion. This increased urinary ET-1 excretion was not accompanied by renal 
overexpression of  the genes encoding for preproET-1 or for endothelin converting 
enzyme. This finding suggests that this urinary ET-1 is mainly plasma-derived, reaching 
the urine by glomerular filtration, as also supported by the observed correlation between 
proteinuria and endothelinuria. 
Selective, genetic, embryonic deletion of  VEGF-A from renal tubules results in a 
decrease in peritubular capillaries and the formation of  a small kidney.4 Because of  this 
crosstalk between tubular-derived VEGF-A and peritubular microvessels we explored 
whether administration of  sunitinib was associated with a decrease in peritubular vascular 
density. This appeared not to be the case, suggesting that such a phenotype only occurs 
following embryonic interruption of  the tubular VEGF pathway, which is supported by 
studies in patients who develop renal injury while treated with anti-angiogenic agents. 
In these patients by far the most frequently reported lesion is glomerular thrombotic 
microangiopathy and not tubulointerstitial injury.13, 21, 29-31
In conclusion, this study shows that a HS diet in normotensive WKY rats is associated 
with a marked rise in BP and exacerbation of  renal glomerular renal injury in response 
to a dose of  sunitinib that induces a rise in BP comparable to that observed in patients 
treated with this agent. We acknowledge that the duration of  administration of  sunitinib 
was relatively short. Whether more prolonged administration will eventually result in 
renal tubulointerstitial injury and peritubular rarefaction requires further investigation. 
The observation that a HS diet aggravates the rise in BP and renal injury may have 
implications for patients treated with angiogenesis inhibitors. These patients, especially 
when on long-term treatment with these agents as occurs in the neoadjuvant setting, 
should be advised to limit their dietary salt intake.
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CHAPTER 8
cumulatiVe dose oF beVaciZumab is 
associated WitH albuminuria ratHer tHan 
podocyturia in cancer patients
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abstract
Angiogenesis inhibition with bevacizumab, a monoclonal antibody against VEGF, is 
an effective anti-cancer treatment associated with hypertension and renal glomerular 
toxicity referred to as a preeclampsia-like syndrome. In preeclampsia, podocyturia, i.e. 
shedding of  viable podocytes in the urine, predates proteinuria and clinical features of  
preeclampsia, and as such is regarded as a biomarker of  ongoing glomerular injury. Using 
a recently validated quantitative polymerase chain reaction of  the podocyte-specific 
molecules nephrin, podocin and vascular endothelial growth factor A (VEGF-A) in 
the urine, we examined whether podocyturia is present in bevacizumab-treated cancer 
patients, and to what extent it relates to proteinuria, and the cumulative dose of  
bevacizumab. Urine samples were cross-sectionally collected from bevacizumab-treated 
patients (n=33), chemotherapy treated patients (n=19), and healthy controls (n=6). 
Urinary protein-to-creatinine ratio (geometric mean and range) was 20.09 mg/mmol 
[range 5.15-284.4] in the bevacizumab group, compared to 11.03 mg/mmol [1.14-28.57] 
in the chemotherapy group (P<0.05) and 6.80 mg/mmol [3.87-12.12] (P<0.05) in the 
healthy controls. For the urinary albumin-to-creatinine ratio values were respectively 
2.72 mg/mmol [0.14-227.7], compared to 1.04 mg/mmol [0.20-3.51] and 0.21 mg/
mmol [0.12-0.67] (P<0.05). The cumulative dose of  bevacizumab ranged from 550 
to 93628 mg. Urinary podocin mRNA expression was not detectable, urinary nephrin 
mRNA expression (expressed per mmol creatinine) ranged from 0.01 to 8.09 and 
urinary VEGF-A mRNA from 0.01 to 0.27. Urinary nephrin mRNA expression was 
not correlated to the albumin-to-creatinine ratio or the cumulative dose of  bevacizumab 
in bevacizumab-treated patients, whereas the latter correlated with the albumin-to-
creatinine ratio (r=0.77; P<0.001). Our results demonstrate that a cumulative dose 
of  bevacizumab is closely correlated with albuminuria but not with podocyturia as 
measured with the qPCR technique, challenging the feasibility of  this measurement to 
monitor ongoing glomerular injury in patients chronically treated with bevacizumab. 
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introduction
Inhibition of  angiogenesis with humanized monoclonal antibodies to vascular 
endothelial growth factor (VEGF) or with tyrosine kinase inhibitors targeting VEGF 
receptors (VEGFRs) has become an established treatment for various tumor types.1-3 
For example, in colorectal and breast cancer the monoclonal antibody bevacizumab is 
used in combination with chemotherapy.1, 4 
Although successful, this therapy is associated with several side effects including 
hypertension and renal toxicity in a substantial proportion of  patients. These side effects 
may especially become problematic with prolonged treatment and may even be a reason to 
withdraw treatment.5, 6 The renal toxicity associated with angiogenesis inhibition includes 
proteinuria, renal function impairment and glomerular endotheliosis.7, 8 Hypertension 
and proteinuria during angiogenesis inhibition are also referred to as a preeclampsia-
like syndrome.9, 10 Preeclampsia (PE) is a pregnancy-related disorder characterized by 
proteinuria and hypertension. One of  the underlying pathogenetic mechanisms is an 
increased placental production of  soluble fms-like tyrosine kinase 1 (sFlt-1).11 Within 
the maternal circulation sFlt-1 binds VEGF thereby abrogating the VEGF-signaling 
pathway, and creating a condition similar to that induced by monoclonal antibodies to 
VEGF or VEGFRs currently used in cancer treatment.12
In the kidney, VEGF plays a dominant role in maintaining the integrity of  the glomerular 
filtration barrier.13, 14 VEGF is expressed in glomerular epithelial podocytes (epithelial 
cells) that form the final barrier to protein loss. Several podocyte proteins, including 
podocin, nephrin, synaptopodin and podocalyxin, maintain the structural and functional 
integrity of  the glomerular slit diaphragm through complex interactions.15 Podocyte 
loss, either due to apoptosis or through detachment from the glomerular basement 
membrane, followed by podocyturia, may cause disruption of  the glomerular filtration 
barrier leading to proteinuria.15 A prospective clinical study in pregnant women at the 
end of  the second trimester has demonstrated that podocyturia predates proteinuria 
and clinical features of  PE.15 In this study podocyturia was assessed using the laborious 
cell culture and immunofluorescence technique. Recently, Kelder et al demonstrated 
that quantitative polymerase chain reaction (qPCR) of  the podocyte-specific molecules 
nephrin, podocin and VEGF-A in urine distinguished preeclamptic patients from 
healthy pregnant and hypertensive controls and is a rapid and accurate tool for the 
detection of  urinary podocyte excretion.16 
Considering the comparable clinical and histopathological features of  PE and VEGF-
inhibition-associated toxicity, we examined whether podocyturia, based on the recently 
developed qPCR technique, is present in bevacizumab-treated cancer patients, and to 
what extent is relates to proteinuria, and the cumulative dose of  bevacizumab.
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material and metHods
Clinical study
Using a cross-sectional study design, for the period of  one year, all patients who were 
on bevacizumab treatment at the department of  Oncology of  the Amphia Hospital, 
were invited to participate in this study. Since treatment with bevacizumab is often 
combined with chemotherapeutic drugs such as paclitaxel, trastuzumab, oxaliplatin and 
capecitabine, a group, treated with one or more of  these chemotherapeutics without 
bevacizumab, was included. A second control group consisted of  healthy subjects who 
visited the outpatient clinic for other medical issues (e.g. fatigue) without malignancy. 
Healthy controls with abnormal kidney function and/or proteinuria, and patients with 
known renal insufficiency and/or proteinuria, previous therapy with bevacizumab and 
concomitant chemotherapy commonly (>10% of  patients) associated with renal injury, 
were excluded. Abnormal kidney function was defined as an estimated glomerular 
filtration rate (eGFR)<60 ml/min, and proteinuria as a protein-to-creatinine ratio >45 
mg/mmol or albumin-to-creatinine-ratio >30 mg/mmol. In all patients, morning spot 
urine samples were collected during routine visits at the outpatient clinic to measure 
albumin, protein, creatinine and podocyturia. Furthermore, a blood sample was collected 
for determination of  serum levels of  sodium, potassium, urea, creatinine, albumin and 
calcium which were measured at the clinical chemical laboratory of  the Amphia hospital. 
eGFR was calculated using the MDRD formula. In addition, office blood pressure 
(BP) was measured. Patient’s characteristics, including type of  malignancy, use of  an 
angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, history of  
hypertension and diabetes mellitus, gender, age and cumulative dose of  bevacizumab, 
were collected. Urine samples were coded and processed anonymously. The study was 
approved by the medical ethical review committee of  the Amphia hospital. Written 
informed consent was obtained from each patient.
Urine Collection and Cell Isolation
Clean-catch urine samples were processed within 2 hours of  collection. Urine samples 
were transferred to tubes and centrifuged at 500 g for 5 minutes. Centrifuged urine samples 
were stored at -20°C. Albumin, protein and creatinine levels were measured from these 
urine samples. Pellets of  centrifuged urine samples were washed with phosphate buffered 
saline and centrifuged again at 500 g for 5 minutes. The pellets were suspended in RNAlater 
and stored at -20°C until RNA isolation. The RNA was isolated using the TRIzol method. 
Briefly, the cell suspension in RNAlater was centrifuged at 13 000 rpm for 2 minutes. 
Pellets were then dissolved with TRIzol, and RNA was isolated as described previously.17 
Quantitative Polymerase Chain Reaction
cDNA was generated with avian myeloblastosis virus reverse transcriptase (20 U/μL) 
(Roche), according to manufacturer instructions. For the qPCR reaction, iQ SYBR 
Green super-mix (BioRad) was used. Expression of  a podocyte-specific marker was 
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measured using  gene-specific primers. The primer sequences used are shown in Table 
1. Podocyturia was determined by measuring the expression of  nephrin and podocin, 
coding for proteins that are localized to the slit diaphragm of  podocyte foot processes. 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a positive control. 
The levels of  VEGF-A mRNA were also measured. In the kidney, VEGF is expressed 
in podocytes and in the proximal tubular epithelium. Relative mRNA levels detected 
by qPCR were corrected for creatinine concentration and calculated per mL of  urine.18
Table 1. Human primer sequences used for qpcr analyses
Statistical methods
Data are presented as mean±SEM or geometric mean and range for non-normally 
distributed values. Patient characteristics were compared using an unpaired t-test. 
mRNA levels of  nephrin, podocin and VEGF-A were compared using repeated-
measures ANOVA followed by Newman-Keuls or Dunnett’s multiple testing. Data 
were logarithmically transformed before analysis in case of  non-normal distribution. 
Correlations among the expression of  the different markers and clinical characteristics 
were calculated using Spearman r coefficient. P<0.05 was considered significant. 
GraphPad Prism version 5.0 was used for all statistical analysis.
results
Patients characteristics 
Patient characteristics are shown in Table 2. The cumulative dose of  bevacizumab 
ranged from 550 to 93628 mg. As expected, patients treated with bevacizumab had 
higher systolic BP compared to patients on chemotherapy (P=NS). The systolic BP in 
the healthy control group was lower than in both other groups, likely related to their 
much younger age (P<0.05).
Albuminuria and Proteinuria
Mean protein-to-creatinine ratio was 20.09 mg/mmol [5.15-284.4] in the bevacizumab 
group, compared to 11.03 mg/mmol [1.14-28.57] in the chemotherapy group (P<0.05) 
and 6.80 mg/mmol [3.87-12.12] (P<0.05) in the healthy controls. Proteinuria was 
present in 18% of  bevacizumab treated patients. Mean albumin-to-creatinine ratio 
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was 2.72 mg/mmol [0.14-227.7] in the bevacizumab group compared to 1.04 mg/
mmol [0.20-3.51] in the chemotherapy group (P<0.05) and 0.21 mg/mmol [0.12-0.67] 
in healthy controls (P<0.05). Microalbuminuria was present in 18% of  bevacizumab 
treated patients. The albumin-to-creatinine, but not the protein-to-creatinine ratio, was 
significantly correlated with cumulative dose of  bevacizumab (Figure 1A). 
Table 2. patient characteristics
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Figure 1. relation of cumulative dose of bevacuzimab with albuminuria (a), with nephrinuria (b) and of 
albuminuria with nephrinuria in bevacuzimab treated patients (c). nephrinuria is presented as mrna 
expression/mmol creat.
Podocyturia 
The house-keeping gene GADPH was detected in every sample, and its expression 
levels were similar among the three groups suggesting that the quality of  RNA isolated 
from urinary cells was sufficient for amplification. Urinary nephrin mRNA expression 
(expressed per mmol creatinine) ranged from 0.01 to 8.09 and urinary VEGF-A mRNA 
from 0.01 to 0.27. Relative VEGF-A and nephrin mRNA expression between the 
groups did not differ (data not shown) and podocin mRNA was not detectable in any 
of  the analyzed urine samples (data not shown). Relative VEGF-A and nephrin mRNA 
expression were correlated (r=0.61;P<0.01). Nephrin mRNA expression was not 
correlated with either the cumulative dose of  bevacizumab or the albumin-to-creatinine 
ratio in bevacizumab-treated patients. In addition, no correlations were found between 
podocyturia and BP and eGFR (data not shown). VEGF-A mRNA expression was not 
correlated with either the cumulative dose of  bevacizumab or the albumin-to-creatinine 
ratio in bevacizumab-treated patients. 
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discussion
To our knowledge, this is the first study to describe the use of  qPCR to quantify 
podocyturia in the context of  angiogenesis inhibition. In the present study, no elevated 
levels of  nephrin mRNA or VEGF-A mRNA were detected in the urine of  patients 
treated with the VEGF inhibitor bevacizumab when compared to patients treated 
with chemotherapy only or to healthy controls. Furthermore, there was no significant 
relationship between qPCR nephrinuria and albuminuria or between qPCR nephrinuria 
and the cumulative dose of  bevacizumab. However, albuminuria was positively 
correlated to the cumulative doses of  bevacizumab.  
There is increasing evidence that podocyte injury plays a key role in the renal 
manifestations of  PE, a pregnancy-related disease with similar renal pathological 
changes as angiogenesis inhibition-induced toxicity, including glomerular endotheliosis, 
and the presence of  hypertension and proteinuria. Podocyte-specific conditional 
knockout of  VEGF-A in mice is known to result in podocyte loss, proteinuria and 
glomerular thrombotic microangiopathy.13 Likewise, anti-VEGF-treatment in patients 
is associated with comparable renal abnormalities as observed in preeclamptic women.13 
Yu et al. have shown that podocyturia may be a more sensitive marker of  ongoing 
glomerular damage than proteinuria, due to the fact that the tubules are capable of  
reabsorbing filtered protein.19 To date, several studies reported the presence of  
podocyturia in preeclamptic patients and observed that it can predict the development 
of  PE.15, 16, 20-22 Podocyturia has also been reported in proteinuric patients during anti-
VEGF treatment.23, 24 In a small cross-sectional study of  27 patients reported by Muller-
Deile et al., albuminuria and podocyturia were found in 95% and 32% respectively, of  
bevacizumab treated patients, compared to 100% and 13% of  sunitinib treated patients.23 
Remarkably, the incidence of  albuminuria was much higher than that of  podocyturia. 
A recent study of  Garovic et al. showed that 60% of  patients treated with a VEGF 
inhibitor had evidence of  podocyturia.24 In addition, they demonstrated a correlation 
between the cumulative dose of  bevacizumab and both proteinuria and podocyturia, 
as well as a correlation between the number of  urinary podocytes and the amount 
of  proteinuria, suggesting that these variables are mechanistically related. It must be 
mentioned that patients treated with the combination of  anti-VEGF therapy and 
cytotoxic agents known to induce renal injury in over 10% of  patients, such as cisplatin, 
were also included in that study. The same holds true for patients on anti-VEGF agents 
in combination with other targeted therapies. Compared to our own study, in which 
patients on cytotoxic agents known to induce renal toxicity or on previous or dual-
targeted therapy were excluded, the inclusion of  these patients in the study of  Garovic 
et al. might account for the higher incidence of  proteinuria and podocyturia and the 
positive correlation between these two variables, despite the lower cumulative dose of  
bevacizumab.
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In all of  the mentioned studies, cell culture and immunofluorescence techniques by 
counting podocyte positive cells were used. A drawback of  that method is that it is 
time-consuming with a test result obtained after 2 days at the earliest. Kelder et al., by 
using a more rapid qPCR method have demonstrated significantly elevated nephrin, 
podocin, and VEGF-A mRNA in the urine of  preeclamptic women when compared to 
levels in healthy pregnant controls and healthy non-pregnant controls.16 Cell culture and 
immunofluorescence techniques of  the same urine samples revealed that the number of  
podocytes closely correlated with the levels of  nephrin mRNA. However, similar to the 
present results, podocyturia and albuminuria were not correlated.16 Since in our study 
only 18% of  the bevacizumab-treated patients had albuminuria a correlation might 
be difficult to find, moreover podocyturia can be present without the appearance of  
proteinuria.25 Considering these differences, and the fact that in the mentioned study 
of  Muller-Deile et al. the incidence of  albuminuria was much higher than that of  
podocyturia in their cancer patients on bevacizumab or sunitinib treatment, podocyturia 
and albuminuria might provide different information.
Why we did not observe any differences in podocyturia between the groups of  subjects 
in contrast to previous studies on anti-VEGF therapies and studies in PE is not clear. 
The different anti-VEGF mechanisms, anti-VEGF monoclonal antibody (bevacizumab) 
versus receptor tyrosine kinase inhibitor (sunitinib) or circulating sFlt-1, might induce 
different degrees of  VEGF inhibition. To further explore this, it would be interesting 
to determine podocyturia using the qPCR method in patients treated with one of  the 
receptor tyrosine kinase inhibitors. Also, the qPCR-technique might be less specific 
than the cell culture and immunofluorescence technique, since it cannot differentiate 
between viable and non-viable podocytes. However, Kelder et al. demonstrated that 
mRNA levels of  podocyte-specific markers correlated with the number of  viable 
podocytes in patient’s samples.16 
In conclusion, our results demonstrate that a cumulative dose of  bevacizumab is 
correlated with albuminuria but not with podocyturia as measured with the qPCR 
technique. This contrasts with observations in PE, notwithstanding the clinical and 
pathophysiological similarities of  both conditions. Compared to angiogenesis inhibition 
with bevacizumab the development of  sometimes severe proteinuria occurs in a much 
shorter time span in PE, indicating more intensive, acute renal damage in this condition. 
This likely implies more extensive podocyte damage as reflected by more pronounced 
podocyturia. Finally, podocyturia in our study was assessed while almost all patients were 
on bevacizumab treatment for extended periods. Possibly, the presence of  podocyturia is 
more pronounced at the beginning of  anti-VEGF treatment, predating the development 
of  proteinuria, and attenuates during prolonged treatment. This could explain the 
absent association between the cumulative bevacizumab dose and podocyturia in our 
study. Prospective studies with repeated measurements of  podocyturia are needed to 
further explore this.
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summary
Angiogenesis, the formation of  new vessels from preexisting vasculature, is critical 
to solid tumor growth as well as metastasis. This process is regulated by numerous 
factors among which vascular endothelial growth factor (VEGF) plays a dominant 
role. Angiogenesis inhibition, by targeting VEGF or its receptors, has become an 
established treatment of  various types of  cancer. Bevacizumab is a humanized 
monoclonal antibody against VEGF, whereas sunitinib is an orally active angiogenesis 
inhibitor that blocks VEGF receptors -1, -2 and -3 and other tyrosine kinase receptors. 
VEGFR-1 and VEGFR-2 are predominantly expressed on vascular endothelial cells, 
whereas VEGFR-3, stimulated by VEGF-C, is restricted to lymphatic endothelial cells. 
Unfortunately, this therapy is associated with severe side effects, including hypertension 
and renal injury, the latter reflected by proteinuria and renal function impairment. 
Because the occurrence of  these adverse effects can be a reason to lower the dose of  
the anti-VEGF agent or even to discontinue anticancer therapy, thereby compromising 
its potential efficacy, the present studies explored new therapeutic approaches, as well 
as the dose- and salt dependency of  these side effects. 
In virtually every patient exposed to anti-VEGF treatment blood pressure (BP) rises. The 
incidence of  hypertension induced by anti-VEGF treatment ranges from 9% to 67%, 
whereas Grades 3 to 4 hypertension has been reported in 3-18% of  patients.1 The risk 
to develop severe hypertension is increased in patients with a history of  hypertension. 
The incidence of  hypertension is dose-dependent and increases to over 90% when 
bevacizumab and sunitinib are combined.2 The rise in BP is caused by a rise in systemic 
vascular resistance and can develop within hours to days after treatment initiation.3, 
4Although hypertension has initially been considered to be a toxic effect of  anti-
angiogenic therapy, evidence has accumulated that the development of  hypertension is 
predictive for a favourable anti-tumor response and improved survival.5-7 The incidence 
of  proteinuria associated with angiogenesis inhibition appears to be lower than that of  
hypertension and its severity may vary from <1 gram/day (Grade 1) to nephrotic range 
proteinuria.8, 9 (Chapters 1 and 2). 
Since binding of  VEGF to its receptors increases endothelial nitric oxide synthase 
(eNOS) and thus nitric oxide (NO) bioavailability, it has been suggested that inhibition 
of  the VEGF-pathway reduced NO bioavailability resulting in vasoconstriction and 
rise in BP. Additionally, decreased NO bioavailability disturbs the balance between the 
vasodilator NO and the vasoconstrictor endothelin-1 (ET-1), favoring ET-1 production 
as well its action, thereby inducing further vasoconstriction and an additional rise in 
BP. The first clinical evidence for the involvement of  an activated ET-1 system during 
VEGF inhibition stems from a study with sunitinib by our group.3 In patients with 
either metastatic renal cell cancer or imatinib-resistant gastrointestinal stromal tumors, 
administration of  sunitinib was associated with a doubling of  circulating ET-1 levels. In 
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successive studies in rats, we found that administration of  sunitinib was also associated 
with an increase in serum ET-1 concentration, returning to pre-sunitinib values after 
its discontinuation.10 In addition, co-administration of  the dual endothelin (ETA/ETB) 
receptor blocker macitentan could to a large extent prevent the sunitinib-induced BP 
rise and proteinuria (Chapter 2). 
Since endothelin receptor (ET-R) blockers are not approved for the treatment of  systemic 
hypertension and renal injury.11, we determined the most optimal way to prevent the 
sunitinib-induced adverse effects and explored their interdependency, by investigating 
also other antihypertensive agents; the calcium channel blocker (CCB) amlodipine, the 
angiotensin-converting enzyme (ACE) inhibitor captopril and the phosphodiesterase 
type 5 (PDE5) inhibitor sildenafil in our sunitinib rat model. After sunitinib start, mean 
arterial pressure (MAP) increased rapidly by about 30 mmHg. Co-administration of  
macitentan or amlodipine attenuated the sunitinib-induced rise in BP by 73% and 63% 
respectively, whereas co-administration of  both dosages of  captopril and sildenafil had 
no BP-lowering effect. In rats, proteinuria increased to about 30 mg per day during 
sunitinib administration. The rise in proteinuria was attenuated by macitentan, captopril 
and sildenafil. Conversely, proteinuria tended to increase further with amlodipine. Of  
interest, both captopril and sildenafil increased the steady-state sunitinib concentrations. 
We conclude that in our experimental model ET-R antagonism and calcium channel 
blockade are suitable to prevent angiogenesis inhibition induced-hypertension, while 
ET-R antagonism, ACE and PDE5 inhibition can prevent angiogenesis-inhibition 
induced proteinuria (Chapter 4). 
In our previous rat studies, we used a sunitinib dose of  26.7 mg/kg.day by oral gavage. 
This high dose was associated with a rapid development of  severe hypertension, 
proteinuria and irreversible glomerular renal injury, making it difficult to infer to what 
extent the renal injury is BP-independent. Additionally, the extent of  sunitinib-mediated 
side-effects in this particular model at this dose is much more severe than seen in 
patients, rendering it questionable whether this dose adequately reflected the off-target 
effects of  sunitinib in clinical practice. By applying 3 different doses of  sunitinib, we 
tested the dose-dependency of  these side effects, aiming to find a sunitinib dose that, 
with regard to hemodynamic and renal side effects, including ET-1 elevation, better 
resembles the dose applied in patients. With this approach, we also wanted to unravel 
whether the proteinuria observed during antiangiogenic treatment occurs irrespective 
of  the presence of  glomerular histological changes. BP rose dose-dependently from 
13 to 30 mmHg. Proteinuria was present at all doses, but a rise in cystatin C occurred 
only at the intermediate and high dose. Circulating ET-1 increased dose-dependently, 
whereas 24-hour urinary endothelin excretion did not. Glomerular endotheliosis 
and ischemia were present with the intermediate and high doses of  sunitinib, but no 
histological abnormalities were observed with the low dose. From these findings we 
conclude that the sunitinib-induced rise in BP requires lower doses than its induction of  
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renal function impairment and that functional changes in glomerular filtration barrier 
contribute to the occurrence of  proteinuria, given the lack of  histopathological changes 
with the low dose of  sunitinib (Chapter 5).
Recent evidence indicates that in response to a high salt (HS) diet, sodium and 
chloride accumulates in the skin in excess of  water.12 This results in a hypertonic 
interstitial fluid compartment, stimulating skin lymphangiogenesis via activation of  the 
mononuclear-phagocyte system (MPS) cell-derived VEGF-C-VEGF type 3 receptor 
signalling pathway.13, 14 Inhibition of  this pathway results in salt-sensitive hypertension. 
Since sunitinib, aside from blocking VEGFR-1 and VEGFR-2 signaling, also blocks 
the VEGFR-3 signaling that mediates lymphangiogenesis, we hypothesized that 
sunitinib administration impairs lymphangiogenesis in response to a HS diet, and that 
this impairment leads to Na+ and especially Cl- accumulation in the skin interstitium, 
contributing to salt-sensitive hypertension. Rats were exposed to a normal (NS) or HS 
diet with or without sunitinib administration. Sunitinib induced a 15 mmHg rise in BP, 
which was aggravated by a HS diet, resulting in a decline of  the slope of  the pressure-
natriuresis curve. This rise in BP was not accompanied by an increase in body weight or 
changes in plasma sodium concentration or renal function impairment. Furthermore, a 
HS led to a proportionally comparable increase in Na+ and Cl- which is higher than the 
proportional increase in water content in the skin, and associated with an accentuated 
MPS cells infiltration in the skin that was not affected by sunitinib administration. 
Independent of  diet, sunitinib tended to decrease lymphangiogenesis. We therefore 
concluded that sunitinib administration is associated with salt-sensitive hypertension 
that can be explained by impaired skin lymphangiogenesis only partly, suggesting that 
other factors are involved (Chapter 6).
In previous studies we have shown that the hypertension induced by sunitinib is 
accompanied by a decreased NO production and renin suppression.3, 10, 15 i.e. conditions 
related to an increased sensitivity of  BP to salt.16, 17 In the present study, we explored 
whether the augmented rise of  BP during a HS diet, as obtained in chapter 6, also 
translates into more pronounced renal damage, and whether or not this is exacerbated 
by a HS diet. The HS diet itself  had no effect on proteinuria, endothelinuria or plasma 
levels of  ET-1, creatinine, and cystatin C. Only with the HS diet, sunitinib administration 
massively increased proteinuria and endothelinuria. Likewise, renal glomerular pathology 
was enhanced during sunitinib with the HS diet, whereas tubulointerstitial injury or 
reduced peritubular capillary density did not occur (Chapter 7).
The combination of  hypertension and renal injury during angiogenesis inhibition is 
often referred to as a preeclampsia-like syndrome. Preeclampsia, a condition occurring 
after 20 weeks of  pregnancy, is characterized by hypertension, proteinuria, elevated 
circulating ET-1 levels as well as glomerular endotheliosis. Indeed, we demonstrated 
that angiogenesis inhibition with sunitinib in rats induced similar clinical and renal 
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histopathological characteristics (Chapters 4 and 5). The renal injury during angiogenesis 
inhibition associates with podocyte injury. It has been suggested that the appearance of  
podocytes in urine, i.e., podocyturia, could be a sensitive marker for ongoing glomerular 
disease predating proteinuria. Using a recently validated quantitative polymerase chain 
reaction (qPCR) of  the podocyte-specific molecules nephrin, podocin and VEGF-A 
in the urine.18, we examined whether podocyturia is present in bevacizumab-treated 
cancer patients, and to what extent it relates to proteinuria, and the cumulative dose of  
bevacizumab. We observed no elevated levels of  nephrin mRNA or VEGF-A mRNA 
in the urine of  patients treated with the VEGF inhibitor bevacizumab when compared 
to patients treated with chemotherapy only or to healthy controls. Furthermore, there 
was no significant relationship between qPCR nephrinuria and albuminuria or between 
qPCR nephrinuria and the cumulative dose of  bevacizumab. Only albuminuria was 
positively correlated to the cumulative doses of  bevacizumab, challenging the feasibility 
of  the qPCR measurement of  podocyte-specific molecules to monitor ongoing 
glomerular injury in bevacizumab treated patients (Chapter 8).
discussion
Administration of  the multi-target VEGF receptor blocker sunitinib is accompanied 
by a rise in BP, renal injury and proteinuria, activation of  the ET-1 axis and renin 
suppression. Previously, we found that the rise in BP and proteinuria could be largely 
prevented by the dual (ETA/ETB) receptor antagonist macitentan, indicating that 
activation of  the ET-1 axis is critical for the development of  these side effects.10
Co-administration of  amlodipine with sunitinib was associated with a marked attenuation 
of  the rise in BP, comparable to the degree observed with macitentan. However, renal 
injury could not be prevented while proteinuria even tended to increase. In contrast, co-
administration of  captopril and sildenafil was associated with a decrease in proteinuria 
and renal injury, but without effect on BP. These findings strongly suggest that these side 
effects are, at least in part, unrelated. Obviously, over more prolonged periods of  time 
hypertension may further aggravate the renal injury by angiogenesis inhibition, whereas 
vice versa, renal injury may contribute to a further rise in BP. Based on the present 
observations together with other experimental and clinical studies, showing that the 
hypertension induced by sunitinib is associated with renin suppression, dihydropyridine 
calcium channel blockers, rather than agents targeting the renin-angiotensin system 
(RAS), are probably more effective for the treatment of  hypertension.19 Given their 
beneficial effects on the occurrence of  proteinuria, an anti-RAS agent can be combined 
with a calcium channel blocker in case of  the development of  renal injury. Although 
NO-donors like nitrates or PDE5 inhibitors may also be beneficial, it has been suggested 
that these agents may potentially compromise the anti-angiogenic effect and therefore 
they can best be avoided.20 (Chapter 4).
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With the lowest dose of  sunitinib applied (7 mg/kg.day), the BP rise of  about 10 mmHg 
is of  similar magnitude as the BP rise we have observed in patients after 2 and after 4 
weeks administration of  sunitinib in rats, stressing the potential relevance of  our low-
dose model for the clinical situation.3 Of  note, the plasma sunitinib concentration with 
the low dose of  sunitinib was comparable to the concentration measured in patients 
treated with a standard dose of  sunitinib of  50 mg per day.21 However, the concentration 
of  its active metabolite n-desethyl sunitinib was markedly higher, indicating increased 
metabolism of  the parent compound in rats, as has been reported previously.22 In line 
with our previous observations, sunitinib treatment was associated with activation of  the 
circulating endothelin system, which was already present at the low dose of  sunitinib.3, 
10 The observed rise in ET-1 may be a direct consequence of  VEGF inhibition, as 
shown in human lung microvascular endothelial cells.23 The rise may also be related 
to the activation of  the endothelium in response to VEGF inhibition. This, however, 
was not supported by the finding that, despite activation of  glomerular endothelial 
cells as reflected by the presence of  glomerular endotheliosis and increased glomerular 
expression of  ICAM-1, expression of  the gene encoding for ET-1 within the kidney 
was not increased. In addition to a direct adverse effect of  VEGF inhibition on 
podocyte function and expression of  slit-diaphragm proteins, ET-1 can exert negative 
effects on podocyte function, which, additionally to the disruption of  VEGF pathway, 
may contribute to glomerular injury and proteinuria.24-27 Given the present observation 
that urinary ET-1 excretion was not increased during sunitinib administration or even 
decreased, the possibility that activation of  ET-1 axis has contributed to the proteinuria 
in our rat model remains questionable. If  ET-1 is involved it should, based on the present 
findings and an earlier study, reach the podocytes by ultrafiltration.26 (Chapter5). 
Machnik and colleagues have shown that skin electrolyte accumulation, in response to 
a HS diet, stimulates the formation of  lymph capillaries, driven by MPS cells infiltrating 
the interstitium of  the skin.14 The authors also demonstrated that macrophage-derived 
VEGF-C mediates this lymphangiogenesis and that interruption of  this pathway leads to 
salt-sensitive hypertension. In our study, a HS diet was indeed accompanied by increased 
MPS cells infiltration and lymphangiogenesis. Yet, despite the fact that sunitinib has 
shown shown to inhibit lymphangiogenesis.28, we observed only a very modest decrease 
in the HS diet-induced lymphangiogenesis during sunitinib administration. Although 
an insufficient dose is the most obvious explanation, this is not supported by previous 
pharmacokinetic and in vitro studies.28 In Chapter 5 we reported that the same dose 
of  sunitinib as used in the present study was associated with a plasma concentration 
of  sunitinib and its active metabolite N-desethyl sunitinib of  about 350 nanogram/
mL or 875 nmol/L. In an in vitro study, sunitinib concentrations as low as 30 nmol/L 
were shown to impair lymphangiogenesis.28 Based on these data it is not very likely that 
the dose of  sunitinib was the limiting factor to impair lymphangiogenesis. As reported 
earlier, administration of  tyrosine kinase inhibitors is associated with activation of  the 
endothelin system as well as suppression of  the NO pathway and renin suppression 
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(Chapter 4).3, 10 As suggested by Gu et al., suppression of  the NO pathway can 
contribute to the salt-sensitive BP observed with anti-VEGF treatment.29 Likewise, it is 
well established that renin suppression is associated with salt-sensitive hypertension.17, 
30, 31 To what extent activation of  the endothelin system, occurring during sunitinib 
administration, contributes to salt-sensitive hypertension is not easy to answer because 
of  the opposing effects on natriuresis mediated by the renal ETA and ETB receptors.
32 
However, it has been reported that infusion of  ET-1 in Sprague-Dawley rats induces 
hypertension when rats are on a high - but not on a low salt diet.33, 34 Similarly, transgenic 
mice overexpressing endothelial ET-1 had a significantly higher BP when on a HS diet 
than their wild-type littermates.35 These studies support the contention that an activated 
ET-1 system may contribute to salt-sensitive hypertension (Chapter 6).
Despite the marked rise in BP, a HS diet was not accompanied by proteinuria, impairment 
of  renal function or histological glomerular or tubulointerstitial changes. However, with 
regard to renal injury, a clear interaction between the HS diet and suntinib exposure 
was present. Administration of  sunitinib to rats on a HS diet as compared to rats on 
a NS diet was associated with pronounced proteinuria and endothelinuria, as well as 
glomerular epithelial cell swelling. Although histologically tubulointerstitial injury was 
not apparent, sunitinib administration induced an increased expression of  the gene 
encoding for NGAL, a marker of  tubular injury, in rats exposed to the HS diet. In 
previous preclinical and clinical studies, we and others have reported that administration 
of  tyrosine kinase inhibitors or a rise in sFlt-1 in preeclamptic patients, is associated 
with activation of  the endothelin system and that this activated endothelin system plays 
a central role in the rise in BP.3, 10, 36, 37 In the present study, circulating ET-1 levels 
tended to be higher during sunitinib administration, but especially the combination of  
a HS diet and sunitinib was associated with a huge increase in urinary ET-1 excretion. 
Remarkably, this increased urinary ET-1 excretion was not accompanied by an increased 
renal expression of  the genes encoding for preproET-1 or endothelin converting 
enzyme. This suggests that this urinary ET-1 is plasma-derived. The observed 
glomerular injury may be due to enhanced filtration of  ET-1, which is supported by 
the correlation between proteinuria and endothelinuria. Selective, genetic, embryonic 
deletion of  VEGF from renal tubules results in a decrease in peritubular capillaries 
and the formation of  a small kidney.38 Because of  this crosstalk between tubular-
derived VEGF-A and peritubular microvessels we explored whether administration of  
sunitinib was associated with a decrease in peritubular vascular density. This appeared 
not to be case, suggesting that such a phenotype may only occur following embryonic 
interruption of  the tubular VEGF pathway. This is indirectly supported by studies in 
patients treated with antiangiogenic agents who develop renal injury. In these patients 
the most frequently reported lesion is glomerular thrombotic microangiopathy, likely 
preceded by glomerular endotheliosis.39-43 (Chapter 7).
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Podocyte-specific conditional knockout of  VEGF-A in mice is known to result in 
podocyte loss, proteinuria and glomerular thrombotic microangiopathy.39 Likewise, 
anti-VEGF-treatment in patients is associated with comparable renal abnormalities as 
observed in preeclamptic women.39 The first study which describes podocyturia during 
VEGF inhibition is reported by Muller-Deile et al.; here albuminuria and podocyturia 
were found in 95% and 32% respectively, of  bevacizumab treated patients, compared to 
100% and 13% of  sunitinib treated patients.44 Remarkably, the incidence of  albuminuria 
was much higher than that of  podocyturia. A recent study of  Garovic et al. showed 
that 60% of  patients treated with a VEGF inhibitor had evidence of  podocyturia.45 In 
addition, they demonstrated a correlation between the cumulative dose of  bevacizumab 
and both proteinuria and podocyturia, as well as a correlation between the number of  
urinary podocytes and the amount of  proteinuria, suggesting that these variables are 
mechanistically related. It must be mentioned that patients treated with the combination 
of  anti-VEGF therapy and cytotoxic agents known to induce renal injury in over 10% 
of  patients, such as cisplatin, were also included in that study. The same holds true for 
patients on anti-VEGF agents in combination with other targeted therapies. Compared 
to our own study, in which patients on cytotoxic agents known to induce renal toxicity 
or on previous or dual-targeted therapy were excluded, the inclusion of  these patients 
in the study of  Garovic et al. might account for the higher incidence of  proteinuria and 
podocyturia and the positive correlation between these two variables, despite the lower 
cumulative dose of  bevacizumab. Since in our study only 18% of  the bevacizumab-
treated patients had albuminuria a correlation might be difficult to find, moreover 
podocyturia can be present without the appearance of  proteinuria.46 Considering these 
differences, and the fact that in the above-mentioned study of  Muller-Deile et al. the 
incidence of  albuminuria was much higher than that of  podocyturia in their cancer 
patients on bevacizumab or sunitinib treatment, podocyturia and albuminuria might 
provide different information. 
Why we did not observe any differences in podocyturia between the groups of  subjects 
in contrast to previous studies on anti-VEGF therapies and studies in PE is not clear. 
Our results demonstrate that a cumulative dose of  bevacizumab is correlated with 
albuminuria but not with podocyturia as measured with the qPCR technique. This 
contrasts with observations in PE, notwithstanding the clinical and pathophysiological 
similarities of  both conditions.18 Compared to angiogenesis inhibition with bevacizumab, 
the development of  sometimes severe proteinuria occurs in a much shorter time span 
in PE, indicating more intensive, acute renal damage in this condition. This likely 
implies more extensive podocyte damage as reflected by more pronounced podocyturia. 
Furthermore, podocyturia in our study was assessed while almost all patients were on 
bevacizumab treatment for extended periods. Possibly, the presence of  podocyturia is 
more pronounced at the beginning of  anti-VEGF treatment, predating the development 
of  proteinuria, and attenuates during prolonged treatment. This could explain the 
absent association between the cumulative bevacizumab dose and podocyturia in our 
study (Chapter 8). 
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perspectiVes
Given the lack of  large clinical studies, we provided further insight into the mechanisms 
underlying sunitinib-induced hypertension and proteinuria as well as ways to counteract 
these adverse events using a recently developed rat model.  Translation of  the findings 
in this model to the clinic strongly suggests that dependent on the toxicity encountered, 
different classes of  antihypertensive agents should preferably be used, i.e. a CCB in 
the case of  hypertension and a RAS blocker in the case of  renal injury. Of  interest, 
both captopril and sildenafil increased the steady-state sunitinib concentrations. The 
underlying pharmacokinetic interaction is currently unknown, but warrants further 
investigation in humans, not only because it may enhance the anti-cancer effectiveness 
of  sunitinib, but potentially also its side-effect profile. With respect to the relatively 
short observation period of  8 days during our previous studies, it would be interesting 
to see whether the rise in BP and renal pathology is progressive during more prolonged 
exposure to sunitinib (Chapter 4).  
With the lowest dose of  sunitinib the serum concentration of  the active metabolite 
was considerably higher than observed in patients, yet the rise in BP was comparable. 
Finally, although in the present study we have focussed on the renal effects of  sunitinib, 
it is well known that VEGF inhibition can also have negative effects on other organs, 
especially the myocardium and endocrine organs. In more long-term studies it would be 
interesting to see whether the lowest or even a still lower dose of  sunitinib as used in 
the present study still preferentially affects the kidney or also has adverse effects on the 
myocardium and endocrine organs when administrated for prolonged periods. In future 
experiments it should be explored whether blockade of  the endothelin pathway can 
completely prevent the development of  hypertension and renal injury in rats exposed 
to low doses of  sunitinib for prolonged periods. This would provide evidence that 
activation of  the endothelin pathway is an essential mediator of  the rise in BP and 
renal toxicity associated with antiangiogenic treatment. Moreover, it should be explored 
whether ETA-selective receptor antagonism is more favourable than blockade of  both 
the ETA and ETB receptor (Chapter 5).  
Sunitinib administration to rats, in a relatively low dose not inducing renal function 
impairment, is associated with salt-sensitive hypertension. Impairment of  the skin MPS 
cells-TonEBP-VEGF-VEGFR-3-lymphangiogenesis pathway has been recognized 
as a novel mechanism involved in salt-sensitive hypertension. Unexpectedly, because 
sunitinib is known to block the VEGFR-3-signaling pathway (thereby inhibiting 
lymphangiogenesis in in vitro studies), we only observed very modestly blocked 
lymphangiogenesis during sunitinib treatment. Therefore, it is more likely that other 
mechanisms such as renin suppression, a decrease in NO production and activation of  
the endothelin system contribute to a larger extent to the salt-sensitive hypertension 
during sunitinib administration. Whether more prolonged administration of  sunitinib 
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impairs the formation of  lymph vessels in response to a HS diet, and eventually results in 
renal tubulointerstitial injury and peritubular rarefaction requires further investigation. 
Furthermore, the observation that a HS diet aggravates the rise in BP and renal injury 
may have implications for patients treated with angiogenesis inhibitors. These patients, 
especially when on long-term treatments as occurs in the neoadjuvant setting, should be 
advised to limit their dietary salt intake. Finally, given that interruption of  the VEGF-
signaling pathway is associated with activation of  the endothelin system, it would be 
interesting to explore whether the sunitinib-induced salt-sensitive hypertension can be 
prevented by ETA-selective or ETA/ETB receptor blockade (Chapters 6 and 7).
Since only albuminuria was positively correlated to the cumulative doses of  bevacizumab, 
it challenges the feasibility of  the measurement of  podocyturia to monitor ongoing 
glomerular injury in bevacizumab treated patients. The different anti-VEGF modalities, 
anti-VEGF monoclonal antibody (bevacizumab) versus receptor tyrosine kinase 
inhibitor (sunitinib) or circulating sFlt-1, might induce different degrees of  VEGF 
inhibition. To further explore this, it would be interesting to determine podocyturia 
using the qPCR method in patients treated with one of  the receptor tyrosine kinase 
inhibitors. Prospective studies with repeated measurements of  podocyturia are needed 
to further explore this (Chapter 8).
reFerences
1. Lankhorst S, Kappers MH, van Esch JH, Danser AH, van den Meiracker AH. 
Hypertension during vascular endothelial growth factor inhibition: Focus on nitric 
oxide, endothelin-1, and oxidative stress. Antioxid Redox Signal. 2014;20:135-145.
2. Escalante CP, Zalpour A. Vascular endothelial growth factor inhibitor-induced 
hypertension: Basics for primary care providers. Cardiol Res Pract. 2011;2011:816897.
3. Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AH, van den Meiracker AH. 
Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with 
increased circulating endothelin-1 levels. Hypertension. 2010;56:675-681.
4. Maitland ML, Kasza KE, Karrison T, Moshier K, Sit L, Black HR, Undevia SD, Stadler 
WM, Elliott WJ, Ratain MJ. Ambulatory monitoring detects sorafenib-induced blood 
pressure elevations on the first day of  treatment. Clin Cancer Res. 2009;15:6250-6257.
5. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of  axitinib versus 
sorafenib in advanced renal cell carcinoma (axis): A randomised phase 3 trial. Lancet. 
2011;378:1931-1939.
6. Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of  sunitinib 
activity. Ann Oncol. 2007;18:1117.
7. Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, Cascinu 
S. Arterial hypertension correlates with clinical outcome in colorectal cancer patients 
treated with first-line bevacizumab. Ann Oncol. 2009;20:227-230.
8. Kandula P, Agarwal R. Proteinuria and hypertension with tyrosine kinase inhibitors. 
chapter 9
151
Kidney Int. 2011;80:1271-1277.
9. Gurevich F, Perazella MA. Renal effects of  anti-angiogenesis therapy: Update for the 
internist. Am J Med. 2009;122:322-328.
10. Kappers MH, Smedts FM, Horn T, van Esch JH, Sleijfer S, Leijten F, Wesseling S, 
Strevens H, Jan Danser AH, van den Meiracker AH. The vascular endothelial growth 
factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation 
of  the endothelin system. Hypertension. 2011;58:295-302.
11. Weber MA, Black H, Bakris G, Krum H, Linas S, Weiss R, Linseman JV, Wiens BL, 
Warren MS, Lindholm LH. A selective endothelin-receptor antagonist to reduce blood 
pressure in patients with treatment-resistant hypertension: A randomised, double-
blind, placebo-controlled trial. Lancet. 2009;374:1423-1431.
12. Wiig H, Schroder A, Neuhofer W, et al. Immune cells control skin lymphatic electrolyte 
homeostasis and blood pressure. J Clin Invest. 2013;123:2803-2815.
13. Machnik A, Dahlmann A, Kopp C, Goss J, Wagner H, van Rooijen N, Eckardt KU, 
Muller DN, Park JK, Luft FC, Kerjaschki D, Titze J. Mononuclear phagocyte system 
depletion blocks interstitial tonicity-responsive enhancer binding protein/vascular 
endothelial growth factor c expression and induces salt-sensitive hypertension in rats. 
Hypertension. 2010;55:755-761.
14. Machnik A, Neuhofer W, Jantsch J, et al. Macrophages regulate salt-dependent volume 
and blood pressure by a vascular endothelial growth factor-c-dependent buffering 
mechanism. Nat Med. 2009; 15: 545-552.
15. Lankhorst S, Kappers MH, van Esch JH, Smedts FM, Sleijfer S, Mathijssen RH, 
Baelde HJ, Danser AH, van den Meiracker AH. Treatment of  hypertension and renal 
injury induced by the angiogenesis inhibitor sunitinib: Preclinical study. Hypertension. 
2014;64:1282-1289. 
16. Nakanishi K, Hara N, Nagai Y. Salt-sensitive hypertension in conscious rats induced by 
chronic nitric oxide blockade. Am J Hypertens. 2002;15:150-156.
17. Weinberger MH, Miller JZ, Luft FC, Grim CE, Fineberg NS. Definitions and 
characteristics of  sodium sensitivity and blood pressure resistance. Hypertension. 1986; 
8:II127-134.
18. Kelder TP, Penning ME, Uh HW, Cohen D, Bloemenkamp KW, Bruijn JA, Scherjon 
SA, Baelde HJ. Quantitative polymerase chain reaction-based analysis of  podocyturia is 
a feasible diagnostic tool in preeclampsia. Hypertension. 2012;60:1538-1544.
19. Langenberg MH, van Herpen CM, De Bono J, Schellens JH, Unger C, Hoekman K, 
Blum HE, Fiedler W, Drevs J, Le Maulf  F, Fielding A, Robertson J, Voest EE. Effective 
strategies for management of  hypertension after vascular endothelial growth factor 
signaling inhibition therapy: Results from a phase ii randomized, factorial, double-blind 
study of  cediranib in patients with advanced solid tumors. J Clin Oncol. 2009;27:6152-
6159.
20. Curwen JO, Musgrove HL, Kendrew J, Richmond GH, Ogilvie DJ, Wedge SR. 
Inhibition of  vascular endothelial growth factor-a signaling induces hypertension: 
Examining the effect of  cediranib (recentin; azd2171) treatment on blood pressure in 
summary, discussion and perspectives
152
rat and the use of  concomitant antihypertensive therapy. Clin Cancer Res. 2008;14: 3124-
3131.
21. Yu H, Steeghs N, Kloth JS, de Wit D, van Hasselt JG, van Erp NP, Beijnen JH, Schellens 
JH, Mathijssen RH, Huitema AD. Integrated semi-physiological pharmacokinetic model 
for both sunitinib and its active metabolite su12662. Br J Clin Pharmacol. 2014;79:809-
819.
22. Speed B, Bu HZ, Pool WF, Peng GW, Wu EY, Patyna S, Bello C, Kang P. 
Pharmacokinetics, distribution, and metabolism of  [14c]sunitinib in rats, monkeys, and 
humans. Drug Metab Dispos. 2012;40:539-555.
23. Star GP, Giovinazzo M, Lamoureux E, Langleben D. Effects of  vascular endothelial 
growth factor on endothelin-1 production by human lung microvascular endothelial 
cells in vitro. Life Sci. 2014;118:191-194.
24. Collino F, Bussolati B, Gerbaudo E, Marozio L, Pelissetto S, Benedetto C, Camussi 
G. Preeclamptic sera induce nephrin shedding from podocytes through endothelin-1 
release by endothelial glomerular cells. Am J Physiol Renal Physiol. 2008;294:F1185-1194.
25. Buelli S, Rosano L, Gagliardini E, et al. Beta-arrestin-1 drives endothelin-1-mediated 
podocyte activation and sustains renal injury. J Am Soc Nephrol. 2014;25:523-533.
26. Saleh MA, Pollock JS, Pollock DM. Distinct actions of  endothelin a-selective versus 
combined endothelin a/b receptor antagonists in early diabetic kidney disease. J 
Pharmacol Exp Ther. 2011;338:263-270.
27. Saleh MA, Boesen EI, Pollock JS, Savin VJ, Pollock DM. Endothelin-1 increases 
glomerular permeability and inflammation independent of  blood pressure in the rat. 
Hypertension. 2010;56:942-949.
28. Kodera Y, Katanasaka Y, Kitamura Y, Tsuda H, Nishio K, Tamura T, Koizumi F. 
Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a 
breast cancer model through inhibition of  vascular endothelial growth factor receptor 
3. Breast Cancer Res. 2011;13:R66.
29. Gu JW, Manning RD, Jr., Young E, Shparago M, Sartin B, Bailey AP. Vascular endothelial 
growth factor receptor inhibitor enhances dietary salt-induced hypertension in sprague-
dawley rats. Am J Physiol Regul Integr Comp Physiol. 2009;297: R142-148.
30. Gennari-Moser C, Escher G, Kramer S, Dick B, Eisele N, Baumann M, Raio L, Frey FJ, 
Surbek D, Mohaupt MG. Normotensive blood pressure in pregnancy: The role of  salt 
and aldosterone. Hypertension. 2014;63:362-368.
31. Luft FC, Weinberger MH. Sodium sensitivity and resistance of  blood pressure: The 
role of  the kidney and the renin-aldosterone axis. Kidney Int Suppl. 1987;22:S234-241.
32. Kohan DE, Rossi NF, Inscho EW, Pollock DM. Regulation of  blood pressure and salt 
homeostasis by endothelin. Physiol Rev. 2011;91:1-77.
33. Elmarakby AA, Dabbs Loomis E, Pollock JS, Pollock DM. Eta receptor blockade 
attenuates hypertension and decreases reactive oxygen species in etb receptor-deficient 
rats. J Cardiovasc Pharmacol. 2004;44 Suppl 1:S7-10.
34. Mortensen LH, Fink GD. Salt-dependency of  endothelin-induced, chronic hypertension 
in conscious rats. Hypertension. 1992;19:549-554.
chapter 9
153
35. Amiri F, Ko EA, Javeshghani D, Reudelhuber TL, Schiffrin EL. Deleterious combined 
effects of  salt-loading and endothelial cell restricted endothelin-1 overexpression on 
blood pressure and vascular function in mice. J Hypertens. 2010;28: 1243-1251.
36. Lankhorst S, Baelde HJ, Kappers MH, Smedts FM, Hansen A, Clahsen-van Groningen 
MC, Sleijfer S, Mathijssen RH, Danser AH, van den Meiracker AH. Greater sensitivity 
of  blood pressure than renal toxicity to tyrosine kinase receptor inhibition with 
sunitinib. Hypertension. 2015;66:543-549.
37. Verdonk K, Saleh L, Lankhorst S, Smilde JE, van Ingen MM, Garrelds IM, Friesema 
EC, Russcher H, van den Meiracker AH, Visser W, Danser AH. Association studies 
suggest a key role for endothelin-1 in the pathogenesis of  preeclampsia and the 
accompanying renin-angiotensin-aldosterone system suppression. Hypertension. 2015; 
65:1316-1323.
38. Dimke H, Sparks MA, Thomson BR, Frische S, Coffman TM, Quaggin SE. 
Tubulovascular cross-talk by vascular endothelial growth factor a maintains peritubular 
microvasculature in kidney. J Am Soc Nephrol. 2015;26:1027-1038.
39. Eremina V, Jefferson JA, Kowalewska J, et al. Vegf  inhibition and renal thrombotic 
microangiopathy. N Engl J Med. 2008;358:1129-1136.
40. Lankhorst S, Kappers MH, van Esch JH, Danser AH, van den Meiracker AH. 
Mechanism of  hypertension and proteinuria during angiogenesis inhibition: Evolving 
role of  endothelin-1. J Hypertens. 2013;31:444-454.
41. Izzedine H, Brocheriou I, Deray G, Rixe O. Thrombotic microangiopathy and anti-
vegf  agents. Nephrol Dial Transplant. 2007;22:1481-1482.
42. Bollee G, Patey N, Cazajous G, Robert C, Goujon JM, Fakhouri F, Bruneval P, Noel LH, 
Knebelmann B. Thrombotic microangiopathy secondary to vegf  pathway inhibition by 
sunitinib. Nephrol Dial Transplant. 2009;24:682-685.
43. Izzedine H, Perazella MA. Thrombotic microangiopathy, cancer, and cancer drugs. Am 
J Kidney Dis. 2015; 66:857-868.
44. Müller-Deile J, Bröcker V, Grünwald V, Hiss M, Bertram A, Kubicka S, Ganser A, 
Haller H, Schiffer M. Renal side effects of  vegf-blocking therapy. NDT Plus. 2009: 
45. Hayman SR, Calle JC, Jatoi A, Craici IM, Wagner SJ, Weaver AL, Greene EL, Grande 
JP, Garovic VD. Urinary podocyte excretion and proteinuria in patients treated with 
antivascular endothelial growth factor therapy for solid tumor malignancies. Oncology. 
2014;86:271-278.
46. Aita K, Etoh M, Hamada H, Yokoyama C, Takahashi A, Suzuki T, Hara M, Nagata M. 
Acute and transient podocyte loss and proteinuria in preeclampsia. Nephron Clin Pract. 
2009;112:c65-70.
summary, discussion and perspectives

APPENDICES
       
nederlandse samenVatting
curriculum Vitae
list oF publications
phd portFolio
danKWoord
156
nederlandse samenVatting 
Angiogenese, de vorming van nieuwe bloedvaten uit het reeds bestaande vaatstelsel, 
is essentieel voor de groei van tumoren en metastasering. Angiogenese wordt door 
meerdere factoren gereguleerd, met een dominante rol voor de vasculaire endotheliale 
groeifactor (VEGF). Angiogeneseremming, door remming van VEGF of  VEGF-
receptoren, heeft een vaste plaats verworven bij de behandeling van verschillende vormen 
van kanker. Bevacizumab is een gehumaniseerd monoclonaal antilichaam tegen VEGF, 
terwijl sunitinib een oraal werkzame  angiogeneseremmer is die de VEGF-receptoren 1, 
2 en 3 en andere tyrosinekinasereceptoren blokkeert. VEGF-receptoren 1 en 2 komen 
voornamelijk tot expressie in vasculaire endotheelcellen, terwijl de VEGF-receptor 3, 
die gestimuleerd wordt door VEGF-C, tot expressie komt in de endotheelcellen van 
de lymfevaten. VEGF-remming gaat gepaard met ernstige bijwerkingen, waaronder 
hypertensie en nierschade. Het optreden van deze bijwerkingen kan een reden zijn om 
de dosis van het anti-VEGF middel te verlagen of  om het zelfs helemaal te stoppen, 
met belangrijke repercussies voor de kankerbehandeling. In onze studies hebben we 
gekeken naar de dosis- en zoutafhankelijkheid van de bijwerkingen van sunitinib en naar 
mogelijke therapieën om deze bijwerkingen te verminderen of  te voorkomen. 
Bij vrijwel iedere patiënt die behandeld wordt met een anti-VEGF middel stijgt de 
bloeddruk. De incidentie van hypertensie geïnduceerd door anti-VEGF behandeling 
varieert van 9% tot 67%. Ernstige (graad 3 en 4) hypertensie wordt gezien bij 3-18% 
van de patiënten. Het risico op het ontwikkelen van ernstige hypertensie neemt toe 
bij patiënten met hypertensie in de voorgeschiedenis. De incidentie van hypertensie is 
dosisafhankelijk en neemt toe tot meer dan 90% wanneer bevacizumab en sunitinib 
gecombineerd worden. De bloeddrukstijging wordt veroorzaakt door een toename van 
systemische vaatweerstand en kan binnen een paar uur na start van de behandeling 
ontstaan. Hoewel hypertensie een bijwerking is van anti-VEGF behandeling blijkt het 
ontstaan van hypertensie ook een voorspeller te zijn voor een gunstige antitumorrespons 
en verbeterde overlevingskans. De incidentie van proteïnurie geassocieerd met 
angiogeneseremming is lager dan die van hypertensie. De proteïnurie kan variëren van 
<1 gram/per dag (graad 1) tot massale proteïnurie (Hoofdstukken 1 en 2). 
Binding van VEGF aan receptoren stimuleert het endotheliale stikstofmonoxide 
synthase (eNOS) en verhoogt daarmee de beschikbaarheid van stikstofmonoxide 
(NO). Remming van de VEGF-route zal de beschikbaarheid van NO verlagen, 
resulterend in vaatvernauwing en stijging van de bloeddruk. Daarnaast verstoort 
de verlaagde beschikbaarheid van NO de balans tussen het vaatverwijdende NO en 
het vaatvernauwende endotheline-1 (ET-1), waardoor de ET-1 productie en ET-1-
gemedieerde vasoconstrictie de overhand krijgen, met verdere vaatvernauwing en 
bloeddrukstijging tot gevolg. Het eerste bewijs voor de betrokkenheid van een geactiveerd 
ET-1 systeem tijdens VEGF-remming kwam voort uit een klinische studie met sunitinib 
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uitgevoerd door onze groep. Bij patiënten met een gemetastaseerd niercelcarcinoom 
en imatinib-resistente gastrointestinale stromale tumoren, veroorzaakte sunitinib 
behandeling een verdubbeling van de ET-1 waarden in het bloed. In vervolgstudies in 
ratten vonden we dat de toediening van sunitinib leidde tot een toename van de serum 
ET-1-concentratie, dalend tot pre-sunitinib waarden na het stoppen van sunitinib. 
Bovendien kon het tegelijkertijd met sunitinib toedienen van de duale endotheline 
(ETA/ETB) receptorblokker macitentan de sunitinib-geïnduceerde bloeddrukstijging en 
proteïnurie  grotendeels voorkomen (Hoofdstuk 2). 
Omdat endotheline receptorblokkers niet geregistreerd zijn voor de behandeling 
van systemische hypertensie en nierschade, hebben we het effect van een aantal 
antihypertensiva op de sunitinib-geïnduceerde hypertensie en nierschade onderzocht in 
ratten. Toediening van sunitinib veroorzaakte een 30 mmHg stijging van de gemiddelde 
arteriële bloeddruk. Het tegelijkertijd toedienen van macitentan of  de calciumantagonist 
amlodipine verminderde de sunitinib-geïnduceerde bloeddrukstijging met respectievelijk 
73% en 63%, terwijl het tegelijkertijd toedienen van een lagere en hogere dosering van 
de ACE-remmer captopril en de fosfodiesterase-5-remmer sildenafil de bloeddruk niet 
verlaagde. Door sunitinib steeg de proteïnurie tot 30 mg per dag. Deze stijging werd 
grotendeels voorkomen door macitentan, captopril en sildenafil. Anderzijds leidde 
toediening van amlodipine juist tot een toename van de proteïnurie. Opvallend was 
dat captopril en sildenafil de steady-state sunitinibserumconcentratie verhoogden. Op 
grond van bovengenoemde bevindingen concluderen we dat in ons experimentele 
model endothelinereceptor- en calciumkanaalblokkade geschikt zijn om VEGF-
remming-geïnduceerde hypertensie te voorkomen, terwijl endothelinereceptorblokkade, 
ACE-remming en fosfodiesterase-5-remming juist de VEGF-remming-geassocieerde 
proteïnurie kan voorkomen (Hoofdstuk 4). 
In onze eerste rattenstudies gebruikten we sunitinib in een orale dosering van 26.7 
mg/kg per dag. Deze relatief  hoge dosis leidde binnen enkele dagen tot een ernstige 
hypertensie, proteïnurie en irreversibele glomerulaire nierschade, waardoor het 
moeilijk is om een uitspraak te doen in hoeverre de nierschade onafhankelijk is van 
de bloeddrukstijging. Daarnaast zijn de sunitinib-geïnduceerde bijwerkingen in dit 
specifieke model bij de gebruikte sunitinib dosering ernstiger dan de bijwerkingen die 
in patiënten worden waargenomen. We testten daarom de dosisafhankelijkheid van de 
bijwerkingen door het toedienen van verschillende doseringen van sunitinib, met als 
doel een sunitinib dosis te vinden die met betrekking tot de hemodynamische en renale 
bijwerkingen (waaronder ET-1 verhoging) beter overeenkomt met de bijwerkingen 
die we aantreffen bij patiënten. Met deze aanpak wilden we ook onderzoeken of  de 
proteïnurie die tijdens VEGF-remming optreedt onafhankelijk is van het optreden van 
histologische afwijkingen in de glomerulus. Met de verschillende doseringen sunitinib 
steeg de bloeddruk dosis-afhankelijk van 13 tot 30 mmHg. Proteïnurie was aanwezig bij 
alle drie de doseringen, maar cystatine C als maat voor de glomerulaire filtratiesnelheid 
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steeg alleen met de middelste en hoogste sunitinibdosering. Circulerend ET-1, maar 
niet de 24-uurs urine endotheline-uitscheiding, steeg dosisafhankelijk. Glomerulaire 
endotheliose en ischemie werden gezien bij de middelste en hoogste dosis van sunitinib, 
maar niet bij de laagste dosering. Op grond van deze bevindingen concluderen we dat 
de drempeldosis van sunitinib voor het ontwikkelen van hypertensie lager is dan die 
voor het ontwikkelen van een verminderde nierfunctie en dat functionele veranderingen 
in de glomerulaire filtratiebarrière mede bijdragen aan het optreden van proteïnurie, 
gezien het ontbreken van histologische veranderingen bij de laagste dosering van 
sunitinib (Hoofdstuk 5).
Uit recent onderzoek is gebleken dat tijdens een hoog zout (HS) dieet er een relatief  
grotere ophoping is van natrium- en chloride- dan waterionen in de huid. Dit leidt 
tot een hypertonisch, interstitiëel vloeistofcompartiment met stimulatie van de 
lymfangiogenese in de huid via activering van het mononucleaire-fagocytaire celsysteem 
(MPS). Door het geactiveerde MPS wordt VEGF-C geproduceerd dat vervolgens via 
VEGF-receptor 3 de lymfangiogenese stimuleert. Remming van deze signaleringsroute 
in muizen en ratten leidt tot zout-gevoelige hypertensie. Omdat sunitinib, naast de 
blokkade van VEGF-receptoren 1 en 2, ook  de VEGF-receptor 3 blokkeert, was onze 
hypothese dat sunitinib de lymfangiogenese in respons op een HS dieet remt, en dat 
deze remming leidt tot ophoging van natrium- en chloride-ionen in de huid, bijdragend 
aan zout-gevoelige hypertensie. Ratten werden blootgesteld aan een normaal (NS) 
of  HS dieet met of  zonder toediening van sunitinib. Sunitinib veroorzaakte een 15 
mmHg bloeddrukstijging, die versterkt werd door een HS dieet en resulteerde in een 
afname van de hellingshoek van de bloeddruk-natriurese curve. Deze bloeddrukstijging 
ging niet gepaard met een toename van het lichaamsgewicht, veranderingen in plasma 
natriumconcentratie of  verslechtering van de nierfunctie. Wel leidde een HS dieet tot 
een stijging van de hoeveelheid natrium- en chloride-ionen in de huid die hoger was dan 
de stijging van de hoeveelheid water. Deze stijging ging gepaard met een toename van 
MPS cellen in de huid die niet geremd werd door sunitinib. Onafhankelijk van het NS 
of  HS dieet was er een tendens tot een verminderde lymfangiogenese tijdens sunitinib. 
Op grond van deze bevindingen concluderen we dat de toediening van sunitinib leidt 
tot een zout-gevoelige hypertensie, maar dat deze slechts zeer dele verklaard kan worden 
door een verminderde lymfangiogenese in de huid, erop wijzend dat andere factoren 
een rol spelen bij de zoutgevoelige hypertensie tijdens sunitinib toediening (Hoofdstuk 
6).
In eerdere studies hebben we laten zien dat de sunitinib-geïnduceerde hypertensie 
gepaard gaat met een afname in NO-productie en renine onderdrukking; een situatie die 
gepaard gaat met een toegenomen zoutgevoeligheid. In de huidige studie onderzochten 
we of  de sunitinib-geïnduceerde toegenomen bloeddrukstijging tijdens een HS dieet, 
zoals we zagen in hoofdstuk 6, ook leidt tot meer uitgesproken nierschade. Door het HS 
dieet alleen was er geen toename van de proteïnurie, endothelinurie, circulerend ET-1, 
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creatinine, en cystatine C. Alleen tijdens het HS dieet leidde toediening van sunitinib 
tot een aanzienlijke stijging van de proteïnurie en endothelinurie. Tevens namen tijdens 
het HS dieet in combinatie met sunitinib de histologische glomerulaire afwijkingen in 
de nier toe, maar tubulointerstitiële schade of  een afname in peritubulaire capillaire 
dichtheid werd niet gezien (Hoofdstuk 7).
De combinatie van hypertensie en nierschade tijdens angiogeneseremming wordt 
ook wel een pre-eclampsie-achtig syndroom genoemd. Pre-eclampsie is een 
zwangerschapsgerelateerde aandoening die gekarakteriseerd wordt door hypertensie, 
proteïnurie, verhoogde circulerende ET-1 waarden en glomerulaire endotheliose 
optredend na de 20ste zwangerschapsweek. We lieten eerder zien dat angiogeneseremming 
met sunitinib afwijkingen in de nier veroorzaakt overeenkomend met de histologische 
afwijkingen die gezien worden bij pre-eclampsie (Hoofdstukken 4 en 5). Beschadiging 
van de podocyten speelt een belangrijke initiële rol bij de nierschade tijdens VEGF-
remming. Gesuggereerd is dat het verschijnen van podocyten in de urine (podocyturie) een 
gevoelige marker is  voor glomerulaire ziekteactiviteit, die voorafgaat aan de proteïnurie. 
Gebruikmakend van een recentelijk gevalideerde kwantitatieve polymerasekettingreactie 
(qPCR) van de podocyt-specifieke moleculen nefrine, podocine en VEGF-A in 
de urine, onderzochten we of  podocyturie aanwezig is bij patiënten met kanker die 
behandeld worden met bevacizumab, en of  deze  gerelateerd is aan de proteïnurie en 
de cumulatieve doses van bevacizumab. We zagen geen verhoogde waarden van nefrine 
mRNA of  VEGF-A mRNA in de urine van patiënten die behandeld werden met de 
VEGF-remmer bevacizumab in vergelijking met patiënten die behandeld werden met 
alleen chemotherapie of  met gezonde controles. Bovendien was er geen relatie tussen 
de qPCR nefrinurie en albuminurie of  tussen de qPCR nefrinurie en de cumulatieve 
doses van bevacizumab. Albuminurie en de cumulatieve doses van bevacizumab waren 
wel gerelateerd. Op grond van deze bevindingen concluderen we dat de qPCR meting 
van podocyt-specifieke moleculen ter monitoring van actieve glomerulaire schade in 
patiënten die met bevacizumab behandeld worden geen toegevoegde waarde heeft in 
vergelijking met het bepalen van proteïnurie (Hoofdstuk 8).
nederlandse samenvatting
160
appendices
161
curriculum Vitae
Stephanie Lankhorst werd geboren op 1 november 1986 te Amstelveen. Na het voltooien 
van het VWO atheneum aan het Hermann Wesselink College te Amstelveen, startte zij 
in 2006 met de opleiding Biomedische Wetenschappen aan de Vrije Universiteit van 
Amsterdam. Na een algemene bachelor van 3 jaar koos zij voor de klinisch georiënteerde 
specialisatie Cardiovascular Research aan het VU Medisch Centrum Amsterdam, waarin 
zij tijdens haar laatste stage tevens kennis leerde maken met de afdeling Inwendige 
Geneeskunde, sector Vasculaire Geneeskunde & Farmacologie in het Erasmus Medisch 
Centrum te Rotterdam. Na het behalen van haar Master diploma begon zij in 2011 
onder leiding van Dr. Anton H. van den Meiracker en Prof. dr. A.H. Jan Danser aan 
haar promotieonderzoek, naar de behandelingsopties en zoutafhankelijkheid van 
angiogenese remming-geïnduceerde hypertensie en nierschade, dat beschreven is in het 
huidige proefschrift. 
curriculum vitae
162
list oF publications
Lankhorst S, baelde HJ, clahsen-van groningen mc, smedts Fmm, danser aHJ, van den 
meiracker aH. effect of high salt diet on blood pressure and renal damage during VegF inhibition 
with sunitinib. Nephrol Dial Transplant. 2016 in press
Lankhorst S, danser aHJ, van den meiracker aH. endothelin-1 and antiangiogenesis. Am J 
Physiol Regul Integr Comp Physiol. 2015 (Review)
Lankhorst S, baelde HJ, Kappers mHW, smedts Fmm, Hansen a, sleijfer s, mathijssen aHJ, 
danser aHJ, van den meiracker aH. greater sensitivity of blood pressure than renal toxicity to 
tyrosine-kinase receptor inhibition with sunitinib. Hypertension 2015; 66(3):543-549
Lankhorst S, saleh l, danser aHJ, van den meiracker aH. etiology of angiogenesis inhibition-
related hypertension. Curr opin pharmacology 2015; 21:7-13 (Review)
Lankhorst S, Kappers mHW, van esch JHm, smedts Fmm, sleijfer s, mathijssen rH, baelde HJ, 
danser aHJ, van den meiracker aH. treatment of hypertension and renal injury induced by the 
angiogenesis inhibitor sunitinib: preclinical study. Hypertension 2014; 64(6):1282-1289
Lankhorst S, Kappers mHW, van esch JHm, danser aHJ, van den meiracker aH. Hypertension 
during vascular endothelial growth factor inhibition: focus on nitric oxide, endothelin-1, and 
oxidative stress. Antioxid Redox  Signal. 2014; 20(1):135-145 (Review)
Lankhorst S, Kappers mHW, van esch JHm, danser aHJ, van den meiracker aH. mechanism 
of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1. 
J Hypertension. 2013; 31(3):444-454 (Review)
Van den meiracker aH, Lankhorst S, van esch JHm, danser aHJ, Kappers mHW. Hypertension 
induced by antiangiogenic therapy: clinical and pathophysiological aspects. Eur J Hospital 
Pharmacy. 2012; 19:327-329 (Review)
 
 
 
 
 
 
 
 
 
appendices
163
Publications on other topics
Verdonk K, saleh l, lankhorst s, smilde Jei, van ingen mm, garrelds im, Friesema ecH, steegers 
eap, van den meiracker aH, Visser W, danser aHJ. association studies suggest a key role for 
endothelin-1 in the pathogenesis of preeclampsia and the accompanying renin-angiotensin-
aldosterone system. Hypertension. 2015; 65(6):1316-1323
lankhorst s, Keet sWm, bulte cse, boer c. the impact of autonomic dysfunction on peri 
operative cardiovascular complications. anesthesia. 2014; 70(3):336-43 (review)
ruiter g, lankhorst s, boonstra a, postmus pe, Zweegman s, Westerhof n, van der laarse WJ, 
Vonk-Noordegraaf A. Iron deficiency is common in idiopathic pulmonary arterial hypertension. 
eur respir J. 2011; 37(6):1386-1391
publications
164
COEUR Courses       Year
7.5 ECTS         
Intensive care research       2012 
Arrhythmia research methodology      2012 
Clinical cardiovascular epidemiology      2012
Cardiovascular pharmacology      2012
Vascular medicine        2013
Erasmus MC courses       Year
5.1 ECTS          
ERCATHAN masterclass cardio module     2012 
Laboratory Animal Science       2012 
Photoshop & Illustrator CS6 Workshop  (MolMed)    2013 
Basiscursus Regelgeving en Organisatie voor Klinisch       2014
Onderzoekers (BROK)
CPO course: patient oriented research: design, conduct, analysis and  2015 
clinical implications
PhD PORTFOLIO
Name PhD Student   Stephanie Lankhorst
Erasmus MC Department   Department of Internal Medicine, 
     Sector Vascular Medicine & Pharmacology
Research School:    Cardiovascular Research School (COEUR)
Promotor:     Prof. dr. A.H.J. Danser
Copromotoren:     Dr. A.H. van den Meiracker
     Dr. M.H.W. Kappers
PhD period:     2011-2015
Appendices
165
Courses from Dutch Heart/Kidney Foundation   Year
4 ECTS         
Vascular biology, papendal       2012 
Winterschool, driebergen        2013
COEUR Research Seminars and lectures     Year
3.3 ECTS         
several                     2012-2014
Didactic skills        Year
5.9 ECTS         
practical lessons Junior med school, 5th year high school students (5VWo) 2012
Vo autonoom zenuwstelsel, 1st year medical students    2012-2014
practical lessons cardiovascular pharmacology, 2nd year medical students  2013-2014
education to clinical pharmacologists      2014
practical lessons Junior med school, 5th year high school students (5VWo) 2015
Symposia and conferences       Year
17.4 ECTS           
         
Oral Presentations
23rd annual scientific meeting of the European Society of Hypertension,  2013  
milan, italy  
3rd ISH New Investigators’ Symposium, New Orleans,  United States  2013
 
max-delbruck centre for molecular medicine, charité medical Faculty,  2013       
berlin, germany     
Wetenschapsdagen internal medicine, antwerp, belgium   2014 
24th/25thJoint meeting of the european and international society of  2014
Hypertension, athens, greece
phd por tfolio
166
ledenvergadering nederlandse Hypertensie Vereniging, Zeist   2015
nederlandse nefrologiedagen, Veldhoven     2015
25th annual scientific meeting of the European Society of Hypertension,  2015  
milan, italy 
Work meetings                2012-2015
Poster Presentations
High blood pressure research council of the american Heart association,  2013  
new orleans, united states 
High blood pressure research council of the american Heart association,  2014  
san Francisco, united states 
Wetenschapsdagen internal medicine, antwerp, belgium   2015 
Hypertension council of the american Heart association,    2015
Washington d.c, united states
Attendance
Wetenschapsdagen internal medicine, antwerp, belgium   2012 
phd day nai, rotterdam        2012
phd day nai, rotterdam       2013
Grants
Jaap van schouten Foundation travel grant to attend Hbpr 2015  
(Washington d.c, united states)
esH accommodation grant to attend esH 2015 (milan, italy)
esH/isH investigator grant to attend esH/isH 2014 (athens, greece)
esH accommodation grant to attend esH 2013 (milan, italy)
appendices
167
phd por tfolio
168
appendices
169
danKWoord
Het maken van dit proefschrift was niet mogelijk geweest zonder de grote bijdrage 
en betrokkenheid, plezierige samenwerking en enthousiasme van vele collega’s. De 
volgende personen wil ik in het bijzonder bedanken:
Mijn promotor, Prof. dr. A.H.J. Danser, beste Jan, zonder jouw onuitputtelijke kennis, 
betrokkenheid en laagdrempelige toegankelijkheid, had dit proefschrift niet tot stand 
kunnen komen. Jouw kritische blik spoorde mij aan altijd scherp te zijn; de vele discussies 
vond ik dan ook zeer leerzaam en fascinerend, en motiveerde me door te gaan ook al zat 
het soms tegen. Ik stond bovendien altijd versteld, in welke tijdzone je je ook bevond, 
dat ik altijd binnen een dag antwoord had op mijn email. Je bent behalve een professor 
in ‘hart en nieren’ oprecht een fijn mens!
Mijn eerste copromotor, Dr. A.H. van den Meiracker, beste Ton, ik kan ons eerste 
gesprek nog goed herinneren. Waarvan ik dacht dat het een oriënterend gesprek was, 
begon ik niet veel later, blij verrast, als beginnend PhD student. En wat zijn deze 4 jaar 
voorbij gevlogen! De afgelopen jaren heb ik met veel plezier met jou samengewerkt. 
Jouw analytisch vermogen, ontelbare woordenschat en bondige manier van schrijven 
bewonder ik enorm. Jij wist jouw klinische expertise bovendien altijd feilloos te vertalen 
naar wetenschappelijk onderzoek, en leverde hiermee een onmiskenbare bijdrage aan dit 
proefschrift. Tevens wil ik je bedanken voor het goede gezelschap tijdens congressen, 
van Bourbon Street in New Orleans tot China Town in San Francisco, it was never a dull 
moment. Ik wens jou en Marianne al het geluk voor de toekomst!
Mijn tweede copromotor, Dr. M.H.W. Kappers, beste Mariëtte, mede door jouw eigen 
onderzoek 7 jaar geleden te starten is mijn huidige proefschrift tot stand gekomen. 
Het zal niet makkelijk zijn geweest om jouw werk uit handen te geven, maar hopelijk 
ben ik daar in jouw ogen toch wel in geslaagd ;). Ik waardeer het zeer dat je, ondanks 
grote belasting met andere werkzaamheden en je werk als vasculair geneeskundige, altijd 
betrokken bleef.  
Dr. D.N. Müller, dear Dominik, it was a pleasure to meet you and I enjoyed our 
collaboration. I am thankful we started the salt study 2 years ago, which eventually 
has become a major part of  my thesis. I want to thank you and your colleagues for the 
warm welcome during my visit in Berlin, and for your presence today. I wish you all 
the best; keep up the good work! Dr. L. Marko, dear Lajos, thank you for the extensive 
contribution to chapter 6.
Prof. dr. R. Zietse, Prof. dr. G.A. Rongen en Prof. dr. A.H.J. Mathijssen, hartelijk dank 
voor het kritisch lezen en beoordelen van dit proefschrift. Tevens wil ik Prof. dr. R.P 
Peeters bedanken voor het zitting nemen in de grote promotiecommissie. 
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Prof. dr S. Sleijfer wil ik graag bedanken voor de bijdrage aan hoofdstukken 4 en 5 van 
dit proefschrift.
Van de afdeling Pathologie van het Reinier de Graaf  Gasthuis te Delft, Leiden Universitair 
Medisch Centrum en het Erasmus MC wil ik graag respectievelijk Dr. F.M.M. Smedts 
Dr. H.J. Baelde en Dr. M.C. Clahsen-van Groningen bedanken. Beste Frank, ontzettend 
bedankt voor de eindeloze histologische tellingen en scoringssystemen voor de nieren. 
Ik vond de uurtjes achter de microscoop altijd erg gezellig en leerzaam. Beste Hans, 
bedankt voor al je input in onze studies en de fijne samenwerking met betrekking tot 
de nierhistologie. Marian, bedankt voor je enthousiasme en tevens alle intensieve scores 
voor de nieren die je hebt uitgevoerd. Dr. Alastair Hansen, thank you for the beautiful 
electron microscopic pictures of  the kidneys. 
De vele (oud) collega’s van de afdeling Inwendige Geneeskunde/Farmacologie, Anton, 
Antoinette, Wendy, Mahdi, Arthur, Dominique, Koen, Luuk, Estrellita, Charles, Sieneke, 
Nils, Edith Friesema, Bruno, Haiyan, Usha, Ingrid, Frank, Jeanette, Evelien, Sven, Rene 
en Birgitte wil ik bedanken voor al hun inzet, maar bovenal voor de enorm goede 
werksfeer en de bereidheid elkaar te helpen indien nodig. Our new colleagues from 
abroad: Kristian, Eloisa, Alejandro, Alexandre and Eliana, good luck with your future 
studies and enjoy Rotterdam! Joep en Richard, wat had ik zonder jullie moeten beginnen? 
Zonder jullie hulp had een groot gedeelte van dit onderzoek niet kunnen plaatsvinden. 
Ik heb altijd grote bewondering gehad voor jullie technische vaardigheden. Bedankt 
voor jullie enorme inzet, gezelligheid en interesse in zowel mijn onderzoek als privé. Ik 
heb dit altijd erg gewaardeerd. David, bedankt voor al je praktische hulp en denkwerk 
de afgelopen 1,5 jaar! Alvast succes met de laatste loodjes!
Beste kamergenoten, Kayi, Khatera, Katie, Langeza, Lodi, en Paula. Het grootste 
gedeelte van mijn laatste jaar was onze kamer een echte meidenkamer! Ik wil jullie 
bedanken voor alle steun en hulp de afgelopen jaren, maar vooral de gezelligheid 
tijdens en buiten werk. Ik zal de sushi avondjes zeker missen! Lieve Khatera, allebei 
afzonderlijk als stagiaires begonnen, maar toch uitgegroeid tot ware PhD’s. Ook al 
deden we totaal verschillend onderzoek, het was leuk om te merken dat we vaak tegen 
dezelfde obstakels aanliepen en dat met elkaar konden delen. Hopelijk heb je, tussen je 
co-schappen door, nog af  en toe even tijd om bij te kletsen! Katie en Lodi, alvast veel 
plezier en succes met jullie verdere promotieonderzoek en opleiding tot specialist. Het 
was fijn om medische kennis altijd zo snel paraat te hebben! Kayi, succes met je verdere 
(wetenschappelijke) carrière en alle geluk toegewenst voor jou en je gezin. Paula, good 
luck with the continuation of  your PhD! 
Mijn familie en vrienden wil ik bedanken voor hun interesse en support tijdens 
mijn promotietraject en voor de gezellige avonden van ontspanning en afleiding in 
de afgelopen jaren. Bedankt voor jullie begrip dat de bezoekjes aan Amstelveen de 
afgelopen maanden zeer schaars waren.
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Vriendinnen voor het leven: Anoek, ik ken je al sinds de basisschool maar ondanks dat 
we steeds verder uit elkaar zijn gaan wonen, zijn we nog steeds vriendinnen, en weet 
zeker dat we dat altijd zullen blijven! Studiegenoten Bibi, Elvira, Melissa, Elianne en 
Lennart. Wat hebben wij een gezellige tijd gehad! Wij zien elkaar gelukkig nog steeds 
met enige regelmaat, ook al zijn we ieder ons weegs gegaan. Melissa, wie had ooit 
gedacht dat we tijdens onze PhD een kamer konden delen tijdens de Winterschool 
en Nederlandse Nefrologiedagen! Bedankt voor alle leuke herinneringen en voor jullie 
aanwezigheid op deze dag. 
Mijn Vero ladies, Anne, Selma en Niki. No words needed… jullie hebben een speciaal 
plekje in mijn hart! 
Mijn paranimfen, Bibi en Langeza, bedankt dat jullie mij wilden bijstaan op deze 
belangrijke dag. 
Lieve Bieb, sinds het begin van onze studie hebben wij een hele mooie vriendschap 
opgebouwd. Bedankt voor jouw betrokkenheid en dat je de afgelopen 10 jaar altijd 
voor mij klaar hebt gestaan wanneer je kon. Door jou voel ik me altijd begrepen en 
gesteund en waardeer onze gesprekken, gezellige etentjes en thee-momentjes dan ook 
zeer. Ik heb bewondering voor jou enorme doorzettingsvermogen, en kijk uit naar alle 
momenten die we samen nog gaan beleven.
Lieve Langeza, fashionista en Amsterdam-lover. Ik ken je nog maar 1,5 jaar maar had al snel 
door dat je een echte levensgenieter bent, met in mijn ogen onuitputtelijke energie ;) 
Je staat werkelijk voor iedereen klaar en dat siert je enorm! Bovendien ontdekten we al 
snel dat we veel gemeen hebben, wat leidde tot vaak grappige situaties. Hierdoor weet 
ik zeker dat we elkaar, ook buiten werktijden, nog blijven zien. Ik wens je alle succes 
toe tijdens je verdere studies en…als je ooit nog een room-mate nodig hebt tijdens 
congressen, dan hou ik mij graag aanbevolen! 
Lieve pap en mam, bedankt voor jullie onvoorwaardelijke steun, jullie vertrouwen in 
mij en dat jullie er altijd voor mij zijn. Ik ben blij dat jullie beiden het geluk in de liefde 
hebben hervonden. Enjoy life to the fullest! Ik hou van jullie. 
Lieve Chris, eigenlijk is het niet in woorden uit te drukken hoe dankbaar ik ben voor 
jouw onvoorwaardelijke liefde, steun, betrokkenheid en geduld rondom het uitvoeren 
van mijn proefschrift. Mede door jouw relativeringsvermogen, heb ik geleerd dingen 
sneller los te laten wanneer nodig. Het waren voor ons beiden 4 drukke jaren, maar het 
harde werken is beloond. Ik hou zielsveel van je en kijk enorm uit naar een nieuwe fase 
in ons leven. 
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